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ABSTRACT
This thesis describes the regulation of alveolar macrophage (AM) and peripheral blood 
monocyte (PBM) derived tumour necrosis factor (TNF-a) by the cytokine interleukin-10 
(IL-10) and the p-55 soluble TNF receptor (TNF-R). The relationship between TNF-a, 
IL-10 and TNF-R was explored first in AMs and PBMs from normal subjects and then 
compared to cells derived from patients with the inflammatory lung diseases sarcoidosis, 
cryptogenic fibrosing alveolitis (CFA) and adult respiratory distress syndrome (ARDS). 
The distribution of three distinct AM phenotypes (accessory, suppressor and tissue AMs) 
and their ability to produce TNF-a protein was also assessed in these subjects.
AMs and PBMs were isolated by bronchoalveolar lavage (BAL) and venepuncture 
respectively. Cells were cultured for twenty four hours to permit protein determination 
by enzyme-linked immunosorbent assay (ELISA), or two to four hours when 
determining messenger RNA (mRNA) expression. mRNA was extracted and measured 
by northern analysis. The bacterial cell wall component lipopolysaccharide (LPS) was 
added to cultures as a non-specific inflammatory stimulus, with appropriate controls.
The major findings of this thesis were as follows:
(1). IL-10 reduced TNF-a production by AMs and PBMs in normal subjects, and this 
inhibition was due at least in part to suppression of TNF mRNA expression. The activity 
of IL-10 in this respect was not dependent upon de novo protein synthesis, nor did IL-10 
enhance the rate of mRNA degradation.
(2). TNF-a was enhanced in the plasma and bronchoalveolar lavage fluid (BALF) of 
sarcoidosis subjects when compared to normal subjects, but the AM was not the source 
any enhanced production. TNF-R was enhanced in the plasma and BALF and was shed 
by AMs and PBMs in vitro. IL-10 was not enhanced, but there was increased potency of 
IL-10 inhibition of TNF-a in AMs derived from sarcoidosis subjects.
(3). TNF-a production by AMs derived from subjects with CFA was increased in 
response to LPS when compared to normal subjects. TNF-R was also increased, and the
AMs and PBMs had enhanced capacity to produce IL-10. The potency of IL-10 
inhibition of TNF-a was one hundred-fold stronger than that observed in normal AMs.
(4). TNF-a production by AMs derived from subjects with ARDS was enhanced when 
compared to subjects with pre-disposing risk factors (at risk subjects). TNF-R was 
elevated in the plasma and BALF of both groups but was undetectable in the 
supernatants of AM and PBM cultures. BALF IL-10 was significantly elevated in the 
ARDS group, indicating that IL-10 may be protective in acute lung injury, and the AM 
may be a major source.
(5). Distribution of AM phenotypes was altered in sarcoidosis and CFA BAL in favour 
of accessory and suppressor AMs. They were not altered in ARDS. The suppressor 
population were able to produce enhanced TNF-a in culture compared to accessory and 
tissue AMs. Accessory AMs were unable to produce TNF-a in culture.
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1. INTRODUCTION
The introduction to this thesis will provide an overview of pulmonary inflammation and 
cell/cytokine regulation in the normal lung. In addition, the mechanisms of three 
pulmonary inflammatory disorders; sarcoidosis, cryptogenic fibrosing alveolitis (CFA) 
and adult respiratory distress syndrome (ARDS) will be described. Investigation into the 
inflammatory processes in these diseases, with particular reference to the production of 
the cytokine tumour necrosis factor alpha (TNF-a) by alveolar macrophages (AMs) 
formed the basis for this study.
1.1 Pulmonary Inflammation
The lung is ideally suited anatomically to fulfill its role as the organ of gas exchange. As 
the airways branch from the trachea, through the bronchi and bronchioles, they terminate 
at the air sacs, which contain many convolutions, or alveoli within them. There are 109 
pulmonary alveoli in the adult lung, providing an enormous surface area required for 
efficient gas exchange. This is further facilitated by the structure of the alveolar walls, 
which consist of flat, thin epithelial cells in immediate proximity to the pulmonary 
capillary network (Keele et al. 1982).




The pulmonary epithelium represents the body’s most fragile interface with the 
environment. The airways are exposed to a constant stream of environmental particulate 
matter, which may or may not be intrinsically harmful. Should microbial pathogens or 
antigens be retained in the airways the lung has highly efficient local mechanisms, 
utilising both the innate and acquired immune systems, to remove them. An inflammatory 
response usually ensues, which in most circumstances leads to rapid and effective 
clearance of particles. The fragility of the airways and the intimate association between 
structure and function of the lung highlights the importance of homeostatic mechanisms 
to maintain and protect the lung environment It has become apparent that inflammatory 
responses, although representing a vital mechanism of host defence, can actually inflict 
lung injury itself, and in the case of an excessive response may lead to more injury than 
the supposed pathogen could itself alone inflict (Walters and du Bois 1995). This is 
particularly true in circumstances where the pathogen may be local viruses or 
environmental debris incapable of inflicting physical damage. Inflammation harms the 
host environment when mechanisms normally used to kill organisms such as parasites 
and bacteria are permitted to inflict local cell damage (see section 1.2.4). This can lead to 
loss of alveolar structure and the development of pulmonary fibrosis with the 
concomitant reduction in gas exchange. In the normal lung there are sophisticated 
mechanisms in place to distinguish between harmful pathogens and non-pathogenic 
environmental antigens, and so prevent unnecessary inflammation. However, there are 
incidences where an inappropriate inflammatory response can develop, which, if 
persistent, can lead to serious destruction of the pulmonary structure. Lung diseases 
which may be characterised by inappropriate responses include the granulomatous 
disorder sarcoidosis and the interstitial lung diseases cryptogenic fibrosing alveolitis 
(CFA) and adult respiratory distress syndrome (ARDS). All three disorders have an 
unknown aetiology, although ARDS is commonly associated with sepsis syndrome, and 




Innate immunity is the most primitive form of immunological protection and combines 
barrier protection with non-memory cell-mediated protection (Stites and Terr, 1987). 
Since the airways are under bombardment from environmental particulate matter, barrier 
protection is very important. It mainly comprises of a mucus secretion which traps 
debris which is then removed from the airways by beating ciliated epithelium acting as a 
mucilliaiy escalator. The airways are also patrolled by phagocytic cells of the myeloid 
lineage of haemopoietic cells, most notably AMs of the alveolar space and 
polymorphonuclear neutrophils (PMNs) which enter the lungs during inflammation. 
When these cells encounter debris they activate complement and release acute phase 
proteins such as C reactive protein, which coat, or opsonise bacteria, so promoting their 
ingestion by phagocytes. In addition complement has an enzymatic action allowing it to 
lyse bacterial cell walls and host cells infected with microorganisms. AMs also have a 
large battery of soluble mediators, the most important of these in terms of innate 
immunity are TNF-a and interferon gamma (IFN-y) (Mantovani and Dejana, 1989). 
Both of these cytokines are important for activation of AM killing of bacterial cells or 
infected host cells, and IFN-y is particularly effective in triggering autolysis in virally 
infected cells (Mantovani and Dejana, 1989). The innate immune system does not work 
in isolation however, since components of acquired and cell-mediated immunity are 
activated in response to the particulate matter itself, and also in response to the 
mediators released by activated AMs and PMNs.
1.2.2 Acquired immunity
This response developed later in evolutionary terms than innate immunity and depends 
on cells of the lymphoid, rather than the myeloid lineage i.e. T and B lymphocytes (Stites 
and Terr, 1987). Acquired immunity is based upon immunological memory; T cells 
resident in lymphoid tissues such as bronchus-associated lymphoid tissue (BALT) screen 
antigen (see section 1.2.3), and should they encounter antigenic material they induce 
clonal expansion of antigen-specific B cells leading to production of large amounts of
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specific antibody. Antibody binding to antigen promotes clearance by triggering 
ingestion by phagocytic cells through its interaction with the Fc receptor, or by attracting 
the attention of complement, cytotoxic T cells, AMs or natural killer cells, a type of 
lymphocyte capable of cell killing. Antibodies can also neutralise bacterial toxins.
1.2.3 T lymphocytes
T cells are lymphocytes which have been “educated” in the thymus of the foetus. While 
resident in this lymphoid gland the populations of immature T cells are decimated, since 
cells recognising self antigens as foreign are eliminated by apoptosis, a vital process to 
prevent the onset of autoimmune disease (Stites and Terr, 1987). Identification of self is 
mediated through the expression of major histocompatibility complex (MHC) or human 
leucocyte antigens (HLA). Class I MHC, or HLA-A, B and C are ubiquitous, found on 
all somatic cells, whereas class II or HLA-DR, DQ and DP are found on all antigen 
presenting cells (APCs) such as macrophages, dendritic cells (DCs), peripheral blood 
monocytes (PBMs) and B cells (Roitt et al. 1989). T cells can be divided into two major 
subsets based on the expression of CD4 and CD8 cluster of differentiation markers. 
CD4, or T helper (Th) cells recognise class II MHC, whereas CD8 or T 
cytotoxic/suppressor (Tc/s) cells recognise class I MHC. T helper cells are so-called 
since they “help” or promote the establishment of an inflammatory response once they 
have encountered antigen processed by APCs in conjunction with class II MHC. They 
can be further divided into Thl and Th2 on the basis of their cytokine profiles; Thl cells 
produce IFN-y, IL-2 and IL-3, whereas Th2 cells release IL-4, IL-5 and IL-10 
(Mosmann et al. 1986). These distinctions were made in mouse T cells populations, 
however and human T cells do not appear to totally conform to this pattern (Kelso, 
1995). CD8 cells, in contrast to CD4 are thought to have a role in dampening down the 
inflammatory response. In the normal lung the number of T cells is usually less than five 
per cent of the total inflammatory cells (Walters and du Bois 1995) and CD8 outnumber 
CD4 by approximately 2:1. This is thought to be an important mechanism for preventing 
inappropriate inflammatory responses. A ratio of 2:1 CD4:CD8, however, is a feature of 
sarcoidosis (Spiteri et al. 1992) and this T cell balance promotes a more vigorous
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response in terms of cytokine release, B cell activation, AM activation and granuloma 
formation (see section 1.4).
1.2.4 Polymorphonuclear neutrophils
PMNs are the dominant immune cell in the circulation, accounting for sixty to seventy 
per cent of circulating leucocytes. There are few in the normal lung, but during an 
inflammatory response PMNs are drawn in by chemokines such as interleukin-8 (IL-8) 
(Downey et al. 1993) (see section 1.3 .3). The first step in extravasation of PMNs is the 
up-regulation of adhesion molecules L-selectin, CD 18 and CD 11 on the PMN and their 
ligands E-selectin and ICAM-1 (inter-cellular adhesion molecule-1) on vascular 
endothelial cells (MacNee and Selby, 1993). This up-regulation can occur in response to 
a range of cytokines, including EL-8, TNF-a and IL-1 (MacNee and Selby, 1993), and 
their interaction causes rolling and then adhesion of PMNs to the endothelium (Figure 
1.2). Once stationary, the PMNs undergo morphological change, or diapedesis, allowing 
them to squeeze through the EC barrier, across the interstitium and into the alveolar 
space.
Figure 1.2 Extravasation of PMNs







The PMN is a multi-functional cell. As part of the myeloid lineage, it is an efficient 
phagocyte, engulfing particulate matter and digesting it in phagolysosomes packed with 
proteolytic enzymes (Ogawa et al. 1981). Phagocytosis, and activation by C5a 
(complement), FMLP (bacterial cell wall component), immune complexes, opsonised 
microbes and cytokines can lead to PMN degranulation and the release of these enzymes 
(collagenase, lysozyme, peroxidase) and the respiratory burst of superoxide anions 
(Nathan, 1989). These can all inflict damage not only to invading organisms, but to the 
host tissues themselves.
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1.2.5 Alveolar macrophages
Although T cells and PMNs are important effector cells in pulmonary inflammation, they 
are not apparent in significant numbers in the normal lung. In fact AMs account for more 
than ninety per cent of pulmonary inflammatory cells (see Plate 1.1). Derived from the 
myeloid lineage, they are not resident in the lung at birth, but populate the lung in the 
first month post partum from the circulating monocyte pool (Stites and Terr, 1987) (see 
Figure 1.3).










PROMONOCYTE MONOCYTE TISSUE MACROPHAGE
GM-CSF = granulocyte macrophage colony stimulating factor 
M-CSF = macrophage colony stimulating factor 
IL-3 = interleukin-3
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In the adult it is thought that the majority of AMs are derived directly from PBMs 
(Henson and Riches, 1994) although there have been in vitro studies suggesting that 
AMs are capable of local proliferation (Nakata et al. 1991). It has also become apparent 
that AMs are not a heterogeneous population of cells, but may consist of at least three 
different phenotypes, separated on the basis of cell density and/or surface antigen 
expression (Spiteri and Poulter, 1991). These sub-populations differ in their ability to 
present antigen to T cells and to phagocytose debris. Such differences may be a feature 
of different maturation states, but it is also possible that modulation or phenotype 
switching in existing resident AMs may occur.
As AMs mature from PBMs they undergo alterations to their surface marker expression, 
increasing expression of CD68 macrophage maturation marker, and decreasing CD 14 
(the lipopolysaccharide receptor) expression (Stites and Terr, 1987). They are also less 
efficient APCs. Accessory cell function is an important property of AMs since they are 
the scavenger cells of the normal lung and are the first to detect foreign matter. They are 
capable of processing antigen and presenting it in association with class II MHC to 
resident T helper cells but in normal AMs this ability is much reduced. It is believed that 
in the normal lung dendritic cells (DCs) are responsible for most initial antigen 
presentation and they migrate from the interstitium to the BALT in order to elicit T cell 
activation. It is thought that only after activation by Thl-derived IFN-y (which up- 
regulates class II MHC) are AMs capable of efficient accessory cell activity (Krakauer 
and Oppenheim, 1993). The requirement for priming is probably very important in the 
prevention of potentially hazardous inappropriate inflammatory response. Thus the major 
role for the resting AM is phagocytosis of debris, and it achieves this in the same manner 
as PMNs, although the AM is a more aggressive phagocyte. Cytokine production by 
AMs is usually reduced as they mature from PBMs (Kotloff et al. 1990; Elias et al. 
1988), with the exception of TNF-a, which is an important cytokine for the microbicidal 
activity of AMs (Kelley, 1990). However, they do posses an armementarium of over one 
hundred different soluble mediators. These mediators, including cytokines, 
prostaglandins and leukotrienes can then act on other effector cells such as T cells, ECs 
and PMNs in a paracrine manner and/or autocrine manner on AMs. Thus AMs have the 
capability to produce an array of factors involved in the initiation and maintenance of the 
pulmonary inflammatory response. In the normal lung it appears that there is very tight
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regulation of AM activity to prevent excessive cytokine release in response to 
immunogens which may be intrinsically harmless. A loss of regulation could lead to a 
chronic inflammatory response, so it seems that the inflammatory status of the AM may 
be important in the development of pathological inflammatory lung disease.
1.3 Cytokines and pulmonary inflammation
Cytokines are peptide mediators of inflammation with a molecular weight of 7 - 30 
kilodaltons. Their actions are similar to endocrine hormones since they can elicit 
responses such as cell mitosis and metabolic changes as well as modification of gene 
expression and protein synthesis in many cells of the body. Where they differ from 
hormones is their source; hormones are secreted by discrete endocrine glands and usually 
impinge upon cells at a distant site, via the circulation. Cytokines, by contrast, can be 
produced by many different cell types and usually act locally in an autocrine or paracrine 
fashion. They also have a short half-life. Cytokines are fundamental in orchestrating the 
inflammatory response of the lung and the network is usually under tight regulation to 
prevent inappropriate inflammation.
1.3.1 Tumour necrosis factor
TNF-a was so-called since it was initially described as a mediator of necrosis in 
transplantable tumours in mice (Carswell et al. 1975). However, it has since become 
apparent that TNF-a is a cytokine with a widely pleiotropic range of activity, including 
microbicidal activity, inflammatory effects and promotion of bone resorption (Fiers 
1991). TNF-a is a 17.5 kDa polypeptide derived from a gene on the short arm of 
chromosome six, closely linked to the HLA locus and TNF-B. Pulmonary TNF-a can be 
derived from a number of sources including T cells (Fiers, 1991) and PMNs (Xing et al. 
1993), but the majority of TNF-a in the lung is thought to be derived from the AM 
(Strieter et al. 1989a). AMs are one of the first lines of defence in the lung, being the 
dominant sentinel cell (Cohen and Cline, 1971) and following activation by 
lipopolysaccharide/endotoxin (LPS), a component of gram negative bacterial cell walls,
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there is a three-fold increase in TNF-a mRNA and a hundred-fold increase in protein 
translation and release (Han et al. 1990; Beutler et al. 1986). This up-regulation occurs 
very rapidly, with mRNA increased at 1-2 hours, and the first protein release at 3-4 
hours, optimal at 12-16 hours (Frei et al. 1993). Elevated levels of LPS are a feature of 
septic shock, a disease where patients have a high probability of developing acute lung 
injury, which may result in the adult respiratory distress syndrome (ARDS) (Fowler et al. 
1983; Ashbaugh et al. 1967) and the response of AMs to LPS does suggest a possible 
role for TNF-a in this disease. Plasma TNF-a, likely to be derived from activated PBMs, 
is elevated in septic shock and ARDS, and it may correlate to severity and mortality 
(Cannon et al. 1990; Damas et al. 1989). TNF-a has also been found to be elevated in 
the bronchoalveolar lavage fluid (BALF) of patients with ARDS (Suter et al. 1992) and 
other forms of lung injury. Interest in the role of TNF-a in acute lung injury led to the 
development of animal models, which demonstrated that TNF-a infusion could lead to 
lung injury in animals (Tracey et al. 1987b; Tracey et al. 1986; Lo et al. 1992), and that 
these infusions could mimic the effects of LPS infusion models (Beutler et al. 1985). 
Further studies using anti-TNF antibodies have demonstrated protection against lethality 
in LPS animal models of injury including baboons (Tracey et al. 1987a) and mice 
(Beutler et al. 1985). More recently an animal model using mice transgenic for the TNF- 
a  gene, (resulting in pulmonary over-expression of TNF-a) demonstrated the 
development of lethal interstitial pneomonitis (Piguet et al. 1995). The major response of 
the lung to TNF-a infusion are pulmonary oedema (Stephens et al. 1988), PMN 
infiltration (Schollmeier et al. 1990), increase in respiratory burst (Leff et al. 1993) and 
an increase in BALF cytokines such as interleukin-1 (IL-1) (Debs et al. 1988). Indeed 
EC permeability and PMN degranulation have been shown to be directly inducible by 
TNF-a (Horvath et al. 1988; Lo et al. 1992; Tracey et al. 1986) and it can mediate 
effects such as PMN influx and degranulation indirectly through the actions of another 
cytokine, IL-8 (Willems et al. 1989; Brandt et al. 1992). Characteristics of more chronic 
inflammatory lung diseases, such as pulmonary fibrosis, granuloma formation and T cell 
infiltration can also be mediated by TNF-a either directly or indirectly. Indeed, studies 
have demonstrated a protective effect of anti-TNF antibodies in animal models of 
pulmonary fibrosis, highlighting the important role of TNF-a in the pathogenesis of 
fibrotic lung injury (Piguet et al. 1989; Piguet et al. 1990). These known properties of
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TNF-a underline the importance of this cytokine, and the paramount need to regulate its 
production and/or activity. There are many in-built regulatory mechanisms in the 
cytokine network, including production of inhibitory molecules. With reference to TNF- 
a, these include the cytokines IL-10 (Fiorentino et al. 1991), IL-6 (Aggarwal and 
Pocsik, 1992), IL-4 (Essner et al. 1989) and IL-13 (Yanagawa et al. 1995) which inhibit 
TNF-a production by many cells including AMs, and TNF soluble receptor (TNF-R). 
Two types of soluble receptor have been identified; p55 or type I and p75 or type II 
(Engelmann et al. 1990) and are identical to the membrane-bound forms of TNF 
receptor. p55 is thought to have a major role in cell signalling and is ubiquitous, whereas 
the p75 receptor may predominate on the surface of immune cells (Joyce et al. 1995; 
Kalthoff et al. 1993; KrOnke et al. 1990). Both are capable of inhibiting biological 
activity (Leeuwenberg et al. 1994) although there is the possibility that p75 increases the 
stability of the TNF molecule, prolonging its presence and activity at the site of 
inflammation (Mohler et al. 1993; Aderka et al. 1992). Structural instability is another 
regulatory mechanism. The TNF molecule is most potent as a trimer, since this form 
permits cross-linking of the membrane bound p55 receptor resulting in enhanced 
signalling (Aderka et al. 1992). TNF-a only maintains its trimeric structure for a matter 
of minutes, dissociating to dimers and the inactive monomer (Corti et al. 1992). There is 
also in-built instability in the TNF-a mRNA. Many LPS-inducible cytokines, including 
TNF-a contain an octomeric sequence of nucleotides at the 3* untranslated region (3’ 
UTR). This sequence is preferentially hydrolysed by ribonucleases so restricting the 
storage of cytokine transcripts (Han et al. 1991a; Beutler et al. 1988).
Regulatory mechanisms for TNF-a appear to be insufficient in inflammatory lung 
diseases, and it has been suggested that anti-TNF antibody treatment may be efficacious. 
However, proof of such mechanisms is difficult to attain, not only because TNF-a is a 
very early mediator and thus the therapeutic window is very narrow, but also because it 
is not solely responsible for the injury. Other implicated cytokines include IL-l-p, which 
has a high degree of cross-over in terms of activity with TNF-a (see section 1.3.2), and 
IFN-y. IFN-y is thought to be very important in acute lung injury. Indeed anti-IFN 
antibodies can protect against lethality in a mouse model of lung injury in a similar 
fashion to anti-TNF antibodies (Doherty et al. 1992). Also in the Schwartzman reaction,
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where LPS administration, followed at 24 hours by TNF-a administration led to the 
onset of fatal shock, neutralisation of IFN-y with antibodies prevents lethality (Billiau, 
1988). It must also be remembered that TNF-a is in itself a beneficial cytokine, 
important for host defence and microbial cell killing, as in Listeria monocytogenes 
(Nakane et al. 1989) and in the prevention of autoimmunity by its regulation of a subset 
of B cells implicated in autoantibody production (Ishida et al. 1994). Thus total removal 
of TNF-a during an inflammatory response may lead to some undesired consequences. 
Therefore a more thorough understanding of regulatory mechanisms in inflammation 
could lead to the design of more appropriate therapeutic manoevres.
1.3.2 Interleukin- 1-B
The cytokine network is characterised by a certain amount of redundancy, or overlap 
between various mediators. This is certainly the case for IL-l-B and TNF-a. Not only 
are they able to induce production of each other on AMs and PBMs (Bachwich et al. 
1986a; Nathan, 1987), but they also overlap in terms of fibroblast proliferation (Kohase 
et al. 1987), EC proliferation (Thornhill and Haskard, 1990), procoagulant activity 
(Bevilacqua et al. 1986) and production of other cytokines such as IL-8 (Matsushima 
and Oppenheim, 1989) and IL-6 (Jablons et al. 1989). However, they do differ in some 
circumstances, since IL-l-B is unable to elicit the PMN respiratory burst, or produce the 
same degree of shock in animal models. It remains the case, however that these two 
structurally distinct and unrelated cytokines share a number of functions. This 
redundancy at first glance seems perplexing, but the existence of overlap may enhance 
the efficiency of the cytokine response in critical situations and permits synergistic 
relationships which can cause enormous amplification of the cytokine cascade should 
circumstances warrant it
1.3.3 The Chemokines
Movement of effector cells from the peripheral circulation to the tissues is a key event in 
the establishment of an inflammatory response. Recent studies have identified the 
existence of a superfamily of related cytokines, designated the chemokines, which can be
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divided into two groups on the basis of conserved cysteine residues in the peptide 
sequence; C-C and C-X-C. IL-8 is one of the best characterised of the chemokines, and 
has been implicated in lymphocyte homing and PMN infiltration (Baggiolini et al. 1989). 
It is also capable of triggering the respiratory burst (Serra et al. 1994). TNF-a can 
initiate the release of IL-8 from EC and AMs (Brown et al. 1993; Cohen et al. 1988) and 
many of the indirect effects of TNF-a on PMNs are likely to mediated by IL-8. PBM 
influx is thought to be under the control of two other chemokines, macrophage 
inflammatory protein (MIP-l-a) and monocyte chemotactic peptide (MCP-1). Both are 
products of AMs (Schall et al. 1993; Brieland et al. 1995), as is the chemokine 
RANTES (Folkard et al. 1995) which is a T cell and eosinophil chemoattractant. TNF-a 
can trigger the release of MIP-l-a and MCP-1 from AMs, but its relationship to 
RANTES is unknown. It is apparent however, that chemokine production does lag 
behind TNF-a production, thus suggesting a possible role for TNF-a in triggering the 
cytokine network, which can then lead to the establishment of a full inflammatory 
response.
1.3.4 Interleukin-10
IL-10 was first described as a cytokine synthesis inhibitory factor (CSIF) and was 
initially discovered to be a product of T cells (human and cell lines) (Yssel et al. 1992; 
Ralph et al. 1992), maximally synthesised at 24-48 hours after T cell activation. In 
mouse models it was defined as a product specifically of Th2 cells, with an ability to 
inhibit Thl cytokine synthesis (Yssel et al. 1992) and thus had similar properties to IL-4 
(Oswald et al. 1992a; Sieling et al. 1993; Mulligan et al. 1993), but a recent study on 
human T cell populations suggests that Thl and Th2 subsets cannot be distinguished on 
the basis of their production or response to IL-10 (Del Prete et al. 1993). The ability of 
IL-10 to inhibit pro-inflammatory cytokine (TNF-a, IL-1 and IL-6) release by human 
peripheral blood mononuclear cells (PBMCs) is well documented (Wang et al. 1994; De 
Waal Malefyt et al. 1991b; Fiorentino et al. 1991; Ralph et al. 1992). It has also been 
demonstrated to inhibit TNF-a and IL-8 release (Kasama et al. 1994; Cassatella et al. 
1993) and M IP-l-a production (Kasama et al. 1994) by PMNs. IL-10 can also prevent 
T cell proliferation by inhibiting accessory cell function in APCs (Ding and Shevach,
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1992; de Waal Malefyt et al. 1991b), and it achieves this possibly by reducing class II 
MHC expression (Ding et al. 1993b) or down-regulating expression of B7, the CD28 
ligand required for T cell activation (Enk et al. 1993). Interestingly, IL-10 appears to 
have no effect on dendritic cell accessory cell function (Macatonia et al. 1993). These 
anti-inflammatory properties of IL-10 generated much interest among those investigating 
inflammatory disease. IL-10 has been found to be elevated in septic shock (Marchant et 
al. 1994), ARDS (Donnelly et al. 1993), rheumatoid arthritis and osteoarthritis (Katsikis 
et al. 1994), and with reference to the latter, inhibition of IL-10 with antibodies elevated 
the pro-inflammatory cytokines in synovial fluid (Katsikis et al. 1994). Use of exogenous 
IL-10 has been demonstrated to prevent lethality in animal models of shock initiated by 
LPS infusion (Gerard et al. 1993; Howard et al. 1993; Smith et al. 1994) and the use of 
anti-IL-10 antibodies in one model using sub-lethal doses of LPS resulted in 30% 
lethality (Florquin et al. 1994). This effect may well be due to the inhibitory activity of 
IL-10 on TNF-a and IL-1. Interest in a putative regulatory role for IL-10 on TNF-a has 
been given further support by the finding that IL-10 can be produced by PBMs 
(Fiorentino et al. 1991; Wanidworanun and Strober, 1993; Abrams et al. 1992), possibly 
in response to LPS and TNF-a (Wanidworanun and Strober, 1993). Indeed, anti-TNF 
antibodies added to PBMC cultures reduced the production of IL-10, suggesting the 
possible existence of a sensitive autocrine regulatory loop in mononuclear cells. The fact 
that IL-10 is produced at least ten hours after TNF-a in mouse macrophages supports 
this hypothesis (Frei et al. 1993). Naturally, IL-10 does have relationships with other 
cytokines. It is thought that many of the anti-inflammatory effects of IL-10 could be due 
to inhibition of IFN-y production by Thl cells, so inhibiting the IFN macrophage 
activation pathway. IL-10 has also been frequently studied alongside IL-4 (see section 
1.3.5) since they are both Th2 products. It should also be pointed out however, that IL- 
10 is not merely inhibitory in its activity. Protein synthesis up-regulation has been 
observed in response to IL-10, notably elastin (Reitamo et al. 1994) which could be 
important in healing, and the regulatory proteins IL-1 receptor antagonist (IL-lra) and 
soluble TNF receptor (TNF-R) (Joyce et al. 1995).
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1.3.5 Interleukin-4 and Interleukin-13
IL-4 has frequently been described as an anti-inflammatory cytokine, with the ability to 
inhibit the production of IL-1 and TNF-a by AMs (Nishioka et al. 1991). A product of 
Th2 cells, it can inhibit the production of IFN-y by Thl cells, a property in common with 
IL-10 (Paul, 1987). There have been a number of studies exploring the relationship 
between IL-10 and IL-4. A putative synergy has been suggested to exist in the 
establishment of type IV hypersensitivity (Powrie et al. 1993) which may be important in 
sarcoidosis (see section 1.4). However, another study on Mycobacterium leprae 
demonstrated an antagonistic relationship, with IL-4 inhibiting IL-10 production by Th2 
cells (Sieling et al. 1993). Another cytokine closely associated with IL-4 is IL-13. This T 
cell product has been found to share many functions with IL-4 (Herbert et al 1994) and 
this is due at least in part to shared receptor components (Aversa et al. 1993). IL-13 has 
been demonstrated to down-regulate TNF-a production by human AMs and PBMs 
(Yanagawa et al. 1995; McKenzie et al. 1993), but its relationship to IL-10 and 
pulmonary inflammation remains to be established.
1.4 Sarcoidosis
Sarcoidosis is a chronic systemic disorder of unknown aetiology, characterised by the 
accumulation of inflammatory cells, most notably T cells and mononuclear phagocytes, 
into the tissues, and the development of non-caseating epithelioid granuloma with 
concomitant tissue injury developing in a minority of cases (Walters and du Bois 1995). 
Currently the incidence varies between three and fifty cases per hundred thousand in 
developed countries (Walters and du Bois 1995). Any part of the body can be affected, 
including the skin, where erythema nodosum may be the presenting symptom, and the 
eyes, where uveitis is often present (Walters and du Bois 1995). The lung however, is a 
favoured site; ninety per cent of sarcoidosis patients present with a pulmonary 
manifestation and twenty per cent will progress to some degree of pulmonary fibrosis. Of 
these cases, fifty per cent will die as a result of respiratory failure. The remainder of 











Sarcoidosis may be chronic or acute in nature, and the factors determining the likely 
progression of disease remain unknown (Walters and du Bois 1995). The actual cause of 
sarcoidosis remains contentious. It is likely that antigen recognition is important in the 
formation and maintenance of granulomas (Walters and du Bois 1995), but no specific 
causative organism has been identified. This is in contrast to other granulomatous 
diseases such as schistosomiasis (Thome and Mazza, 1991) {Schistosoma mansoni) and 
tuberculosis {Mycobacterium tuberculosis) (Rook et al. 1987), where pathogenicity has 
been established. It remains to be established whether sarcoidosis is caused by a specific 
pathogen or is an exaggerated response to common-place non-pathogenic 
organisms/antigens. The blood of sarcoidosis patients has been found to contain elevated 
serum immunoglobulins and immune complexes as well as autoantibodies (Semenzato, 
1986; Walters and du Bois 1995). This may suggest a failure of immune regulation, with 
a non-specific antigen acting as the trigger. The genetic element of the disease supports 
the likelihood of an inflammatory, rather than infectious disease. There is a higher dual 
incidence in monozygotic than dizygotic twins, and there is also a suggested MHC 
component which is hereditary, with HLA-B8, Al, CW7 and DR3 pre-disposing to 
acute sarcoidosis and HLA-B13 more prevalent in the chronic form of the disease 
(Semenzato, 1986). In addition there is circumstantial evidence of a racial element; 
African Americans have a higher risk of developing sarcoidosis than their Caucasian 
counterparts (Sharma and Johnson, 1988). Despite this evidence, the case is still strong 
for an infectious cause. Some studies have proposed the existence of mycoplasma in the
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lung of sarcoidosis patients, although it is unclear whether it is as a pathogen or 
passenger (Thomas and Hunninghake, 1987). There is also the Kveim-Siltzbach test 
(Munro and Mitchell, 1987) where human sarcoid spleen extract injected intra-dermally 
into sarcoidosis patients results in localised granuloma formation within four to six 
weeks. Interestingly, there is no effect in normal individuals suggesting that the 
sarcoidosis patients do have an abnormal response to whatever agent is contained within 
the splenic extract, be it immunological or antigenic in nature.
1.4.2 Pathology
Sarcoidosis is characterised by the presence of multiple non-caseating granulomas. In the 
lung they are found mainly in the alveolar septa (Crystal et al. 1981b), but they can also 
be found in the walls of the bronchi, and the pulmonary arteries and veins. In the 
broadest terms, granulomas are collections of mononuclear inflammatory cells at an 
inflammatory locus. The cells are mostly epithelioid in nature, but there are also some 
multi-nucleated giant cells present (Crystal et al. 1981b). Epithelioid cells are believed to 
be derived from the monocyte/macrophage lineage and are strongly HLA-DR positive. 
They also contain large amounts of endoplasmic reticulum suggesting that they are active 
secretory cells (Semenzato, 1986). The Kveim-Siltzbach test has shed light on the 
development of granulomas and suggests that the mononuclear cells arrive at a particular 
site (where antigen is present, possibly) and mature into epithelioid cells. During 
maturation the T helper CD4 cells infiltrate, with some CD8 cells and together with AMs 
and newly arrived monocytes, form a perimeter around the epithelioid cells (Munro and 
Mitchell, 1987). The granuloma is surrounded by extracellular material, or reticulin, 
which consists of a collagenous matrix. This rim of collagen is implicated in the fibrotic 
end-stage disease, which may be ultimately fatal (Crystal et al. 1981b). Indeed the 
behaviour of the dynamic granuloma is pivotal to the pathogenesis of sarcoidosis since it 
is this structure which is responsible for the alveolar structure derangement and the 
consequent pulmonary complications, such as breathlessness and the fibrosis of end- 
stage sarcoidosis (Crystal et al. 1981b; Semenzato, 1986).
The BALF in sarcoidosis has been shown to correlate closely with the lung histology 
from the interstitium (Hudspith et al. 1987). Attention has been drawn to the role of
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AMs in this disease due to increased recovery of these cells in the BALF (Hunninghake 
and Crystal, 1981). This may be due in part to enhanced proliferation in the lung 
compartment, since elevated GM-CSF, which is mitogenic for AMs has been found to be 
elevated in sarcoidosis (Itoh et al. 1990; Itoh et al. 1993). In addition, there is evidence 
for DNA synthesis in AMs, indicative of cell division (Lin et al. 1989). However there is 
evidence that the majority of the additional AMs are newly arrived PBMs which have 
entered the lung in response to chemotactic signals such as M IP-l-a and MCP-1 
(Crystal et al. 1981b). AMs in sarcoidosis have an immature morphology when 
compared to normal AMs (Hance et al. 1985). They also possess a number of monocyte 
antigens such as OKM1, which are generally lost upon maturation into macrophages 
(Hance et al. 1985). Enhanced clustering of sarcoidosis AMs with lymphocytes has been 
observed, which is a feature of monocyte antigen presentation. Indeed AMs, which are 
usually poor APCs are potent in the autologous mixed lymphocyte reaction when 
derived from patients with sarcoidosis (Lem et al. 1985; Gant et al. 1991). This is in part 
a reflection upon enhanced HLA-DR expression in these cells. This function is thought 
to be crucial in the establishment of granulomas. It is thought that the first step in 
granuloma formation is the phagocytosis of an antigen by AMs. In In vitro studies with 
macrophages, ingestion of antigens which are difficult to fully degrade, and are therefore 
persistent, leads to the development of granulomas (Dannenberg, 1975). These antigens 
are processed to some degree and presented to T helper cells in conjunction with class II. 
MHC, and their persistent presentation leads to an ongoing AM/CD4 response which is 
thought to establish and maintain the granulomas through cytokine release. Indeed 
enhanced cytokine release is also a feature of sarcoidosis AMs, with elevations in IL-l-B 
(Steffen et al. 1993; Yamaguchi et al. 1988; Hunninghake, 1984), IFN-y (Robinson et 
al. 1985), and TNF-a (Steffen et al. 1993; Terao et al. 1993; Foley et al. 1992) 
production by these cells. Sarcoidosis AMs also produce elevated levels of oxidant 
species, which may be important in the interstitial scarring, or fibrosis seen in a minority 
of patients (Baughman et al. 1988).
Clearly the T cell is very important in the pathogenesis of sarcoidosis, and they may 
account for up to sixty per cent of the effector cells in sarcoidosis BALF (Campbell et 
al. 1986), compared to less than eight per cent in normal BALF (Crystal et al. 1981b). 
Ninety per cent of the T cells are CD4, compared to sixty five to ninety per cent in the
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normal lung (Crystal et al. 1981b). The balance of T cell subsets is altered in the disease 
state in favour of T helper cells (Hunninghake and Crystal, 1981). Indeed a CD4:CD8 
ratio greater than five (Steffen et al. 1993) has been used to distinguish active 
sarcoidosis from the inactive disease by some investigators. The T cells in the lung 
contrasts sharply with those in the periphery, where T cell anergy has been observed 
(Hudspith et al. 1987; Hunninghake and Crystal, 1981), and the population is balance in 
favour of CD8 T cells. This accounts for the negative response to the tuberculin antigen 
skin test, used previously as a diagnostic indicator (Semenzato, 1986). Pulmonary T cells 
in sarcoidosis have a higher state of activation as determined by the presence of the 
activation marker CD69 (Crystal et al. 1981b) and their enhanced production of Thl 
cytokines such as IFN-y. This demonstrates that sarcoidosis is a compartmentalised 
disease. It is widely believed that cross-talk between AMs and T cells is fundamental to 
the inflammatory response in sarcoidosis, and that resolution of the disease is reliant 
upon T cell suppression by AMs (Ina et al. 1990). AMs are thought to have a major role 
in attracting effector T cells into the lung in sarcoidosis. Their importance has been 
highlighted by studies on sub-populations of AMs which have demonstrated a shift in 
phenotype away from the phagocytic tissue macrophage towards the accessory cell and 
T cell suppressor phenotypes (Campbell et al. 1986). These cells have been shown to 
promote and down-regulate T cell responses respectively (Spiteri and Poulter, 1991) and 
their balance may be crucial to the pathogenesis of the disease (Spiteri et al. 1992). 
Studies have been carried out on the functional properties of these distinct subsets, but 
as yet there has been no published data regarding their cytokine profiles, so it cannot be 
determined whether distorted AM populations are implicated in the changes in cytokine 
release exhibited by heterogeneous sarcoidosis AMs.
1.5 Cryptogenic fibrosing alveolitis
Cryptogenic fibrosing alveolitis (CFA), known as idiopathic pulmonary fibrosis (IPF) in 
the USA, is characterised by an influx of inflammatory cells into the alveolar space and 
progressive fibrosis of the pulmonary interstitium and air spaces (Crystal et al. 1984). 
Lone CFA presents with a pulmonary disorder, but fibrosing alveolitis is often present in 
patients with other diseases such as systemic sclerosis (Miller, 1990) and rheumatoid
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arthritis (Sewell and Trentham, 1993) and the characteristics of the fibrosis are 
indistinguishable from CFA. CFA occurs spontaneously in three to five per hundred 
thousand population in developed countries, the onset is usually between forty and 
seventy years of age (Tumer-Warwick et al. 1980). Once established, the disease is 
relentless in its progression, usually resulting in death from respiratory insufficiency 
within five years of the first symptoms (Stack et al. 1972).
1.5.1 Aetiolgy
The cause of CFA, like sarcoidosis, is unknown although numerous infectious causes 
have been alluded to. Persistent viral infection has been proposed as a trigger for the 
inflammatory process in CFA (Kawanami et al. 1979) since the onset of disease can 
sometimes be associated with flu-like symptoms. Also, a recent study has demonstrated 
the existence of Epstein Barr Virus in seventy per cent of type II pneumocytes 
(surfactant-secreting pulmonary cells) of CFA patients whereas it was only present in 
nine per cent of pneumocytes in control subjects (Egan et al. 1995). However it remains 
to be proven whether there is a definitive association between CFA and a pathogenic 
organism. Genetic factors may well be important, since there is a familial CFA which is 
clinically indistinguishable from the non-familial form of the disease, although the age of 
onset is much lower (Barzo, 1985). This genetic predisposition appears to be linked to 
an increased incidence of HLA-B8, B12, Dw6 and DR2 antigens and a decrease in the 
expression of HLA-Dw3 (Libby et al. 1983). This link is further strengthened by the 
association of fibrosing alveolitis with genetic disorders such as neurofibromatosis, 
tuberous sclerosis and Gaucher’s disease (Walters and du Bois 1995). An important 
trigger for the inflammatory process in CFA appears to be immune complexes, which 
have been found to be elevated in the BALF and plasma of CFA patients (Libby et al. 
1983).These are ingested by scavenging AMs, triggering cytokine release, a vital step in 
the initiation of the inflammatory response, and they can also trigger PMN degranulation 
directly (Zhang et al. 1992). It is not clear however, whether these complexes arise as a 
result of a specific pathogen, or they are a manifestation of an altered immune state 
responding to a harmless environmental agent. Not all environmental agents are harmless 
however, and fibrosis can arise from this type of injury. Pulmonary fibrosis is a feature of
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asbestosis and silicosis and is clinically very similar to CFA (Crystal et al. 1984). Fibrosis 
can also arise iatrogenically, the cardiac drug amioderone can elicit this response (du 
Bois, 1993), as can the anti-neoplastic agent bleomycin, which is administered intra- 
tracheally to produce an animal model of pulmonary fibrosis (Tomioka et al. 1989; 
Thrall et al. 1982).
1.5.2 Pathology
Pulmonary fibrosis is debilitating due to the derangement and progressive loss of alveolar 
structures as a result of excess collagen deposition. Collagens account for sixty per cent 
of the pulmonary extra-cellular matrix, and are interspersed with elastin, structural 
glycoproteins such as fibronectin, and thrombospondins important in wound healing 
(Campa et al. 1993).
The mechanisms which lead to the development of pulmonary fibrosis in CFA are 
partially understood. One of the most important events is the establishment of a 
neutrophil-mediated alveolitis. It is thought likely that intra-pulmonary cellular activation 
leads to production of chemokines such as IL-8, which attracts PMNs into the alveolar 
spaces from the periphery (Baggiolini et al. 1989). Once arrived in the lung the PMNs 
degranulate, releasing a host of proteolytic enzymes including collagenases (Libby et al. 
1983) which can inflict tissue damage directly. There is also the respiratory burst, a 
property of activated AMs and PMNs, whose products are extremely toxic to the local 
environment. Such toxicity leads to further tissue damage and the inevitable scarring. In 
normal circumstances, however the inflammatory response is finite, and following 
removal of the pathogen or irritant resolution of inflammation ensues. This does not 
appear to be the case in CFA. The alveolitis is maintained by the interplay of cytokine 
mediators and inflammatory cells. Ongoing inflammatory events lead to progressive 
fibrosis and eventually death. The role of the AM appears to be crucial in CFA, since it is 
able to release cytokines such as TNF-a and IL-10 which have the ability to promote and 
dampen down the inflammatory response respectively. Indeed the AM in CFA BALF is 
abnormal, with increased capacity to produce TNF-a, IL-8 and M IP-l-a (Standiford et 
al. 1993) and enhanced superoxide production (Schaberg et al. 1993). TNF-a itself may 
be an important mediator in CFA since apart from its ability to trigger PMN
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degranulation and the respiratory burst in AMs (Klebanoff et al. 1986) it is also 
mitogenic for fibroblasts (Kohase et al. 1987) and can increase their deposition of type I 
and III collagen (Campa 1993). TNF-a can also stimulate release of IL-8 from AMs, 
which is vital for the PMN infiltration, and correlates with the severity of CFA (Carre et 
a l  1991).
1.6 Adult respiratory distress syndrome (ARDS)
ARDS was first described in 1967 by Ashbaugh as a disease presenting itself in critically 
ill patients on the intensive therapy unit. It has since been established that ARDS 
develops in 2.5% of all ITU admissions in the United Kingdom, or 0.045 cases per 
thousand population (Webster et al. 1988). It has been recognised that there are pre­
disposing risk factors for the disease, notably severe trauma and sepsis and that ARDS 
develops in fourteen per cent of patients with these risk factors (Webster et al. 1988). 
The syndrome is characterised by respiratory insufficiency, mediated by an acute 
inflammatory process and culminating in severe pulmonary oedema and fibrosis. Death 
ensues within days or weeks in more than fifty per cent of cases (Hert and Albert, 1994). 
These processes can occur however, in other parts of the body, such as the kidney or 
liver, and in this respect ARDS can be considered the pulmonary manifestation of 
multiple organ failure (Fothergill et al. 1987; Hyers et al. 1987).
1.6.1 Aetiology
It has been recognised that certain conditions pre-dispose to the development of ARDS. 
Sepsis syndrome appears to invoke the highest risk of ARDS development, with more 
than forty per cent of sepsis patients succumbing to ARDS (Fothergill et al. 1987). Gram 
negative sepsis patients are particularly prone to ARDS progression, and it is thought 
that endotoxin/LPS may be a key trigger for the catastrophic inflammatory process seen 
in ARDS. The disease can also arise from perforated bowel and acute pancreatitis, where 
the likely existence of a systemic infection is very high. Similarly multiple trauma, 
resulting from road traffic accidents, gun shot injuries and the breaking of two or more 
long bones also pre-disposes, once again possibly as the result of serious infection, or by
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massive activation of the coagulation cascade (Pepe et al. 1982). However ARDS can 
also arise in circumstances where an infectious cause is unlikely. These include 
transfusion of more than eight units of blood, where activation of peripheral blood 
inflammatory cells may be a feature. Direct lung injury can also lead to ARDS, examples 
of which are aspiration of gastric contents and near-drowning episodes. Pulmonary 
infections such as pneumonia are also pre-disposing risk factors.
1.6.2 Pathology
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In contrast to CFA, this process is not necessarily relentless. It may stop at any time and 
can lead to complete resolution (Elliott et al. 1987).
Since ARDS is frequently associated with gram negative sepsis, one of the primary 
triggering events is considered to be endotoxin, a protein shed or released from lysed 
bacterial cell walls. The potential of endotoxin to invoke an inflammatory response with 
the hallmarks of ARDS has been demonstrated in animal models of acute lung injury 
utilising endotoxin (also known as lipopolysaccharide (LPS)) infusion (Rose et al. 1994). 
LPS is capable of triggering the release of monokines such as IL-1 and TNF-a from 
macrophages and monocytes, and these cytokines have been found to be produced in 
high quantities by AMs from ARDS BALF (Suter et al. 1992). These mediators are 
thought to trigger an inflammatory cascade involving other cytokines such as IL-8, 
MCP-1, IL-10 and IFN-y which can promote or regulate the inflammatory response.
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These mediators are not only released in response to LPS, however. Direct trauma to the 
lung can trigger cytokine release from damaged epithelial cells lining the lung walls and 
these cytokines, including TNF-a and IL-1 can lead to AM activation and triggering of 
the inflammatory cascade. The inflammatory process in ARDS is markedly similar to 
CFA, and it is likely that mediators such as TNF-a and EL-8 are similarly important 
Indeed a recent study by Donnelly and co-workers (1993) has indicated that high EL-8 is 
a prognostic indicator for ARDS in at risk subjects. Since the AM is a major source of 
both EL-8 and TNF-a it is likely that this cell is crucial to ARDS pathogenesis, and 
studies have demonstrated enhanced IL-8 activity in ARDS AMs (Donnelly et al. 1993), 
and an increased capacity to produce TNF-a (Tran Van Nhieu et al. 1993).
Figure 1.4 Proposed mechanisms of lung injury in ARDS




1.7 Aims of the Study
The inflammatory response is a fundamental defence mechanism, which if inappropriately 
controlled can lead to host tissue injury. TNF-a is a key inflammatory cytokine. 
Produced early in the inflammatory response, it has the ability to elicit production of 
other mediators within the cytokine network, with beneficial, but also potentially
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deleterious effects. TNF-a itself has known pathogenic effects in the lung, including 
triggering of oxygen radical and proteolytic enzyme release by phagocytes, giving rise 
directly and indirectly to pulmonary oedema and the development of tissue fibrosis. It is 
also elevated in a number of inflammatory disease states. The major source of pulmonary 
TNF-a is thought to be the AM, a sentinel cell which represents the first line of defence 
in the lung. AMs are also known to be altered in pulmonary inflammatory disease. This 
thesis is based upon the hypothesis that AM-derived cytokine regulation is abnormal in 
pulmonary inflammatory disease and has focused specifically on the regulation of AM- 
derived TNF-a. The aims were as follows:
(1). To determine the profile of TNF-a release in AMs and PBMs from normal subjects 
and to examine the regulatory mechanisms involved in its production and bioactivity, 
specifically in relation to IL-10 and TNF-R, and to establish whether these mechanisms 
were lung-specific or extended to the periphery.
(2). To examine the relationship between AM and PBM-derived TNF-a, TNF-R and IL- 
10 in subjects in the three distinct inflammatory lung diseases sarcoidosis, CFA and 
ARDS, and to determine whether any alterations in their relationship were systemic or 
compartmentalised in nature.
(3). To purify AM subpopulations from normal subjects and those with inflammatory 
lung disease in order determine any disease-specific phenotypic variation, or alteration in 
cytokine profile and what implications this may have for pulmonary TNF-a regulation.
(4). To generate the AM phenotypes in vitro in PBMs and monocytic cell lines to permit 
more detailed study of the functional relationships and cytokine profiles of the 
subpopulations.
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2. MATERIALS AND METHODS
2.1 Bronchoalveolar lavage.
Bronchoalveolar lavage fluid (BALF) was obtained from patients and normal volunteers 
consenting to undergo fibreoptic bronchoscopy. Prior to the procedure subjects were 
injected intramuscularly with 0.6 mg of atropine sulphate to reduce airway secretions, 
followed by intravenous sedation with 0-2 mg Alfentanil (Janssen) and 0-10 mg 
Midazolam (Roche). Topical lignocaine was administered to anaesthetise the upper 
airway. 0.9% sterile saline (Baxter Healthcare) was buffered to pH 7.4 with 8.4% sterile 
sodium bicarbonate and instilled into the right middle lobe or lingula in four 60 ml 
aliquots. The resultant BALF was then aspirated into glass bottles (siliconised to 
minimise macrophage adherence), kept at 4°C. Lavages collected for RNA analysis were 
immediately buffered at this point with 100 mis of chilled RPMI 1640 culture medium 
(Gibco) to maximise viability and thus prevent release of RNAses from lysed cells.
2.2 Alveolar macrophage preparation
Chilled BALF was strained through a single layer of sterile coarse gauze (Robinson’s of 
Chesterfield) to remove mucus clumps, and the filtrate was then washed twice at 500 g, 
4°C in complete media consisting of RPMI 1640 supplemented with 100 U/ml penicillin, 
100 pg/ml streptomycin and 0.5 pg/ml fungizone (all Gibco). If large numbers of 
erythrocytes were present in the resultant cell pellet they were lysed by treatment with 
ammonium chloride solution (see appendix). The pellet was then resuspended in 
complete media and viability assessed by 0.1% trypan blue exclusion. Cytospins of total 
BAL cells were taken at this point (see 2.6.1). The cells were then incubated at a 
concentration of 2 x 106per ml in tissue culture petri dishes (Falcon) (no more than 3 mis 
per dish) for 2 hours at 37°C. The non-adherent cells were then discarded and the 
residual non-adherent cells removed by gentle rinsing in PBS. The adherent macrophages 
were removed from the dishes by gentle scraping with a cell scraper (Costar) and a 
cytospin taken for differential staining with Diff-Quick (Baxter-Dade) (see appendix).
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Alveolar macrophages established >95% pure by this method were cultured in complete 
media at a concentration of 1 x 106 cells per ml, in microtitre plates (Nunc), 100 pi per 
well. Cells were cultured for 24 hours unless stated and the viability rechecked with 
trypan blue. Supernatants were harvested after incubation in humidified 37°C incubators 
with 5% C 02, and stored at -70°C until cytokine determination.
2.2.1 Preparation of AMs from ITU patients
Adherence could not be used to purify AMs from ITU patients since the neutrophils in 
the BALF were often in an activated state and thus adhered strongly to plastic. To 
surmount this problem the cells were purified by negative selection with magnetic beads 
(Dynal). Cells were incubated for 30 minutes at 4°C with mouse anti-human CD66b 
(The Binding Site) to remove granulocytes, and mouse anti-human CD3 (Dako) to 
remove T cells. The cells were then washed for 5 minutes in complete medium before 
incubation at 4°C with the magnetic beads (100 pi of beads per 107 cells). The 
contaminating cells were then removed by exposure to a magnet for 1 minute. The 
remaining cells were then washed once in complete media for 5 minutes at 500 g and a 
cytospin taken to assess purity. The resultant AMs were >95% pure, with >90% 
viability. They were then cultured as above.
2.2.3 Preparation of AMs for sub-population analysis
AMs were purified into 3 phenotypically distinct populations; RFD1-D7+, RFD1+D7- 
and RFD1+D7+ according to the protocol of Spiteri et al. (1992). AMs were adherence 
purified as described in section 2.2. The non-adherent cells were incubated with anti- 
CD3 magnetic beads for 30 minutes at 4°C, and the CD3 positive contaminating 
lymphocytes were removed by exposure to a magnet for 1 minute. The remaining cells 
were washed once in culture medium at 500 g, resuspended at 1 x 106 cells per ml and 
cultured for 24 hours. Cytospins were taken to determine purity, and these cells were 
found to be >85% RFD1+D7- accessory AMs.
The adherent AMs, containing RFD1-D7+ and RFD1+D7+ cells were divided in to 
separate cell suspensions of 1 x 106 cell per ml. One population was exposed to
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magnetic beads conjugated with anti-RFDl antibody for 30 minutes at 4°C, with a bead 
to cell ratio of 10:1. The RFD1 positive cells were then removed by exposure to a 
magnet as described above, and the remaining cells washed, resuspended and cultured in 
culture medium as previously described. Cytospins were taken and immunocytochemical 
analysis revealed > 85% pure RFD1-D7+ tissue macrophages.
The remaining adherent AMs were layered on to a metrizamide gradient (14.5 g 
metrizamide dissolved in RPMI 1640, 5 mis used for each separation). This was 
centrifuged at 650 g for 10 minutes at room temperature. This process separated the less 
dense RFD1+D7+ supressor AMs from the tissue macrophages, which pelleted at the 
bottom. The AMs at the interface were removed with a pastette and were washed, 
resuspended and cultured as above. Immunocytochemical analysis of this population 
revealed > 80% pure RFD1+D7+ supressor AMs.
2.3 Peripheral blood monocyte preparation
Venepuncture was performed on healthy volunteers, and on bronchoscopy subjects prior 
to the procedure. Blood was collected into heparinised tubes, or for larger volumes into 
blood packs (Fenwall, Baxter Healthcare) pre-treated with 10 U of Heparin per ml of 
blood. Plasma was removed by centrifugation at 1000 g, 4°C for 6 minutes, and stored at 
-70°C until required. The remaining blood was diluted to twice the original volume with 
complete media, and carefully layered on to a FicoU-Hypaque density gradient (specific 
gravity 1.077, Pharmacia). After 30 minutes centrifugation at 400 g, without braking, the 
resultant interface of mononuclear cells was removed, washed and resuspended in 
complete media supplemented with 10% heat-inactivated foetal calf serum (FCS) 
(Gibco). The cells were then allowed to adhere for 1 hour in tissue culture flasks (15 x 
106 cells per 75 cm2 flask (Nunc)) at 37°C, 5% CO2. The non-adherent cells were 
removed by rinsing with PBS. The adherent peripheral blood monocytes (PBM) were 
then removed by gentle scraping, washed and resuspended in complete media. Cells were 
>95% viable as assessed by trypan blue exclusion, and were >95% PBM as determined 
by morphology under diff-quick staining.
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2.3.1 Twenty four hour monocyte culture
Isolated PBMs were resuspended at 1 x 106 cells per ml in complete media and cultured 
in 96 well microtitre plates, 100 pi per well. They were co-incubated with the cytokine 
mediators of interest and the supernatants harvested after 24 hours. These were stored at 
-70°C until cytokine determination. Viability was checked with trypan blue after cell 
culture.
2.3.2 Monocyte-derived macrophage culture
Isolated PBMs were plated out on to tissue culture petri dishes (Falcon) in complete 
media supplemented with 10% FCS. They were incubated either alone or in the presence 
of a stimulus for up to 2 weeks. Media was changed every 3-4 days. Monocyte-derived 
macrophage (MDM) morphology was determined by taking cytospin samples (see 
section 2.6.1) at intervals over the 2 week period and immunostaining for macrophage 
markers (see sections 2.6.4/5).
2.4 Culture of cell lines
2.4.1 U937 cells
The human histiocytic lymphoma cell line U937 (Larrick et al. 1980) was cultured in 
complete media supplemented with 10% FCS at 37°C, 5% CO2 up to a density of 1 x 
106 cells per ml. The cells were then either diluted 1:5 with fresh media to maintain the 
culture or isolated for experimentation. Before isolation the cells were directed to a more 
macrophage morphology by overnight treatment with 10 nM phorbol myristate acetate 
(Sigma) (other maturation factors were also utilised (see Chapter 7)). The cells were 
then rinsed and detached by gentle scraping with a cell scraper before they were washed 
and resuspended in complete media at 1 x 106 cells per ml. They were then added to 96 
well tissue culture microtitre plates, or 75 cm2 tissue culture flasks and cultured for up to 
24 hours with the appropriate mediators at 37°C, 5% CO2.
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2.4.2 THP-1 cells
The human monocytic cell line THP-1 (Tsuchiya et al. 1980) was maintained in complete 
media supplemented with 10% FCS at 37°C, 5% CO2 in a humidified incubator. They 
were fed at intervals of 4-5 days to maintain the optimum density of 1 x 106 cells per ml. 
Various maturation factors were utilised to achieve macrophage morphology for 
experimentation (see Chapter 7).
2.5 Measurement of protein by enzyme-linked immunosorbent assay (ELISA)
2.5.1 TNF-a
TNF-a protein was determined with a sandwich ELISA, whose antibodies were kindly 
donated by Dr Sue Stephens of Celltech, UK. These antibodies showed no cross­
reactivity with other known cytokines, and their activity was not affected in the presence 
of human plasma or serum. ELISA plates (Nunc Maxisorp) were pre-coated with 
CB0006 mouse anti-human TNF monoclonal antibody at a concentration of 8 |ig/ml, in 
coating buffer (see appendix for constitution of ELISA buffers) and stored for up to a 
month before use. On the day of use TNF-a standards (NIBSC) (range 16 - 1000 pg/ml) 
and samples were diluted 1:4 in sample buffer and added, 50 pi per well in duplicate. An 
inter-asssay control TNF-a standard was added to each plate to assess variance. Inter­
assay variance was less than 3 %. The plates were then incubated at room temperature 
for 1 hour with agitation. The plates were washed 3 times with wash buffer by a 
platewasher (Titertek) and patted dry. Rabbit anti-human TNF (WBRA-PG2) polyclonal 
antibody was then added 100 pi per well at a concentration of 2 pg/ml and incubated for 
a further hour with agitation. Following 3 washes, 100 pi per well goat anti-rabbit IgG 
peroxidase (Sigma) diluted 1:500 was added and incubated for 30 minutes with 
agitation. After 4 washes with PBS 200 pi of tetramethylbenzidine (TMB) substrate 
(Fluka) was added and left for 30 minutes in the dark to develop. The reaction was 
stopped by addition of 50 pi of 1M H2SO4 and the plates read at 450 nm (reference 
wavelength 630 nm) on a platereader. Sample values were extrapolated from the 
standard curve, with a detection limit of 30 pg/ml TNF-alpha.
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2.5.2 Interleukin-10
ELISA plates were coated with 1 pg/ml rat anti-human IL-10 monoclonal antibody 
(Pharmingen), 50 pi per well in coating buffer (see appendix), and left overnight at 4°C. 
The following day the plates were washed twice with wash buffer using a platewasher 
and patted dry. The wells were then blocked with 200 pi of PBS/10% FCS (sample 
buffer) and incubated at room temperature for 2 hours. The plates were subsequently 
washed twice, and IL-10 standards, range 1000 - 2 pg/ml (courtesy of DNAX) and 
samples diluted 1:4 in sample buffer were added, 100 pi per well. After a 4 hour 
incubation at room temperature the plates were washed 4 times with wash buffer. 2 
pg/ml biotinylated rat anti-human monoclonal antibody (Pharmingen), diluted in sample 
buffer was then added, and incubated at room temperature for 45 minutes. Neither 
antibody showed cross-reactivity with other known cytokines, and their activity was not 
affected in the presence of human plasma or serum. After 6 washes with wash buffer a 
1:400 dilution of avidin peroxidase (Sigma) was added, 100 pi per well and incubated 
for 30 minutes at room temperature. The plates were then washed 8 times and 100 pi of 
TMB substrate (see appendix) added and allowed to develop at room temperature in the 
dark for 10 minutes. The reaction was then stopped by addition of 50 pi of 1M H2SO4 
and the plates read at 450 nm (reference wavelength 630 nm). Sample values were 
extrapolated from the standard curve, which gave a detection limit of 4 pg/ml.
2.5.3 p-55 TNF receptor (TNF-R)
ELISA plates were coated with 2 pg/ml IV4E monoclonal antibody (courtesy of Dr 
Terje Espevik, Trondheim, Norway) (Liabakk et al. 1993) in coating buffer (see 
appendix), 100 pi per well, and incubated for 12 hours at 4°C. This antibody showed 
cross-reactivity with other known cytokines, and its activity was not affected in the 
presence of human plasma or serum. The plates were then blocked with PBS containing 
0.5% BSA for 1 hour at 37°C. The wells were then washed 3 times on a platewasher 
with PBS containing 0.1% Tween 20 (Sigma). Samples diluted 1:4 in sample buffer were 
then added, together with the recombinant p-55,100 pi per well and the plates incubated 
overnight at 4°C. The following day plates were washed 4 times in wash buffer, and 100 
pi of biotinylated TNF-a, 50 ng/ml was added to each well. The plates were incubated
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Figure 2.1 TN F-a ELISA standard curve
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Figure 2.2 IL-10 ELISA standard curve
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for 1 hour at 37°C and then washed 4 times with wash buffer. The bound TNF was 
detected with streptavidin peroxidase 1:400 dilution, incubated for 30 minutes at room 
temperature, and the plates washed 4 times. TMB substrate was then added 200 |il per 
well and the plates left to develop in the dark for 15 minutes. The reaction was stopped 
with 50 pi of 1M H2SO4 and the plates read at 450 nm (reference filter 630 nm) on a 
platereader. Sample values were calculated from the resultant standard curve. The 
detection limit was 16 pg/ml
2.6 Detection of protein by immunohistochemistry
2.6.1 Cytospins
Cytospins were generated in order to assess cell suspensions for their purity e.g. AM and 
PBM purification, and also for intra-cellular staining of cytokines. In addition they were 
also utilised for phenotypic identification. The cells in question were resuspended in 
complete media at a density of 3.5 x 105 cells per ml and 200 pi was spun down on to 
each frosted glass slide (Berliner) (pre-treated with poly-L-lysine (Sigma)) in a 
cytocentrifuge (Shandon). After a 5 minute spin at 500 rpm the slides were removed and 
air dried for 30 minutes. If the cytospins were being used for purity assessment they were 
stained following air drying with Diff-Quick stain (see appendix). If the slides were 
destined for immunostaining they were wrapped in tin foil and stored at -70°C until 
required. Prior to the immunostaining procedure, the slides were defrosted and fixed in 
1:1 Chloroform:Acetone for 10 minutes to permeabilise the membranes. The cell area 
was then enclosed within a hydrophobic film drawn with a PAP pen (Agar Scientific) to 
prevent leakage of antibody solution from the staining site. All immunostaining was 
performed in humidified chambers to prevent drying out of the cells.
2.6.2 TNF-a immunostaining
Fixed cytospins were blocked for 2 hours with 2% FCS at 37°C, before addition of the 
polyclonal rabbit anti-human TNF WBRA-PG2 antibody (courtesy of Celltech) at a 
1:500 dilution. Rabbit IgG (Sigma) was added to control slides at the same 
concentration. Sections of human tonsil were used as a positive control. Following a 1.5
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hour incubation at 37°C the slides were washed in PBS for 5 minutes. They were then 
incubated for a further 45 minutes at 37°C with goat anti-rabbit IgG peroxidase (Sigma), 
1:500 dilution, before washing and addition of the 3,3’-diaminobenzidine (DAB) 
substrate (see appendix). This was incubated for 10 minutes at 37°C to develop a brown 
colour. The reaction was stopped by immersion in distilled water and the slides were 
counterstained with Mayer’s haematoxylin (Sigma) for 5 minutes. They were then 
mounted in 9:1 glycerol:PBS and examined on a microscope at x 400 magnification. Five 
fields of view were observed and stain intensity was determined as follows:
0 -  no stain,+ = weak stain,++ = moderate stain,+++ = strong stain
2.6.3 IL-10 immunostaining
Fixed, test slides and the positive control slides (IL-10 transfected COS-7 cells) were 
blocked for 2 hours with PBS/2% FCS, before incubation for 1.5 hours at 37°C with 
biotinylated rat anti-human IL-10 monoclonal antibody (Pharmingen). Negative control 
slides were incubated with an identical concentration of rat IgG (Sigma). The slides were 
then washed as above before a 45 minute incubation with a 1:400 dilution of streptavidin 
peroxidase. Following a further wash the DAB substrate was added and left for 15 
minutes in the dark to develop. Slides were analysed for positivity as above.
2.6.4 AM phenotypic analysis
AM phenotypes were determined by their expression of the markers RFD1 and RFD7. 
RFD1 is a cell membrane antigen identified by the RFD1 IgM mouse antibody, whereas 
the RFD7 mouse IgGl antibody picks up an intracellular antigen. Both antibodies were 
supplied by Dr Len Poulter of the Royal Free Hospital. Fixed cytospins were incubated 
with a 1:5 dilution of each antibody in PBS (pH 7.6), with the control cells incubated 
with mouse immunoglobulins (Sigma) in PBS. Sections of human tonsil were used as a 
positive control. Following a 1 hour incubation the slides were washed for 2 minutes in 
PBS before incubation with a 1:30 dilution of fluoroscein isothiocyanate- (FITC)- 
conjugated rabbit anti-mouse IgM (Sigma) and a 1:50 dilution of TRITC-conjugated 
goat anti-mouse IgGl (Sera-Lab). These secondary antibodies were incubated for 45
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minutes before being washed for 2 minutes in PBS. 9:1 glycerol:PBS was then dropped 
on to the slides which were then covered with a coverslip (Chance-Propper) and kept at 
4°C in the dark before viewing under oil at x 1000 magnification on a fluorescent 
microscope (Nikon Optiphot). Fluorescence was compared to the control cells and 
monitored in 5 fields of view (see Plate 2.1).
2.6.5 CD68 immunostaining
CD68 is a pan-macrophage marker and was thus used to demonstrate the percentage of 
AMs on the cytospins. Briefly, cytospins were treated as above, but incubated with a 
mouse anti-human antibody to CD68 (Dako), at a 1:50 dilution. After a 1 hour 
incubation the slides were washed as above and then incubated with a 1:20 dilution of 
FITC-conjugated anti-mouse Ig’s (Dako). Following a further 45 minute incubation the 
slides were washed, prepared and analysed as above (see Plate 2.1).
2.7 Northern Analysis
2.7.1 Cell culture
AMs, PBMs and U937 cells were all cultured in complete media on tissue culture petri 
dishes, 1 x 107 cells per point at a concentration of 1 x 106 per ml. They were cultured 
with and without inflammatory mediators for periods of up to 24 hours, before removal 
of the culture supernatant and rinsing with sterile PBS.
2.7.2 RNA extraction
All buffers, chemicals, glassware and disposables used in RNA work were sterile and the 
RNAses were removed by treatment with Diethylpyrocarbonate (DEPC). Following 
rinsing the cells were lysed with a guanidinium isothiocyanate buffer (see appendix for all 
buffers used in northern blotting) as previously described (Jonas et al. 1985; 
Chomczynski and Sacchi, 1987). 2 mis of cold buffer was added to 1 x 107 cells, kept 
on ice and the cells scraped vigorously with a cell scraper to disrupt the membranes. The
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Plate 2.1 RFD immuno-fluorescent staining
RFD1+ AM, with a negatively stained RFD1- AM in the foreground
A mixed cytospin of RFD7+ and RFD7- AMs
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Plate 2.2 CD68 immuno-fluorescent staining
A negative control AM incubated with the corresponding isotype mouse IgGl
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lysates were then transferred into 15 ml sterile centrifuge tubes (Falcon) and kept at - 
70°C overnight to facilitate the lysis process. The following day the lysates were 
defrosted on ice and the RNA extracted by addition of 1:1 phenol chloroform and phenol 
extraction buffer. The samples were then centrifuged at 4000 rpm for 10 minutes at 4°C. 
The aqueous phase containing the RNA was transferred to fresh tubes and the process 
repeated. Chloroform isoamyl alcohol (24:1) was then added for a further spin at 4000 
rpm, 4°C for 7 minutes and the aqueous phase transferred to fresh tubes containing 300 
pi of sodium acetate. 3 mis of propan-2-ol was then added and the tubes mixed gently 
before being placed at -70°C for at least an hour. After defrosting the lysates were 
centrifuged at 21000 rpm, 4°C in an ultracentrifuge (Beckman) for 1 hour. The 
supernatants were removed and the RNA precipitates kept in 1 ml of ice cold ethanol 
overnight at -70°C. The following day the pellets of RNA were washed 3 times in ice- 
cold ethanol in a microfuge (Jouan) at 4°C and left in a fume hood for an hour to remove 
all moisture. The pellets were then resuspended in 30 pi of DEPC-treated water. The 
RNA content was determined by addition of 2 pi of the RNA solution to 980 pi of 0.1 M 
NaOH in a quartz cuvette and measuring the absorbance at 260 nm and 280 nm on a 
spectrophotometer. 260 nm gave the RNA content and 280 nm gave the protein content, 
which should never be more than 50% of the RNA value. The RNA concentration was 
established as follows:
A260 x dilution factor x 40 = fig/ml RNA
The RNA concentration was then corrected to ensure equal loading of 10 pg of RNA 
per lane.
2.7.3 Gel electrophoresis of RNA samples
Samples were run on 1% agarose gels with formaldehyde which were set in gel trays in 
the fume hood 1 hour before use. The RNA samples (30 pi volumes) were incubated 
with 30 pi of sample buffer containing 1 pi of 5 mg/ml ethidium bromide, vortex mixed 
and incubated on a hot block (Techne) at 80°C for 30 minutes. 2.5 pi of bromophenol 
blue was then added to each sample and mixed, before loading of the samples on to the 
gel. The gel was maintained in 3-(N-morpholino) propane sulphonic acid (MOPS) buffer 
at 4°C in a horizontal sub-cell (Hoefer) and the electrophoresis performed at 100 V for
2.5 hours to separate out the bands of RNA according to size. The gels were then
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photographed under UV light on a transilluminator (UVP Products) and the image 
photographed with a Polaroid to establish equal loading. The gel was then washed in 
diethyl pyrocarbonate (DEPC) treated water for 30 minutes to remove traces of 
formaldehyde before transblotting the RNA material overnight on to positively charged 
nylon membranes (Boehringer Mannheim) using 20x SSC, and paper towels as the wick.
2.7.4 Probing of nylon membranes
Following overnight transfer of RNA the membranes were fixed by baking in an oven at 
120°C for 30 minutes. The blots were then pre-hybridised at 42°C with 20 mis of 
hybridisation solution for an hour before incubation overnight at 42°C with the DIG- 
labelled oligo probes (R and D Systems) diluted to 10 ng/ml in 2.5 mis of hybridisation 
solution. The following day the blots were washed at the hybridisation temperature with 
SSC and 0.1% SDS, before washing for 5 minutes with shaking, at room temperature 
with a maleic acid (buffer 1 - see appendix) wash buffer. The blots were then blocked for 
30 minutes with a combination of maleic acid and blocking stock solution (buffer 2) 
before a 30 minute incubation with 20 mis of anti-DIG antibody conjugate diluted 
1:10000 in buffer 2. The blots were then washed 3 x 10 minutes in wash buffer before 
addition of 1 ml of lumigen substrate (Boehringer Mannheim) diluted 1:100 in buffer 3. 
The blots were sealed in a fresh hybridisation bag and incubated in the dark for 30 
minutes at 37°C before exposing to x-ray film (Kodak omat) for 1-2 hours in cassettes in 
the dark. The autorads were then developed immediately in a film developer (Fuji).
2.7.5 Densitometry
Developed autorads and gel Polaroid’s were analysed on a calibrated densitometer (GS- 
670, Bio-Rad). The images were relayed on to a processing package (Molecular Analyst, 
Bio-Rad) which permitted volumetric analysis of RNA bands. Polaroid photographs of 
ribosomal RNA were also scanned on the densitometer to determine the quantity of 




Data were analysed using the CStat package for Windows on the PC. ELISA data 
following a normal distribution was analysed using the Student’s Paired T Test, whereas 
non-parametric data was subjected to a Mann Whitney U Test. Wilcoxon Signed Rank 
was the preferred test for analysis of AM phenotype distribution. All data were 
expressed as mean ± SEM. Statistical significance was considered if p  values were less 
than 0.05. Statistical evaluation was only performed if sample groups exceeded n = 3.
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3. TUMOUR NECROSIS FACTOR-a REGULATION BY 
INTERLEUKIN-10 IN NORMAL SUBJECTS
3.1 Introduction
TNF-a was initially recognised as a cytokine which was capable of inducing vascular necrosis 
and tumour shrinkage in mice (Carswell et al. 1975). It has since become apparent that TNF- 
a  is a highly pleiotropic mediator capable of inducing many beneficial as well as deleterious 
effects during an inflammatory response, including vascular endothelial cell permeability 
(Burke-Gaffney and Keenan, 1993; Nawroth and Stem, 1986; Horvath et al. 1988), PMN 
influx and degranulation (Chollet-Martin et al. 1992) and fibroblast proliferation (Sugarman 
et al. 1985). TNF-a can also elicit the release of a range of other pro-inflammatory cytokines 
(Billiau and Vandekerckhove, 1991; Jablons et al. 1989; Camussi et al. 1991). This wide 
range of physiological responses indicates that inappropriate regulation of TNF-a could lead 
to undesirable injurious effects. This is supported by the presence of elevated levels of TNF-a 
release in pulmonary inflammatory diseases such as sarcoidosis (Foley et al. 1992), fibrosing 
alveolitis (Zhang et al. 1993) and ARDS (Tran Van Nhieu et al. 1993; Jacobs et al. 1989), 
and amelioration of animal models of lung injury by the use of anti-TNF antibodies (Piguet et 
al. 1989; Tracey et al. 1987a). Understanding the regulation of pulmonary TNF-a may give 
insight into its role in the pathogenesis of lung injury, and has stimulated research into 
identifying mediators which may fulfill this role.
IL-10 may be one such mediator. A cytokine product of T and B lymphocytes (Yssel et al.
1992) as well as PBMs and macrophages (Fiorentino et al. 1991; Sieling et al. 1993; Howard 
and OGarra, 1992), it has known anti-inflammatory properties such as inhibition of antigen 
presenting cell function (Ding and Shevach, 1992; Villanueva et al. 1993) by reduction of B7 
(Ding et al. 1993a) and class II MHC expression on macrophages (de Waal Malefyt et al.
1993), and monocytes (de Waal Malefyt et al. 1991b). Formerly known as cytokine synthesis 
inhibitory factor (CSIF) its modulation of cytokine production has been documented,
43
showing an ability to inhibit the release of IL-1 (Fiorentino et al. 1991; Ralph et al. 1992; 
Muldoon et al. 1994), IL-6 (Fiorentino et al. 1991) and IL-8 (Cassatella et al. 1993) from 
murine peritoneal macrophages and human blood monocytes. IL-10-mediated inhibition of 
TNF-a has been demonstrated in macrophage cell lines (Fiorentino et al. 1991), mouse 
peritoneal macrophages (Oswald et al. 1992b; Bogdan et al. 1992) and PBMs (Ralph et al. 
1992; Muldoon et al. 1994).
In order to determine the possible pathological effects it was first essential to determine the 
relationship between IL-10 and TNF-a in the normal human lung. This study has investigated 
the effect of IL-10 on TNF-a mRNA and protein production in human PBMs and AMs, in 
order to partially characterise the mechanisms of TNF-a inhibition by IL-10 in these cell 
species. TNF-a protein has been measured by ELISA to establish any effects of IL-10 on 
protein release. In addition mRNA was isolated from AMs and PBMs to determine any 
effects IL-10 may have at the level of transcription. The protein synthesis inhibitor 
cyclohexamide and transcriptional inhibitor actinomycin D were utilised to determine the 





AMs for this study were obtained from seven non-smoking healthy volunteers (mean age
25.3 years ± 1.2) consenting to fibreoptic bronchoscopy and bronchoalveolar lavage (BAL) 
and venepuncture was performed on all bronchoscopy subjects prior to the procedure. Blood 
was collected into heparinised tubes or blood collection bags (Fenwall, Baxter Healthcare). 
50 mis of blood was taken for supernatant analysis, 500 mis for northern analysis. AMs and 
PBMs were isolated from BAL and peripheral blood respectively to establish any differences 
in the relationship between IL-10 and TNF-a in the lung and in the periphery.
Cell Culture
AMs and PBMs were cultured for twenty four hours since this was the optimum timepoint 
for TNF-a protein recovery in the supernatants. Control samples were cultured in medium 
alone without FCS, although each control was matched with a sample containing medium 
plus 5 pg/ml polymyxin B. This compound binds to LPS, and since these samples if 
contaminated with LPS would have lower detectable cytokine levels than the control this 
enables detection of contaminated cultures. Such cultures were eliminated from the study. 
Cells were stimulated with LPS at a dose of 10 pg/ml - a dose found to be optimum for TNF- 
a  production by AMs. The optimum concentration for PBMs was 100 ng/ml, but is was 
desirable to have identical stimuli for both cell species since this is a likely scenario in vivo.
Protein determination
Recombinant human IL-10 was added at a dose range of 1 - 200 U/ml to the cultures, one 
hour prior to LPS addition. Spontaneous TNF-a released by AMs and PBMs was low and 
extrinsic IL-10 had no effect on basal levels (data not shown) therefore only the effects of IL- 
10 on LPS-induced TNF-a were explored. TNF-a protein was determined by ELISA as 
described in Chapter 2.
mRNA determination
PBMs were cultured in the presence of 10 pg/ml LPS alone, and with a dose range of IL-10 
(0.1 -100 U/ml). Control samples contained medium alone. The temporal window for IL-10
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inhibition of TNF-a was established by addition of IL-10 at various time points before and 
after LPS addition. The established optimum for IL-10 addition was found to be 100 U/ml 
IL-10 added 1 hour prior to LPS and this was selected for the AM experiments. Anti-IL-10 
antibody was added at 10 pg/ml to some AM cultures immediately prior to IL-10 to 
determine the specificity of the IL-10 response. 5 pg/ml of the translational inhibitor 
cyclohexamide (Obrig etal. 1971) was administered to some cultures to determine whether 
de novo protein synthesis was required to mediate the effects of IL-10. 5 pg/ml actinomycin 
D, a transcriptional inhibitor (Sobell, 1985) was used to arrest all protein synthesis to 
establish whether the rate of steady state mRNA degradation was altered by IL-10. TNF-a 
mRNA content was determined by northern analysis as described in Chapter 2. The mRNA 
content was related to the levels of ribosomal RNA loaded on to the gels. The detection of 
mRNA from a housekeeping gene such as 6-actin would have been more appropriate but 
methodological difficulties prevented this.
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3.3 Results
3.3.1 IL-10 suppresses the production of extracellular TNF-a from LPS-treated AMs 
and PBMs in a dose and time dependent manner
Constitutively AMs and PBMs produced low levels of TNF-a protein (0.641 ng/ml ±0.160 
and 0.058 ng/ml ± 0.018 respectively) which was elevated to 3.508 ng/ml ± 0.629 and 2.035 
ng/ml ± 0.284 respectively when maximally stimulated with LPS (Figure 3.1a and b 
respectively). The LPS-mediated increase in TNF-a protein was significantly abrogated by 
IL-10 at doses of 50 U/ml and above. 50 U/ml IL-10 reduced AM TNF-a protein by 37% to 
give 2.035 ng/ml ± 0.284 (p < 0.01) whereas PBMs gave a greater than 60% reduction which 
translated to 0.698 ng/ml ± 0.167 (p < 0.01). These data demonstrate that IL-10 significantly 
suppresses LPS-induced extracellular TNF-a from AMs and PBMs.
3.3.2 IL-10 inhibits the expression of TNF-a mRNA from LPS-challenged AMs
Having established a decrease in TNF-a extracellular protein secretion by AMs we wanted to 
assess the effect of IL-10 administration on TNF-a mRNA levels. AMs (107 per point) were 
pre-treated for 2 hours with 100 U/ml IL-10, followed by a further 1 hour incubation with 10 
pg/ml LPS. Northern analysis of AM-extracted mRNA revealed a percentage reduction of 
47.8 ± 15.23 (p < 0.05) in the level of TNF-a message in cultures containing 100 U/ml IL-10 ' 
(Figure 3.2) (n=3). Addition of 10 pg/ml rat anti-human IL-10 abrogated this response 
completely and actually increased the effect of LPS alone by 21.06 ± 9.2 %.
3.3.3 Effect of IL-10 pre- and post-treatment on TNF-a mRNA levels from LPS- 
treated PBMs
To establish the temporal window of IL-10 mediated suppression of TNF-a mRNA, PBMs 
were treated with 100 U/ml IL-10 at either 1 or 2 hours prior to LPS challenge, 
simultaneously, or 15 and 30 minutes post-LPS. Total RNA was extracted 1 hour after LPS 
administration. Pre-treatment with IL-10 ensures substantial suppression of message, as 












Figure 3.1 THE EFFECT OF IL-10 ADMINISTRATION 
ON LPS-INDUCED TNF-a RELEASE BY AMs and PBMs (n = 6)
a
CONTROL lOfig/ml LPS 1 10 50 100 200




CONTROL lOfig/ml LPS 1 10 50 100 200
IL-10 U/ml + lOpg/ml LPS
AMs (a) and PBMs (b) from healthy subjects, 1 x 106 cells per ml, were 
cultured for 24 hours with 10 pg/ml LPS in the presence of absence of 
a dose range of IL-10. The control contained medium alone.
*p  < 0.05, **p < 0.01 Mann Whitney U test.
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Northern analysis of AMs derived from a healthy subject 10 x 106 cells per point. Control 
AMs contained medium alone. Cultures containing IL-10 with and without antibody were 
incubated 1 hour prior to LPS addition. AMs were lysed 1 hour subsequently. Representative 
of three experiments.
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Northern analysis of AMs from a healthy subject 10 x 106 per point. AMs were incubated with 
100 U/ml IL-10 before and after 10 pg/ml LPS addition. AMs were lysed 1.5 hours after LPS 
administration Representative of three experiments.
RNA
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IL-10 of 32 % (from 43 to 11% inhibition) was shown at an interval as short as 15 minutes 
after LPS stimulation.
3.3.4 EL-10 inhibits the expression of TNF-a mRNA from LPS-challenged PBMs
Having established a decrease in TNF-a extracellular protein secretion by PBMs the effect of 
IL-10 administration on TNF-a mRNA levels was assessed. Cells were pre-treated for 2 
hours with IL-10 (dose range 0.1 - 100 U/ml) before addition of 10 pg/ml LPS. Cells were 
lysed after a further hour of incubation and northern analysis was performed to determine 
mRNA levels. The data shows that 100 U/ml IL-10 is the optimum dose for TNF-a mRNA 
suppression, giving a percentage reduction of 83.1 ± 4.17 (p < 0.01) ( see Figure 3.4, 
representative of 6 experiments). No loss of cell viability was observed at all doses of IL-10 
used up to 500 U/mL
3.3.5 IL-10 induced suppression of TNF-a is not dependent upon de novo protein 
synthesis
To determine if de novo protein synthesis was involved in IL-10 induced suppression of 
TNF-a, PBMs were treated with and without IL-10 plus 5 pg/ml cyclohexamide 2 hours 
prior to LPS addition. Cyclohexamide was added 10 minutes prior to IL-10. Total RNA 
was extracted 1 hour later. TNF-a mRNA with and without LPS treatment was elevated 
by cyclohexamide treatment (Fig. 3.5), but addition in the presence of 100 U/ml IL-10 
led to a decrease in LPS and cyclohexamide-induced TNF-a message by 83.4%. This 
data, which is representative of 3 experiments indicates that IL-10 can directly suppress 
the transcription of TNF-a mRNA without the requirement for de novo protein 
synthesis.
3.3.6 The effect of IL-10 administration on the rate of TNF-a mRNA decay
The effect of IL-10 on mRNA half life was assessed by mRNA stability experiments. PBMs 
were cultured with and without 100 U/ml IL-10 pre-treatment before addition of 10 pg/ml 
LPS. Following 1 hour LPS incubation 5 pg/ml actinomycin D was added, and cells lysed at
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Figure 3.4 THE EFFECT OF A DOSE RANGE OF IL-10 





IL-10 U/ml + LPS
•yA tjv  -ft
Ribosomal RNA
Northern analysis of AMs from a healthy subject, 10 x 106 cells per point. AMs 
were pre-incubated fori hour with a dose range of EL-10 before LPS addition. AMs 
were lysed 1 hour subsequently. Representative of six experiments
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Figure 3.5 THE REQUIREMENT OF PROTEIN SYNTHESIS
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Northern analysis of AMs from a healthy subject. 10 x 106 cells per point. AMs were 
pre-incubated with 100 U/ml IL-10 and/or 5 pg/ml CHX for 1 hour before addition of 
lOpg/'ml LPS. AMs were lysed 1 hour subsequent to LPS addition. Representative of 
three experiments
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1, 2, 4 and 8 hours following actinomycin D addition. No differences were seen in the rate of 
TNF-a mRNA decay between the IL-10 treated group and the group treated with LPS alone 
(n=3) (Figure 3.6).
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Figure 3.6 mRNA DEGRADATION IN RESPONSE TO IL-10 AND LPS IN PBMs
- ■ - 1 0  jig/ml LPS 
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AMs, 10 x 106 per point, were cultured with 10 pg/ml LPS in the presence of 
absence of 100 U/ml IL-10 for 1 hour. Actinomycin D, 5 pg/ml was then added to 
arrest transcription and the degredation of TNF-a mRNA was monitored over an 
8 hour period by densitometry.
3.4 Discussion
This study has confirmed that IL-10 is able to down-regulate TNF-a production to some 
extent in AMs and PBMs in normal subjects, but does not reduce its production to base-line 
levels. It first needs to be recognised however that this study (and the remainder of this thesis) 
was an in vitro investigation and it may not reflect the circumstances in vivo. Cells may be 
activated by the retrieval process and the involvement of other cytokines and soluble factors 
in TNF-a regulation by IL-10 cannot be determined by such experiments. However it is still 
valid to perform in vitro studies in order to evaluate the potential relationship between 
cytokines in a tightly controlled setting. Our findings suggest that both PBMs and AMs are 
susceptible to inhibition of LPS-induced TNF-a by IL-10, with PBMs perhaps showing the 
greater sensitivity, as previously reported (Stricter et al. 1989a; Martinet et al. 1988). In this 
study AMs produced more TNF-a protein and were less susceptible to the effects of IL-10 
than PBMs, suggesting that TNF-a may be the major cytokine for host defence in the AM 
but not necessarily the PBM. However the role of IL-10 produced by the cells in culture was 
not taken into account and this would need to be evaluated in future since increased 
production by AMs in vitro could account for the apparent enhanced sensitivity to IL-10. It is 
also noted that not only could the effects of IL-10 be reversed by addition of anti-IL-10 
antibody, but there was also an enhancement of TNF-a production. This may be due to 
intrinsic production of IL-10 by the AMs which is abb to feed back on the cell in an autocrine 
fashion. Both cell types demonstrate a reduction in LPS-induced TNF-a by IL-10, in terms 
of released protein and at the mRNA bvel This could not be explained by cytotoxic effects 
of IL-10, since no loss of cell viability was observed. The data presented indicates that the 
inhibitory effects of IL-10 on PBMs and AMs are seen at the bvel of TNF-a mRNA 
expression when stimulated by LPS. Although the direct effects of IL-10 on translation of 
TNF-a mRNA or the secreted product were not explored, we can say that the reduction in 
protein rebase is due, at least in part, to a reduction on TNF-a mRNA expression. This is an 
important regulatory mechanism in AMs since they contain very littb stored TNF-a protein 
(Kelley, 1990), responding to inflammatory signals with newly synthesised product. Previous 
studies have examined in some detail the regulation of TNF-a gene transcription and 
translation (Beutbr et al. 1986; Beutbr and Cerami, 1989; Han et al. 1990; Han et al. 1991b; 
Han et al. 1991a) and the specific rob of IL-10 inhibition (de Waal Mabfyt et al. 1991a;
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Ralph et al. 1992; Cassatella et a l 1993; Bogdan et a l 1992). Since LPS-induced TNF-a 
was inhibited by IL-10 (IL-10 had no effect on basal levels of TNF-a) an understanding of 
IL-10 inhibition requires consideration of the mechanisms of LPS induction of TNF-a 
Studies which have investigated the mechanisms by which LPS increases TNF-a production 
(and hence the possible site of IL-10 activity) are conflicting. It is possible that LPS increases 
TNF-a production by increasing the rate of transcription of the TNF-a gene to mRNA in the 
cell nucleus, and/or by increasing the efficiency of transcript translation at the ribosome. Two 
in vitro studies have reported an elevation in the transcription rate of the TNF-a gene in 
response to LPS (Han et al. 1990; Han et al. 1991b), whereas Bogdan et al. (1992) found 
that transcription rates were unaffected in mouse peritoneal macrophages. By contrast, Han 
et al. (1991b) report that LPS modified TNF-a at both the transcriptional and translational 
level by regulating the TNF-a gene promoter and the 3' untranslated region respectively, but 
that the increase in TNF-a protein was largely due to translational derepression (Han et al. 
1991a).
The inhibitory effect of IL-10 has been shown to be greatly reduced if added more than 2 
hours after LPS administration as demonstrated here and elsewhere (Bogdan et al. 1992), by 
which time TNF-a mRNA levels have peaked (Han et al. 1991b). This suggests that IL-10 is 
important at the early stage of TNF-a induction. One possible mechanism of IL-10 activity 
would be an increase in the rate of transcript degradation. The TNF-a gene has, in common 
with other cytokines, a 3' untranslated region with a UA rich motif. Such a sequence has been 
shown to confer instability on the resultant mRNA transcript (Shaw and Kamen, 1986). It has 
been reported that LPS-treated murine macrophages have increased ribonuclease activity 
which degrades mRNA containing the UA rich motif (Shaw and Kamen, 1986), and it is 
possible that IL-10 enhances production of this, or another ribonuclease. However, the 
mRNA stability experiments in this study showed no increase in mRNA degradation in 
response to IL-10, which has been also shown in murine peritoneal macrophages (Bogdan et 
al. 1992). This contrasts with a study investigating inhibition of LPS-induced TNF-a in 
human neutrophils by IL-10 (Cassatella et al. 1993), which suggests that enhanced 
degradation of mRNA did occur. Conflicting results from different cell systems and species 
suggest that there are cell and species specific mechanisms of TNF-a inhibition by IL-10.
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The effects of IL-10 on TNF-a mRNA were not mediated by de novo protein synthesis in 
this instance, and thus the effect is likely to be direct. There has been little investigation into 
the specific regulation of TNF-a mRNA by IL-10, but one major study utilising murine 
peritoneal macrophages did find that the IL-10 effects were cyclohexamide sensitive (Bogdan 
et al. 1992). Once again this discrepancy could be explained by differences between the 
mouse and human species, but there were also differences in methodology. Bogdan et al. 
(1992) isolated TNF-a mRNA after three hours of treatment using 100 ng/ml LPS, as 
opposed to one hour of treatment with 10 pg/ml LPS in this study. They also used a dose of 
10 pg/ml cyclohexamide to inhibit protein translation. Thus their cyclohexamide treatment 
was more robust, and their LPS treatment weaker than that used in this study. This calls into 
question the selected dose of LPS used in this study. They also looked at events at a later, 
and possibly more vulnerable point of activation, and should we have examined the effect of 
IL-10 at multiple time points a more accurate picture may have been achieved. It cannot be 
easily determined whether their methodology allowed for a more physiological approach but 
this is a possibility. It needs to be pointed out that the optimum dose for IL-10 of 100 U/ml 
may not be physiological In future chapters of this thesis it will be shown that plasma and 
BALF IL-10 is in the range of 0.2 - 3 ng/mL 100 U corresponds to 10 ng, so this seems a 
little high. However doses of this nature may still be considered appropriate since high 
localised concentrations found in vivo cannot be determined by bulk biological fluid sampling. 
The data presented here appears to suggest that IL-10 must be acting (at least in part) to 
inhibit gene transcription of the mRNA since this is the only other mechanism whereby the 
steady state mRNA level of TNF-a may be reduced. One possible mechanism could be 
inhibition of NFxB, a transcription factor which mediates LPS-induced cytokine triggering by 
binding to the cytokine promoter on the DNA and “switching on” cytokine mRNA 
transcription (Vincenti et al. 1992; Ito et al. 1994), and this possibility deserves further study.
This study contains preliminary findings which demonstrate that IL-10 can inhibit TNF-a 
release by AMs and PBMs to an extent from normal subjects, at least in part by inhibiting 
TNF-a gene transcription. A more thorough understanding of the mechanisms involved 
could allow comparison with inflammatory diseases where failure of TNF-a regulation is 
suspected to play a pathological role.
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4. TNF-a REGULATION IN SARCOIDOSIS
4.1 Introduction
Sarcoidosis is a disease characterised by a T cell-mediated alveolitis (Campbell et al. 
1986; Crystal et al. 1981b) which is largely CD4+ in nature (Semenzato, 1986; 
Hunninghake and Crystal, 1981). This results in the formation of the non-caseating 
granuloma which are a major contributory factor in the alveolar structural derangement 
and compromised lung function which may occur in some cases (Crystal et al. 1981b). 
The maintenance of the chronic inflammatory events in sarcoidosis can potentially lead to 
end-stage fibrosis contributing to the 5% mortality rate associated with the disease 
(Crystal etal. 1981b).
The initial insult which leads to the development of sarcoidosis remains unknown. There 
has been much debate as to whether the stimulus is environmental or an intrinsic 
abnormality of the inflammatory response (Walters and du Bois 1995). It has been 
proposed that infectious agents such as viruses or mycoplasma may be implicated, since 
high serum antibodies to these organisms have been detected in sarcoidosis patients 
(Semenzato, 1986). However, it has been noted that there are elevated levels of serum 
immunoglobulins and circulating immune complexes in patients with sarcoidosis 
(Semenzato, 1986; Popp and Wachtler, 1991), and there is also an association with the 
expression of certain antigens in the MHC locus (Semenzato, 1986), all of which are 
indicative of an autoimmune disease process. It seems possible therefore that the disease 
may be a manifestation of an individuals abnormal or uncontrolled inflammatory 
response to a common insult, which in normal circumstances would not lead to a chronic 
inflammatory event (Walters and du Bois 1995).
An understanding of the mechanisms which lead to the formation and maintenance of the 
chronic inflammation in sarcoidosis may give insight into aspects of immune regulation. 
It is known that the disease is characterised by a T cell infiltrate into the alveolar space 
(Hunninghake and Crystal, 1981; Semenzato, 1986) and that these lymphocytes are in a
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more primed state in active sarcoidosis (Crystal et al. 1981b; Costabel et al. 1985). It is 
believed that these T cells are drawn into the lung by release of chemokines, possibly 
from the AM (Folkard et al. 1995). The AM is known to be present in elevated numbers 
in sarcoidosis (Semenzato, 1986) and it also has enhanced capacity to produce cytokines 
such as TNF-a (Dalhoff et al. 1993; Muller-Quemheim et al. 1992; Steffen et al. 1993), 
M IP-l-a (Elias, 1988) and possibly IL-l-p (Hunninghake, 1984; Steffen et al. 1993; 
Yamaguchi et al. 1988). It is also a more potent antigen presenting cell in the sarcoidosis 
lung (Lem et al. 1985; Gant et al. 1991) and possesses a number of monocyte markers 
such as OKM1 (Hance et al. 1985) which suggests that many sarcoid AMs may have 
recently been drawn into the lung from the circulating monocyte pool (Hance et al. 
1985; Crystal et al. 1981b). This enhancement has lead to the hypothesis that AMs may 
be involved in the generation and maintenance of the pulmonary inflammatory response 
and that, together with the T cells are important in the maintenance of the sarcoid 
granuloma.
A number of studies have addressed the role of the AM in sarcoidosis, and paid 
particular attention to its capacity to release TNF-a. TNF-a has been found to be 
elevated in the BALF of sarcoidosis patients and AMs have demonstrated enhanced 
capacity to produce this cytokine in some studies (Dalhoff et al. 1993; Steffen et al. 
1993; Foley et al. 1992; Terao et al. 1993; Muller-Quemheim et al. 1992), but others 
have shown little or no increase in TNF-a production in sarcoidosis (see discussion) 
(Bachwich et al. 1986b; Foley et al. 1990). In healthy subjects it is assumed that the 
cytokine network is tightly regulated to prevent pathological consequences. Inhibitory 
cytokines such as IL-10, IL-4 and IL-13 (Fiorentino et al. 1991; Essner et al. 1989; 
Yanagawa et al. 1995) have come to prominence as mediators which may have a 
regulatory role, especially with regard to TNF-a. Circulating inhibitors such as the 
soluble TNF receptors (TNF-R) and IL-1 receptor antagonist (IL-lra) are also thought 
to be important in the control of the cytokine network. Indeed, it has previously been 
demonstrated that the ratio of IL-1 to IL-lra in sarcoidosis is balanced in favour of IL-1 
(Rolfe et al. 1993; Kline et al. 1993), so that even if the IL-1 levels are not significantly 
elevated in the disease, the proportion of bioactive to inactive IL-1 is greater.
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This study is based upon the hypothesis that production and/or activity of TNF-a is 
excessive in the lungs of sarcoidosis patients and this may be due to (1) enhanced 
capacity of AMs to produce TNF-a, (2) decreased production and or activity of IL-10 
and/or (3) decreased production of TNF-R. Spontaneous and LPS-induced production 
of TNF-a by AMs and PBMs in sarcoidosis has been measured, together with its 
modification by IL-10, in comparison to normal subjects. In addition, spontaneous and 
LPS-induced production of IL-10 itself has been measured to establish a possible 
autocrine relationship with TNF-a. Finally spontaneous and LPS-induced production of 




AMs and PBMs were isolated from patients with sarcoidosis as described previously 
(Chapter 2). Patients in this study were undergoing flbreoptic bronchoscopy for 
diagnostic purposes and were not receiving steroid treatment prior to the bronchoscopy. 
Patients studied had bilateral hilar lymphadenopathy with minimal pulmonary 
physiological impairment, with evidence of erythema nodosum and arthralgia. Serum 
angiotensin converting enzyme (ACE) was 34.17 ± 13.14 (n = 17) (normal range 23 - 
85). These patients are classified as having stage one sarcoidosis (Studdy et. al. 1990). 
Patients with stage two and three radiological findings (with evidence of pulmonary 
infiltrates and interstitial shadowing) were excluded. Diagnosis of sarcoidosis was 
confirmed by transbronchial biopsy revealing granuloma formation in all patients studied.
Purified AMs and PBMs were cultured at a density of 1 x 106 cells per ml in culture 
medium. Control wells contained medium alone. To eliminate the possibility of 
endotoxin contamination affecting results, all cell cultures had additional control wells 
containing 5 pg/ml polymyxin B sulphate (Sigma) which binds to LPS. Cultures which 
showed a reduced TNF-a response in the presence of polymyxin were considered 
contaminated and therefore not considered for the study.
LPS was used as an immune response stimulus in the cultures. Dose response curves 
were utilised to ascertain sensitivity to LPS, but 10 |ig/ml LPS was shown to be the 
optimum concentration for AMs and was used as the preferred dose when only one 
concentration of LPS was appropriate. 10 pg/ml LPS was also selected for PBM 
cultures, despite an optimum dose of 100 ng/ml LPS, so that both cell species would 
have identical culture conditions. IL-10 was used at a dose range 0.0001 - 100 U/ml in 
isolation and also in conjunction with 10 pg/ml LPS. Supernatants from the cultures 
were removed after 24 hours and frozen at -70°C until required. Plasma and cell-free 
BALF were removed from whole blood and total lavage fluid respectively by 
centrifugation and stored likewise until required. Lavage protein levels were determined 
as grammes of protein per million recovered BAL cells. Repeated freeze-thaw cycles 
were avoided to reduce loss of protein activity.
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4.3 Results
4.3.1 TNF-a in plasma and BALF
Plasma and BALF samples were assayed for TNF-a using a double-ligand ELISA. 
Plasma and BALF from normal volunteers contained no detectable TNF-a protein, in 
contrast to sarcoidosis plasma and BALF, which contained 0.281 ± 0.084 ng/ml and 
0.427 ± 0.077 ng of TNF-a/million BAL cells respectively (Figure 4.1). These values 
indicate significant elevations (p < 0.05 and p < 0.01 respectively) in circulating and 
pulmonary TNF-a in sarcoidosis patients.
4.3.2 TNF-a release by AMs and PBMs spontaneously, and in response to LPS
AMs derived from sarcoidosis patients produced slightly lower levels of TNF-a than 
normal subjects both spontaneously and in response to LPS, with 10 |ig/ml LPS yielding 
only 1.46 ± 1.45 ng/ml in sarcoidosis compared with a value of 3.487 ± 0.927 ng/ml 
from normal AMs (Figure 4.2a). This was not reflected in PBMs, where sarcoidosis and 
normal subjects gave very similar TNF-a profiles in response to LPS, although 
spontaneous TNF-a release by PBMs was elevated at 0.91 ± 0.75 ng/ml compared to 
0.044 ± 0.008 ng/ml TNF-a in normal PBMs. (Figure 4.2b).
4.3.3 Modification of TNF-a release by IL-10
IL-10 did not significantly reduce the TNF-a protein release by AMs at any dose in 
sarcoidosis, although it approached significance at 10 and 100 U/ml (p = 0.074). This is 
in contrast to normal AMs, where 100 U/ml gave a significant abrogation (p < 0.01) 
(Figure 4.3a). The lower doses of IL-10 were effective at reducing TNF-a release by 
sarcoidosis AMs, however, since 0.1 U/ml showed a reduction in this instance whereas 
normal AMs did not respond to doses of IL-10 lower than 10 U/ml. The PBMs of 
sarcoidosis and normal subjects gave a similar profile, and both reduced LPS-induced 
TNF-a optimally at 100 U/ml IL-10 {p <0.05 and p <0.01 respectively) (Figure 4.3b).
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Figure 4.1 TNF-a DETECTED IN THE PLASMA (n = 4)
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Figure 4.2 THE EFFECT OF LPS ON TN F-a RELEASE BY AMs
AND PBMs DERIVED FROM PATIENTS W ITH  SARCOIDOSIS
5 1  I i ! IISARCOID AMs SARCOIDOSIS n =6
NORMAL SUBJECTS n = 7NORMALS
CONTROL o.l 1 10
LPS jig/ml
irm SARCOID  
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PBMs SARCOIDOSIS n = 5 
NORMAL SUBJECTS n = 6
CONTROL 0.1 1 10
LPS iig/ml
AMs (a) and PBMs (b), 1 x 106 cells per ml, were cultured for 24 
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Figure 4 3  THE EFFECT OF IL-10 ON TN F-a RELEASE BY AMs
AND PBMs DERIVED FROM PATIENTS W ITH SARCOIDOSIS
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AMs (a) and PBMs (b) were cultured for 24 hours, 1 x 106 per 
ml with 10 jig/ml LPS in the presence or absence of a dose 
range of IL-10. Control cells were cultured in medium alone.
*p  < 0.05, **p < 0.01 Mann Whitney U test
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4.3.4 IL-10 levels in plasma and BALF
Low levels of IL-10 were detected in the plasma and BALF of both normal volunteers 
and sarcoidosis patients (Figure 4.4). They compared very closely, with plasma levels of 
normal subjects and sarcoids 65.47 ± 28.26 pg/ml and 58.18 ± 31.12 pg/ml respectively 
and BALF levels 334.5 ± 198.16 pg and 406.47 ± 132.79 pg of IL-10 per million BAL 
cells respectively. There were no significant differences between the groups.
4.3.5 IL-10 release by AMs and PBMs, spontaneously and in response to LPS
Spontaneous release of IL-10 from sarcoid AMs was greater than normal AMs (p = 
0.053), with a value of 22.54 ± 9.26 pg/ml from sarcoidosis AMs compared to 11.34 ± 
4.62 pg/ml IL-10 from normal subjects (Figure 4.5a). IL-10 from sarcoidosis AMs was 
elevated by LPS at 0.1 and 1 pg/ml ip = 0.053), whereas normal AMs produced 
elevated IL-10 only in response to 10 pg/ml LPS. Interestingly, PBMs from sarcoidosis 
subjects produced apparently much higher levels of IL-10 than normal PBMs, both 
spontaneously and in response to LPS, but this was not significant due to very high 
standard errors (not shown), (Figure 4.5b).
4.3.6 TNF-R levels in plasma and BALF
TNF-R was significantly elevated in the plasma of sarcoidosis patients compared to 
normal subjects; 1.644 ± 0.161 ng/ml and 0.421 ± 0.055 ng/ml respectively (P < 0.001) 
(Figure 4.6). TNF-R was also increased in the BALF, where sarcoidosis patients gave 
1.482 ± 0.359 ng of TNF-R per million BAL cells compared to 0.254 ± 0.063 ng of 
TNF-R per million BAL cells for normal BALF (p < 0.05).
67
Figure 4.4 IL-10 DETECTED IN THE PLASMA (n = 11) AND BALF (n = 19)
OF SARCOIDOSIS PATIENTS
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Figure 4.5 THE EFFECT OF LPS ON IL-10 RELEASE BY AMs
AND PBMs DERIVED FROM PATIENTS W ITH SARCOIDOSIS
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4.3.7 TNF-R release by AMs and PBMs, spontaneously and in response to LPS
Normal AMs produced a spontaneous level of TNF-R (0.044 ± 0.018 ng/ml) which was 
reduced in a dose-dependent manner by LPS (Figure 4.7a). Sarcoidosis AMs produced a 
similar level of spontaneous TNF-R production (0.028 ng/ml) which was elevated by 
LPS at all doses. Production of TNF-R by normal PBMs was below detectable limits, 
whereas sarcoidosis PBMs produced elevated spontaneous levels which were increased 
by LPS administration (Figure 4.7b).
4.3.8 Modification of TNF-R release by IL-10
IL-10 alone at all doses increased TNF-R release from sarcoidosis AMs whereas IL-10 
in co-culture with LPS resulted in an almost total inhibition of TNF-R (Figure 4.8a). 
Normal AMs did not produce TNF-R in response to LPS. Sarcoidosis PBMs had their 
LPS-induced TNF-R levels returned to basal levels by IL-10 at 1 and 10 U/ml (Figure 














Figure 4.7 THE EFFECT OF LPS ON TNF-R RELEASE BY LPS IN AMs AND PBMs
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AMs (a) and PBMs (b) were cultured for 24 hours, 1 x 106 cells 
per ml, in the presence of a dose range of LPS. Control cells 
were cultured in medium alone.








Figure 4.8 THE EFFECT OF IL-10 ON TNF-R RELEASE BY AMs
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4.4 Discussion
The data for sarcoidosis patients overall gives a picture of altered cytokine profiles in the 
AMs, whereas the PBMs, with the exception of TNF-R follow a pattern which does not 
differ from the normal picture. This is suggestive of a localised pulmonary inflammatory 
event with minimal peripheral involvement, and is supported by published works which 
suggest that PBMs in sarcoidosis are unexceptional (Spatafora et al. 1989). Indeed, 
Muller-Quemheim et al. (1992) have shown elevated levels of TNF-a produced by 
sarcoidosis AMs, but not PBMs. This supports the theory that pulmonary sarcoidosis, 
despite its systemic nature, may be a compartmentalised disease with localised 
pulmonary activation, and immune suppression in the periphery. There is evidence of 
elevated TNF-a and TNF-R in the plasma of patients with sarcoidosis, but with 
reference to the former this may not necessarily be derived from circulating PBMs, but 
derived from pulmonary TNF-a which has entered the circulation from the alveolar 
space or other cells in the circulation.
The TNF-a release demonstrated from sarcoidosis AMs was unexpected since there is 
no significant difference when compared normal subjects. The majority of studies 
indicate enhanced production of TNF-a by AMs in sarcoidosis (Dalhoff et al. 1993; 
Steffen et al. 1993; Terao et al. 1993; Foley et al. 1992; Muller-Quemheim et al. 1992) 
although this has not been a consistent finding (Bachwich et al. 1986b). There could be 
several explanations for this discrepancy. Firstly, it may be an indication of AM damage 
in the sarcoidosis cultures. It has become apparent during this study that AMs derived 
from sarcoidosis patients are less resistant to the purification process employed here than 
equivalent cells form normal volunteers and patients with ARDS or CFA. All cells used 
in this study had their viability confirmed before culture, and sometimes after culture, but 
this would give no indication as to whether the AMs were damaged but not to the point 
of cell death. Other studies showing high TNF-a values used apparently identical 
purification protocols (Dalhoff et al. 1993; Steffen et al. 1993), suggesting that a 
methodological explanation is unlikely. AMs from sarcoidosis patients were isolated on 
the same day as CFA AMs in some instances, with identical protocols and whereas CFA 
AMs produced expectedly high TNF-a, this was not reflected by sarcoidosis AM 
cultures. Assuming that the AMs in the study were robust, it is necessary to seek an
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alternative explanation for the findings. One possible explanation for the discrepancy is 
the selection of patients for this study. Patients were included if they fulfilled the criteria 
of stage one sarcoidosis, which is an acute presentation with a high prospect of complete 
resolution within two years (Studdy et al. 1990). Stages two and three, which 
demonstrate pulmonary infiltrates are more likely to progress to chronic disease and it is 
possible that a study involving patients of this type would have been more appropriate 
for the examination of TNF-a regulation. Indeed some reports of elevated TNF-a 
included patients with stage two and three in their studies (Foley et. al. 1992; Terao et. 
al. 1993). There was also the lack of distinction in this study between active and inactive 
sarcoidosis patients, on the basis of CD4:CD8 T cell ratio. A previous study determined 
that AMs from sarcoidosis patients with active disease produced elevated TNF-a, 
whereas AMs from patients with inactive disease produced normal levels (Muller- 
Quemheim et al. 1992). We did encounter high TNF-a levels in 2 of our patients who 
may well have been the only patients in our study with aggressive disease, but this is 
unconfirmed.
Another likely explanation for the findings could be an inability to detect elevated TNF-a 
release by AMs by the detection assay due to interference from biological inhibitors of 
TNF-a. Much of the published data regarding elevated TNF-a used assays which 
determined total TNF-a, which may or may not be bound to inhibitors and is therefore 
inactive (Steffen et al. 1993; Spatafora et al. 1989). This ELISA measures only free 
TNF-a, so preventing us from detecting TNF-a bound up with TNF-R. It has been 
observed by one study that sarcoidosis AMs and AMs from patients with tuberculosis 
(another granulomatous disorder) produce comparable amounts of TNF-a, but the 
systemic effects of TNF-a are more pronounced in TB, where symptoms such as tissue 
necrosis and cachexia are commonplace (Rook et al. 1987). These manifestations are not 
apparent in sarcoidosis which suggests that the TNF-a released by sarcoidosis AMs may 
undergo extracellular modification which would enhance degradation, be exposed to 
inhibitory cytokines which prevent its actions upon other cells, or be bound up by soluble 
receptors. Markedly elevated TNF-R was detected in the BALF and plasma of 
sarcoidosis patients which indicates that BAL cells and/or blood cells are shedding more 
TNF-R which can then inactive the TNF-a present. This data demonstrates that the
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sarcoidosis AMs although not producing excessive amounts of TNF-R spontaneously 
may produce more TNF-R in response to LPS, so it is possible that autocrine TNF-R 
could be interfering with our TNF-a measurements. It should also be considered that the 
AMs are not the only source of TNF-R in the lung - endothelial cells, neutrophils and T 
cells all have TNF receptors which may be shed (Burke-Gaffney and Keenan, 1993; 
Porteu and Nathan, 1990; Tartaglia et al. 1993). Also, PBMs in sarcoidosis produce 
significant amounts of TNF-R both spontaneously and in response to LPS, whereas 
normal PBMs produced no detectable TNF-R. This puts forward the possibility that in 
vivo the TNF-R may enter the lung from the pulmonary circulation. This study has not 
addressed the role of the type II TNF receptor, since at the time of investigation there 
was no available antibody to measure the trace amounts released into cell supernatants, 
and it is usually produced in much lower quantities (Chikanza et al. 1993). However, it 
has been reported that the type II receptor is the dominant form shed by cells of the 
myeloid lineage, which includes macrophages (Joyce et al. 1995), so it cannot be 
excluded that the type II receptor may be released in large quantities from AMs, thus 
preventing detection of TNF-a in our assay. These data suggest that the levels of 
cytokine may be only half the story, and as shown in studies on IL-1 and IL-lra (Kline et 
al. 1993), it is the balance of cytokine to inhibitor which determines the potency of the 
mediator.
A further possible explanation for the low levels of TNF-a released by sarcoidosis AMs 
in this study is the potential autocrine role of IL-10. Although IL-10 was not found to be 
elevated in plasma and BALF, sarcoidosis AMs did produce more spontaneous IL-10 
than normal subjects. This released IL-10 may feed back on the AM so blocking 
production of subsequent TNF-a. Wanidworanun et al (1993) have suggested an 
autocrine role for IL-10 in human PBMs, but found that IL-10 was released subsequent 
to TNF-a so it would be unable to prevent initial TNF-a release. Unfortunately there 
have been no studies addressing the timecourse of IL-10 production in normal AMs, let 
alone sarcoidosis AMs so this autocrine role remains to be established. The dose- 
responsive effects of IL-10 on LPS-induced TNF-a indicate that sarcoidosis AMs may 
be sensitive to IL-10 doses at least 100-fold lower than normal AMs ( in sarcoidosis 
LPS-induced TNF-a is reduced by 0.1 U/ml IL-10, whereas no reduction is seen in
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normal AMs below 10 U/ml). Therefore it is likely to be a potent autocrine effect of IL- 
10 in sarcoidosis, even when IL-10 levels are comparatively low.
The relationship between IL-10 and TNF-R is complex. IL-10 alone appeared to 
increase TNF-R release when compared to the basal and LPS response in sarcoidosis 
AMs. There was no response to IL-10 however, from normal AMs. Curiously, IL-10 
and LPS together almost completely inhibited the TNF-R response in sarcoidosis AMs, 
and this effect was also observed in PBMs at 1 and 10 U/ml IL-10 with LPS (the effect 
of IL-10 alone in this instance was not determined). A previous study (Joyce et al. 1995) 
has shown that IL-10 can induce the type II TNF-R release in human PBMs, but we 
were unable to detect any type I TNF-R from normal PBMs. It is suggested by this data 
that the presence of IL-10 in the sarcoidosis lung could lead to production of TNF-R, 
thus enhancing the ability of IL-10 to inhibit TNF-a activity in this disease.
These data underline the complex inter-relationship that exists between cytokines in 
inflammation. We did find elevated TNF-a in the plasma and BALF of sarcoidosis 
patients in this study, but is not apparently produced by the AMs. TNF-R production is 
also enhanced, and the AMs may be an important source. In contrast, IL-10 production 
is not elevated in the BALF, but there is enhanced spontaneous IL-10 production by 
sarcoidosis AMs and enhanced sensitivity to IL-10 in terms of inhibition of AM TNF-a 
production. Overall these findings would suggest that TNF-a regulation by IL-10 and 
TNF-R may be altered, but is not necessarily defective in the lungs of the sarcoidosis 
patients in this study, but further evaluation with other mediators in the TNF-a network 
such as IL-13, IL-4 and the type II receptor would give a more complete picture. Study 
of stage one patients with only a mild degree of disease severity is problematic and thus a 
broader study involving patients with more advanced disease may be of value to 
determine whether inappropriate regulation of TNF-a is implicated mainly in the 
pathogenesis of more aggressive forms of sarcoidosis.
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5. TNF-a REGULATION IN CRYPTOGENIC FIBROSING
ALVEOLITIS
5.1 Introduction
Cryptogenic fibrosing alveolitis (CFA) is characterised by progressive loss of pulmonary 
function and fibrosis of the interstitium and it is the most common form of interstitial 
lung disease, with an annual mortality rate in England and Wales of approximately 1500 
(du Bois, 1993). Originally described in 1907 by Sandoz, it has a similar histological 
appearance to other forms of fibrotic lung disease such as asbestosis, where the aetiology 
of the disorder is known (Crystal et al. 1981a). CFA, however, is triggered by an 
unknown event leading to the development of a neutrophil alveolitis which precedes the 
interstitial fibrosis (Crystal et al. 1981a; Turner-Warwick et al. 1980).
There has been a great deal of speculation as to whether CFA is caused by an immune 
response to a particular pathogen, such as Epstein Barr Virus (Egan et al. 1995), or it is 
the manifestation of an uncontrolled inflammatory response to a common environmental 
agent (Libby et al. 1983). CFA has been proposed to have an autoimmune component, 
with as many as 37% of patients testing positive for the presence of autoantibodies, 
among them rheumatoid factor (Stack et al. 1972). Indeed many patients with 
rheumatoid arthritis develop pulmonary fibrosis which is similar in nature to CFA 
(Sewell and Trentham, 1993). The presence of circulating immune complexes in CFA 
patients is also suggestive of autoimmune involvement, and internalisation of these 
complexes by AMs has been proposed as a mechanism for AM activation seen in CFA 
(Libby et al. 1983). Genetic factors, which support the case for an intrinsic disorder may 
also be important, since CFA is also known to be associated with the expression of 
certain HLA markers (Libby et al. 1983) and it can also arise as a familial syndrome 
(Barzo, 1985).
78
In interstitial lung diseases the cells recovered in the BALF have been found to correlate 
very closely with the cell populations in the interstitium, where the disease processes are 
focused (Daniele et al. 1985). Indeed, the name interstitial lung disease may in part be a 
misnomer, since activated effector cells such as AMs, neutrophils and T cells are 
abundant in the alveolar spaces (Watters et al. 1987; Crystal et al. 1981a) as well as the 
interstitium. AMs from CFA subjects are thought to be in an enhanced state of 
activation, indeed they have been found to produce elevated levels of M IP-l-a 
(Standiford et al. 1993), IL-l-P (Kline et al. 1993), TNF-a (Zhang et al. 1993) and EL-8 
(Carrd et al. 1991; Libby et al. 1983). TNF-a has been shown to be increased in the 
bleomycin-induced rat model of pulmonary fibrosis (Everson and Chandler, 1992). 
Indeed, lung injury in animal models of pulmonary fibrosis has been prevented by the use 
of anti-TNF antibodies (Piguet et al. 1989), thus demonstrating a requirement for TNF- 
a  in bleomycin-induced fibrosis. Release of TNF-a by AMs in CFA has also been shown 
to be elevated (Zhang et al. 1993). The timecourse for TNF-a release is such that it may 
feed back on the AM and promote subsequent release of chemokines such as IL-8 and 
MCP-1. These cytokines may be important in the development of the PMN influx 
observed in CFA, although the importance of this is debatable since the PMNs found in 
the BALF may not correlate with disease outcome (Libby et al. 1983). Eosinophils and 
lymphocytes do correlate, however, with elevated numbers in the BALF associated with 
accelerated progression of disease (Daniele et al. 1985; Watters et al. 1987). TNF-a can 
also affect other cells, stimulating proliferation of fibroblast in conjunction with IL-1 
(Elias et al. 1988), or promoting the release of other pro-inflammatory cytokines from 
PMNs, as well as proteases, superoxide and histamine (Libby et al. 1983; Thelen et al. 
1993), which are believed to be involved in the loss of alveolar structure associated with 
CFA. It seems possible therefore that inappropriate regulation of TNF-a could lead to 
many of the pathological hallmarks of CFA.
The previous chapters introduced the regulatory cytokine IL-10, which has been shown 
to inhibit TNF-a release in numerous studies (Ralph et al. 1992) as well as the 
circulating soluble TNF receptor (TNF-R) which has been demonstrated to inhibit TNF- 
a  bioactivity. This study is based upon the hypothesis that TNF-a production/activity 
may be excessive in the lungs of CFA and this may be a consequence of (1) enhanced
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capacity of AMs to produce TNF-a, (2) decreased production and or activity of IL-10 
and/or (3) decreased production of TNF-R. Release of TNF-a by AMs was measured, as 
was TNF-R and IL-10 production. The ability of IL-10 to inhibit TNF-a production and 
induce TNF-R production by AMs was also investigated. Experiments were duplicated 
in PBMs to establish whether TNF-a regulation was altered in mature macrophages 
when compared to their circulating counterparts.
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5.2 Experimental Design
AMs and PBMs were isolated from patients with CFA as described previously (Chapter 
2). Patients in this study were undergoing fibreoptic bronchoscopy for diagnostic 
purposes and were not receiving steroid treatment prior to the bronchoscopy. All the 
subjects had significant pulmonary impairment and transbronchial biopsy revealed 
chronic inflammatory changes consistent with pulmonary fibrosis.
Purified AMs and PBMs were cultured at a density of 1 x 106 cells per ml in culture 
medium. Control wells contained medium alone. To eliminate the possibility of 
endotoxin contamination affecting results, all cell cultures had additional control wells 
containing 5 pg/ml polymyxin B sulphate (Sigma) which binds to LPS. Cultures which 
showed a reduced TNF-a response in the presence of polymyxin were considered 
contaminated and therefore not considered for the study.
LPS was used as an immune response stimulus in our cultures. Dose response curves 
were utilised to ascertain sensitivity to LPS, but 10 pg/ml LPS was shown to be the 
optimum concentration and was used as the preferred dose when only one concentration 
of LPS was appropriate. 10 pg/ml LPS was also selected for PBM cultures, despite an 
optimum dose of 100 ng/ml LPS, so that both cell species had identical culture 
conditions so permitting direct comparison. IL-10 was used at a dose range 0.001 - 100 
U/ml in isolation and also in conjunction with 10 pg/ml LPS. Supernatants from the 
cultures were removed after 24 hours and frozen at -70°C until required. Plasma and 
cell-free BALF were removed from whole blood and total lavage fluid respectively by 
centrifugation and stored likewise until required. Lavage protein levels were determined 
as grammes of protein per million recovered BAL cells. Repeated freeze-thaw cycles 
were avoided to reduce loss of protein activity
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5.3 Results
5.3.1 TNF-a in the plasma and BALF of CFA subjects
In normal subjects TNF-a was below the limit of detection for the assay. In contrast, the 
plasma and BALF of CFA subjects contained considerable amounts of TNF-a, 0.21 ± 
0.064 ng/ml and 0.352 ± 0.063 ng/million BAL cells respectively (p < 0.01) (Figure 5.1).
5.3.2 Spontaneous and LPS-induced TNF-a release by AMs and PBMs from CFA 
subjects
Spontaneous TNF-a release by AMs from normal subjects was comparable to CFA 
subjects (1.36 ± 0.97 ng/ml and 0.81 ± 0.29 ng/ml respectively), whereas LPS-induced 
TNF-a in CFA was elevated at all doses of LPS when compared to normal subjects 
(Figure 5.2a) {p = 0.053). Spontaneous release of TNF-a by CFA PBMs was greater 
than in normal subjects (0.77 ± 0.61 ng/ml and 0.044 ± 0.008 ng/ml respectively), 
although this difference was not maintained in response to LPS at any dose, with CFA 
and normal PBMs giving very similar profiles of LPS-induced TNF-a release (Figure 
5.2b).
5.3.3 TNF-a inhibition by IL-10 in AMs and PBMs from CFA subjects
In normal subjects IL-10 reduced LPS-induced TNF-a significantly at doses greater than 
10 U/ml. CFA AMs showed a greater sensitivity to IL-10; TNF-a was reduced by IL-10 
at all doses, significantly at the lowest dose of 0.001 U/ml IL-10 (p < 0.05) (Figure 
5.3a). This translated to a percentage reduction of 75.7 ±20.1  in CFA subjects 
compared to only 35.3 ± 9.4 % in normal subjects with the higher optimum dose of 100 
U/ml IL-10. In contrast, PBMs from normal subjects significantly reduced the TNF-a to 
basal levels at 50 and 100 U/ml IL-10 (p < 0.01), but IL-10 had no effect on TNF-a 
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FIGURE 5.2 THE EFFECT OF LPS ON TN F-a RELEASE BY AMs AND
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AMs (a) and PBMs (b) cultured for 24 hours, 1 x 106 per 
ml, in the presence of a dose range of LPS. Control cells 
were cultured in medium alone.
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FIGURE 5.3 THE EFFECT OF IL-10 ON TNF-ct RELEASE BY
AMs AND PBMs DERIVED FROM  CFA PATIENTS
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AMs (a) and PBMs (b) cultured for 24 hours, 1 x 106 cells 
per ml, with 10 pg/ml LPS in the presence or absence of 
a dose range of IL-10. Control cells were cultured in medium 
alone.
*p  < 0.05, **p  < 0.01 Mann Whitney U test
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5.3.4 IL-10 in the plasma and BALF of CFA subjects
IL-10 was detectable in the plasma and BALF of all CFA and normal subjects (Figure
5.4). The plasma values were 32.0 ± 12.88 pg/ml and 65.47 ± 28.26 pg/ml respectively, 
and the BALF values 389.65 ± 102.15 pg/ml and 334.55 ± 198.16 pg/million BAL cells 
respectively. There were no statistically significant differences between the groups.
5.3.5 Spontaneous and LPS-induced IL-10 production by AMs and PBMs from 
CFA subjects
AMs from normal subjects produced a spontaneous level of 12.6 ± 8.4 pg/ml IL-10 
which was higher than the 4.02 ± 1.90 pg/ml released spontaneously by CFA AMs 
(Figure 5.5a). However, LPS-induced IL-10 was elevated in CFA AMs at all doses when 
compared to normal subjects. Also, PBMs from CFA subjects produced more IL-10 in 
response to 1 and 10 pg/ml LPS compared to normal PBMs (Figure 5.5b), and 
spontaneous IL-10 was once again elevated in CFA subjects, with 26.84 ±13.1 pg/ml 
for CFA PBMs compared to 8.71 ± 4.92 pg/ml for normal PBMs.
5.3.6 TNF-R in the plasma and BALF of CFA subjects
TNF-R was detectable in both the plasma and BALF of CFA and normal subjects 
(Figure 5.6). Plasma TNF-R in CFA subjects was significantly elevated, with 1.621 ± 
0.125 ng/ml compared to 0.421 ± 0.055 ng/ml for normal subjects (p < 0.01). CFA 
BALF also contained elevated TNF-R with 1.024 ± 0.396 ng/million BAL cells 
compared to only 0.254 ± 0.063 ng/million BAL cells for normal subjects, although this 
failed to reach statistical significance (p = 0.12).
5.3.7 Spontaneous and LPS-induced TNF-R release by AMs and PBMs from CFA 
subjects
In normal subjects spontaneous TNF-R was measured at 0.039 ±0.017 ng/ml which then 
declined in response to LPS in a dose dependent manner (Figure 5.7a).
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FIGURE 5.4 IL-10 DETECTED IN THE PLASMA (n = 16) AND BALF (n =20)
OF CFA SUBJECTS
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FIGURE 5.5 THE EFFECT OF LPS ON IL-10 PRODUCTION BY AMs AND PBMs
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FIGURE 5.6 TNF-R DETECTED IN THE PLASMA (n=18)
AND BALF (n=20) OF CFA SUBJECTS
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Figure 5.7 THE EFFECT OF LPS ON TNF-R PRODUCTION BY AMs AND PBMs
DERIVED FROM CFA SUBJECTS
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AMs (a) and PBMs (b) cultured for 24 hours, 1 x 106 cells 
per ml, with a dose range of LPS. Control cells were cultured 
in medium alone.
 detection limit 0.016 ng/ml TNF-R
* p  < 0.05 Mann Whitney U test
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Although spontaneous TNF-R from CFA AMs was comparable to normal subjects at 
0.042 ±0.014 ng/ml, no inhibition was demonstrated in response to LPS at any dose. 
Normal PBMs failed to produce detectable TNF-R at any dose, whereas by contrast 
PBMs from CFA subjects produced spontaneous TNF-R at 0.751 ± 0.042 ng/ml (p < 
0.05) which was reduced in response to LPS at doses of 1 and 10 pg/ml (Figure 5.7b).
5.3.8 The effect of IL-10 on TNF-R release by AMs and PBMs from CFA subjects.
Spontaneous TNF-R levels were significantly reduced by IL-10 alone at 100 U/ml IL-10 
in normal AMs ( p  < 0.05), whereas IL-10 was unable to reduce further the reduction in 
response to 10 pg/ml LPS (Figure 5.8a). In marked contrast, IL-10 alone increased 
TNF-R release by CFA AMs from a basal level of 0.047 ± 0.014 ng/ml to 0.104 ±0.141 
ng/ml. IL-10 in combination with LPS did not lead to any further increases. This is in 
contrast to PBMs from CFA subjects, where LPS and IL-10 reduced TNF-R release 
when added separately from 0.063 ± 0.047 ng/ml to 0.046 ± 0.027 ng/ml and 0.044 ± 
0.031 ng/ml respectively, and when added together they reduced the amount of TNF-R 
released by CFA PBMs to 0.021 ± 0.009 ng/ml (Figure 5.8b). PBMs from normal 
subjects failed to produce any detectable TNF-R.
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FIGURE 5.8 THE EFFECT OF IL-10 AND LPS ON TNF-R RELEASE
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AMs (a) and PBMs (b) cultured for 24 hours, 1 x 106 cells 
per ml plus or minus 10 pg/ml LPS and/or 100 U/ml IL-10. 
Control cells were cultured with medium alone.
—  detection limit 0.016 ng/ml TNF-R 
* p  < 0.05 Mann Whitney U test
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5.4 Discussion
These results demonstrate that TNF-a and TNF-R release by AMs and IL-10 and TNF- 
R release by PBMs derived from CFA subjects are distinct from the cells derived from 
normal subjects. This is indicative of a disease which is not fully compartmentalised, 
reflecting inflammatory changes in the blood compartment as well as the lung. As 
previously shown (Zhang et al. 1993), TNF-a levels in CFA were significantly elevated 
in plasma and BALF when compared to normal subjects. The levels were somewhat 
higher in the BALF which suggests that much of the TNF-a in the plasma may be 
pulmonary-derived TNF-a. This elevated plasma TNF-a may explain the increased TNF- 
R and IL-10 release by PBMs, since TNF-a has been shown to induce production of 
both these regulatory proteins (Porteau and Hieblot, 1994; Wanidworanun and Strober, 
1993).
Spontaneous release of TNF-a was no different from that released by normal AMs, 
which is contrary to the findings of Zhang et al (1993) who found significant elevations 
in spontaneous release. This is the only published report examining TNF-a release by 
AMs in CFA, and different AM purification protocols could possible lead to varying 
amounts of in vitro cytokine induction, and the elimination of possible endotoxin 
contamination is crucial. This thesis used polymyxin B in the cultures to detect the 
presence of endotoxin, and results were only considered valid if cultures were found to 
be endotoxin-free. There were no such controls published in Zhangs study. Since the 
data suggests that CFA AMs have a more potent response to LPS in culture, even trace 
contamination may lead to artificially high control values. In terms of LPS-induced TNF- 
a  release these results do confirm the previous report which demonstrated that TNF-a is 
elevated compared to normal AMs in response to LPS, although this failed to reach 
statistical significance due to high variability in the recorded values. It is also a possibility 
that the TNF-a measured in the BALF was not derived from AMs, since TNF-a can be 
released from other cellular sources such as PMNs (Xing et al. 1993), endothelial cells 
and T cells (Fiers, 1991). The differential cell counts of the BALF of CFA patients 
consistently indicated more than thirty per cent PMNs, suggesting that they may be a 
major source of pulmonary TNF-a in CFA.
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TNF-a has been demonstrated to induce many of the pathological hallmarks of CFA, 
including fibroblast proliferation (Elias et al. 1988) and production of collagen type I and 
II and fibronectin by fibroblasts (Campa 1993), all of which are implicated in the 
development of tissue fibrosis. TNF-a has also been shown to trigger release of IL-8 and 
M IP-l-a (Matsushima and Oppenheim, 1989; Wolpe and Cerami, 1989), possibly in an 
autocrine fashion from AMs, and these chemokines may have a central role in mediating 
the neutrophil alveolitis characteristic of CFA. IL-8 and M IP-l-a can stimulate 
neutrophil degranulation releasing collagenase, elastase and superoxide anions, which are 
able to contribute to tissue injury (Wolpe and Cerami, 1989; Cohen et al. 1988). In this 
scenario it is possible that elevated TNF-a may be a main contributor to the alveolitis 
and tissue fibrosis seen in CFA.
In normal subjects IL-10 was released spontaneously by AMs in small amounts, and this 
was increased in response to LPS at 10 pg/ml. In comparison AMs from CFA subjects 
produced more IL-10 than normal subjects in response to LPS, although spontaneous 
levels were comparable. IL-10 was also not apparent in elevated amounts in the plasma 
or BALF of CFA subjects. Raised IL-10 has been reported to be a control measure to 
counter-act the high levels of TNF-a in inflammatory disease (Katsikis et al. 1994), but 
this does not appear to be the case with CFA, although it needs to be emphasised that 
IL-10 was determined at the optimum time point for TNF-a detection rather than the 
optimum for IL-10 itself so this may not be an accurate interpretation. It has been 
demonstrated that TNF-a release from PBMs has been able to stimulate IL-10 in an 
autocrine fashion (Wanidworanun and Strober, 1993) and this may be an important 
mechanism for TNF-a regulation within the cytokine network. IL-10 has also been 
shown to be elevated in another chronic inflammatory disease, rheumatoid arthritis 
(Katsikis et al. 1994), and inhibition of IL-10 by anti-IL-10 antibody leads to increased 
levels of TNF-a in the synovial fluid, which is demonstrative of a feedback mechanism 
controlling TNF-a production involving IL-10. This data suggests that although 
production of IL-10 does not appear to be compromised in CFA, there is no elevated 
production of IL-10 in response to the TNF-a. Interestingly, IL-10 does demonstrate a 
greater potency on TNF-a inhibition in these cells. In normal AMs IL-10 at the optimum 
dose of 100 U/ml gave a percentage reduction of approximately 35%. In contrast AMs
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from CFA subjects gave more than an 70% reduction in TNF-a in response to an IL-10 
dose as low as 0.001 U/ml. There is little known about the IL-10 receptor on human 
cells at present, but the increased efficacy of IL-10 on AMs in CFA could be explained 
by an increased density of IL-10 receptor on these cells. The apparently increased 
potency may also be explained by autocrine feedback of intrinsic IL-10 on the AM and is 
supported by the increased production of IL-10 by CFA AMs in response to LPS. The 
use of anti-IL-10 antibody in the cultures would have addressed this question since it 
would have inactivated the biological effects of any intrinsically produced IL-10, so 
identifying any additive effects it may have in association with extrinsic IL-10.
This leads to the role of TNF-R in CFA, which has been previously been demonstrated 
to inhibit TNF-a activity. TNF-R was found to be elevated in the plasma and BALF of 
CFA subjects, significantly so in the former. This finding is accentuated by the greatly 
increased TNF-R released by CFA PBMs, compared to normal PBMs which released no 
measurable TNF-R, either spontaneously or in response to LPS. This may be a response 
to the elevated TNF-a which may be leaking into the plasma of CFA subjects. 
Spontaneous release from CFA AMs was comparable to normal subjects, but the 
response to LPS was quite distinct. In normal AMs TNF-R was decreased in a dose- 
dependent manner in response to LPS. This effect was not observed in CFA subjects. 
This could possibly explain the enhanced capacity of AMs from CFA subjects to release 
TNF-R, but it is important to consider that the time point for TNF-R determination may 
not have been appropriate and that CFA AMs do not produce more TNF-R, but have a 
more rapid response to stimulus. It is not presently known whether maintained 
production of TNF-R in CFA is a consequence of enhanced TNF-a release, but it is 
possible that chronic release of TNF-a may trigger receptor shedding in order to dampen 
down the inflammatory response. Indeed it has been demonstrated with IL-1 and IL-lra 
(Galve-de Rochemonteix et al. 1993), as well as TNF-a and TNF-R (Porteau and 
Hieblot, 1994) that receptor shedding can be stimulated by the corresponding cytokine, 
and elevated TNF-R has been detected in the plasma of patients with endotoxaemia, who 
have very high circulating TNF-a levels (Spinas et al. 1992). In contrast, it seems that 
normal AMs which are not chronically activated reduce their production of soluble 
receptor, perhaps permitting a “no holds barred” inflammatory response. IL-10 is also
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implicated in TNF-R shedding; 100 U/ml IL-10 triggered release of TNF-R in CFA 
AMs, whereas it actually inhibited TNF-R release by normal AMs. This effect was not 
seen in PBMs, where LPS and IL-10, both together and separately inhibited TNF-R 
release. A previous study on normal human PBMs found that they did shed increased 
amount of the type II TNF-R, but they support this data suggesting that the type I 
receptor shedding could not be measured (Joyce et al. 1995), since it is present at a 
much lower density.
Overall these results indicate that AMs from CFA subjects may be in an enhanced state 
of activation. It appears that AMs from CFA subjects do not have a reduced capacity to 
release IL-10 and TNF-R, and indeed they may have in increased capacity to produce the 
latter. It seems that these mechanisms themselves may not be sufficient to control the 
TNF-a response fully, and that it is likely that other unexplored mechanisms are 
involved, possibly IL-4 and IL-13. An alternative interpretation would be that the 
elevated TNF-R could have pathological consequences. In inflammatory disease the 
initial response may be defective, possibly due to inappropriate production or activity of 
cytokine inhibitors which prevent an acute “no holds barred” response and thus leads to 
a chronic state of activation, whereas in normal subjects the initial inflammatory response 
may be more potent, allowing for a more rapid resolution.
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6. TNF-a REGULATION IN ADULT RESPIRATORY 
DISTRESS SYNDROME
6.1 Introduction
The Adult Respiratory Distress Syndrome (ARDS) was first recognised in 1967, when 
Ashbaugh and co-workers observed acute respiratory failure in twelve patients on the 
intensive care unit. They reported a mortality rate of 58%, which in the subsequent 
quarter of a century has only moderately improved, indeed a recent study in the UK 
estimating mortality from ARDS to be 38% (Webster et al. 1988). It has been suggested 
that improvements in life support technology are not sufficient to improve the prognosis 
for patients with ARDS, and that only a more thorough understanding of the 
pathophysiology of this acute pulmonary disease will have any major impact on patient 
survival.
ARDS may be regarded as the final common pathway for many causes of acute lung 
injury, with its very rapid progression to obliterative pulmonary fibrosis, confirmed by 
post-mortem examination within three weeks of ARDS onset (Pratt et al. 1979). ARDS 
has often been compared to CFA since both diseases are characterised by neutrophil 
alveolitis, which may precipitate the development of tissue fibrosis (Fowler et al. 1987; 
Miller et al. 1992; Repine, 1992). However, ARDS and CFA are distinct since the 
former is very rapidly debilitating, whereas CFA may take many years to progress to life- 
threatening loss of pulmonary function. In addition, it has been observed that apparent 
fibrosis in ARDS may be reversible in more than 60% of survivors (Elliott et al. 1987; 
Rinaldo and Rogers, 1982) and this feature of the disease is of great interest since it is 
one of the few examples of a resolution of fibrotic injury, and although fibrosis can be 
arrested in CFA it has never been shown to completely resolve. This could be due to 
differences in the nature of the fibrotic process i.e. the collagen laid down may be 
altered, but it may also be a reflection of alterations in the inflammatory cascade which 
precedes the fibrosis.
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ARDS is strongly associated with sepsis syndrome (Marks et al. 1990; Webster et al. 
1988) and there is a likelihood that gram-negative endotoxin may trigger the 
inflammatory events associated with ARDS. Indeed, in animal models of acute lung 
injury, an infusion of endotoxin evokes an injurious response (Tracey et al. 1987a; 
Rabinovici et al. 1994; Eichaker et al. 1991). Such models have highlighted a putative 
role for TNF-a in lung injury since they have demonstrated elevated levels of circulating 
TNF-a (Eichaker et al. 1991; Rabinovici et al. 1994). Also, in animal studies of E. coli 
endotoxaemia use of anti-TNF antibodies can prevent lethality (Windsor et al. 1993; 
Tracey et al. 1987a). Anti-TNF antibodies have also been administered in clinical trials 
to sepsis patients with mixed results (Windsor et al. 1993) In human studies, endotoxin 
infusions have also been shown to result in elevated plasma levels of TNF-a appearing as 
early as sixty minutes after infusion and declining by 4 hours post-infusion (Michie et al. 
1988). Such studies have highlighted the transient nature of TNF-a in inflammation and 
could explain much conflicting data regarding the role of TNF-a in acute inflammation 
and ARDS, although a single bolus of LPS was administered and this is not the scenario 
in sepsis where LPS can be continually released by gram negative bacteria. Some studies 
have detected elevated levels of circulating TNF-a in ARDS subject compared to 
patients with pre-disposing risk factors for ARDS (Marks et al. 1990; Chollet-Martin et 
al. 1994; Suter et al. 1992), but others have found no difference (Parson et al. 1992; 
Roten et al. 1991), and such discrepancies may be due to the timing of samples, since 
peaks of TNF-a production may mirror the peaks and troughs of LPS piasma levels in 
the sepsis patient. Since ARDS is primarily a pulmonary disease, it is probably more 
relevant to measure TNF-a in the BALF, and Millar and co-workers (1989) did find 
elevated TNF-a in the bronchopulmonary secretions of 5 patients with ARDS compared 
to at risk patients. The probable source of this TNF-a production in ARDS has been 
identified as the AM (Tran Van Nhieu et al. 1993; Suter et al. 1992).
It is not surprising that TNF-a should be implicated in the pathophysiology of ARDS 
since many of the features of the disease can be mediated by this cytokine. Vascular 
endothelial permeability and endothelial cell damage are features of ARDS (Braude et al. 
1986; Bone, 1993), contributing to the non-cardiogenic pulmonary oedema characteristic 
of the disease. TNF-a has been shown to enhance vascular endothelial barrier
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permeability in vitro (Nawroth and Stem, 1986). Another cytokine, IL-8 is elevated in 
ARDS (Cohen et al. 1988; Miller et al. 1992), and Donnelley and co-workers (1993) 
have reported that AM-derived IL-8 may be a marker of ARDS progression in at risk 
subjects. TNF-a is known to stimulate IL-8 release from AMs and fibroblasts (Rolfe et 
al. 1991) and thus may contribute indirectly to the neutrophil infiltration and 
degranulation mediated by IL-8 in ARDS. This may be an important mechanism in 
ARDS since neutrophil-derived hydrogen peroxide, oxygen radicals and elastase, all of 
which are elevated in the BALF of ARDS subjects are believed to have an important role 
in the obliterative alveolitis and fibrosis seen in the ARDS lung (Carrd et al. 1991; 
Repine, 1992; Rocker et al. 1989; Lee et al. 1981; HSllgren et al. 1987). Pulmonary 
fibrosis in ARDS is indicated by elevated levels of AM-derived basic fibroblast growth 
factor (bFGF) (Henke et al. 1993) and increased collagen deposition (Rinaldo and 
Rogers, 1982). TNF-a is known to promote the laying down of collagen fibres by 
fibroblasts (Campa 1993) as well as promoting fibroblast proliferation in vitro (Elias et 
al. 1988).
The known pathophysiological effects of TNF-a described above would suggest that 
inappropriate regulation of this mediator may lead to lung injury, and this raises the 
hypothesis that TNF-a regulation in ARDS may be inadequate. This could be due to an 
alteration in the relationship of TNF-a to regulatory proteins such as soluble receptors, 
receptor antagonists or cytokines. IL-10 is one such cytokine which has demonstrated an 
ability to inhibit TNF-a production. The circulating soluble receptor, although not 
known to inhibit production can inhibit biological activity. This study has attempted to 
investigate the source of the TNF-a and how it may be regulated. ARDS subjects were 
compared to subjects with pre-disposing risk factors, to determine any differences in 
TNF-a activity which may be responsible for ARDS progression. AMs and PBMs were 
cultured, and the supernatants analysed for TNF-a protein. TNF-a was also measured in 
the BALF and plasma. IL-10 production and its impact on TNF-a production by AMs 
and PBMs was also measured. Finally TNF-R in the BALF and plasma as well as 
production by AMs and PBMs, was measured to establish any inhibition of TNF-a 
protein by the soluble receptor.
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6.2 Experimental Design
Thirty four patients on the intensive therapy unit (ITU) were included in this study. 







It would have been desirable to include ventilated controls in this study since normal 
volunteers could not be directly compared to ARDS subjects as the effects of ventilation 
on lung physiology could not be taken into consideration. Such controls were 
unavailable however, so ARDS subjects were only compared to other ventilated patients 
who had pre-disposing risk factors. Patients were considered to have ARDS if their 
Murray lung injury score exceeded 2.5. The Murray score (Murray et al. 1988) is based 
on:
(1) Presence of alveolar infiltrate on x-ray
(2) Degree of hypoxia
(3) Reduced pulmonary compliance
(4) Normal capillary wedge pressure
BAL and venepuncture was performed on all patients. A total of 160 mis of sterile 
buffered saline was instilled in 20 ml aliquots into the lung and aspirated into chilled 
siliconised bottles. The BALF was processed as previously described in Chapter 2. 
Blood was collected from an arterial line into heparinised tubes. Cells were cultured for a 
period of twenty four hours since the restricted number of AMs returned by BAL on 
ITU patients meant that only one time point, i.e. the optimum time for TNF-a
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production, could be selected. ELIS As were performed for IL-10, TNF-a and TNF-R as 
previously described in Chapter 2.
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6.3 Results
6.3.1 TNF-a in the plasma and BALF of ARDS and at risk subjects
TNF-a was found to be present in most samples tested. In the plasma samples the mean 
value for TNF-a in ARDS subjects was 0.472 ± 0.237 ng/ml compared to a value of 
0.241 ± 0.078 ng/ml for at risk subjects (Figure 6.1). This represented an increase in 
ARDS plasma TNF-a, which did not reach significance. There was also an elevation in 
the TNF-a in the BALF of ARDS subjects compared to at risk subjects (0.187 ±0.132 
ng/million BAL cells and 0.026 ± 0.008 ng/million BAL cells respectively).
6.3.2 Spontaneous and LPS-induced TNF-a release from AMs and PBMs
Spontaneous TNF-a release by AMs from ARDS subjects was greater than at risk 
subjects and this elevation was maintained in response to LPS, where 10 pg/ml LPS gave 
1.53 ± 0.86 ng/ml TNF-a in ARDS subjects compared to only 0.21 ± 0.06 ng/ml for at 
risk subjects (Figure 6.2a). A similar pattern for TNF-a release was exhibited by PBMs 
(Figure 6.2b), where 10 pg/ml LPS stimulated a significantly greater release of TNF-a 
from PBMs from ARDS subjects compared to those at risk (p < 0.01). There was no 
apparent difference in spontaneous release. Overall TNF-a release by at risk AMs and 
PBMs was very low.
6.3.3 Inhibition of LPS-induced TNF-a production by IL-10
In ARDS subjects IL-10 reduced LPS-induced TNF-a at all doses, with the exception of 
50 U/ml IL-10 (Figure 6.3a). Due to a large degree of sample variation however, there 
was no significant reduction observed at any dose. LPS-induced TNF-a was very low in 
the AMs of at risk subjects, with only 0.21 ± 0.06 ng/ml produced. This was not reduced 
significantly by IL-10 at any dose, although there were apparent reductions at 0.1,1 and
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Figure 6.1 TNF-a DETECTED IN THE PLASMA AND BALF
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Figure 6.2 SPONTANEOUS AND LPS-INDUCED TN F-a RELEASE
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AMs (a) and PBMs (b) were cultured for 24 hours, 1x10  cells 
per ml with a dose range of LPS. Control cells were cultured 
with medium alone.
**/? < 0.01 Mann Whitney U test
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Figure 6.3 THE EFFECT OF IL-10 ADMINISTRATION ON LPS-INDUCED TN F-a
RELEASE FROM AMs AND PBMs DERIVED FROM
ARDS AND AT RISK SUBJECTS
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medium alone.
*p  < 0.05, **p  < 0.01 Mann Whitney U test
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10 U/ml IL-10. The top doses of 50 and 100 U/ml had no effect. PBMs from ARDS 
subjects were much more responsive to IL-10, with a significant reduction occurring in 
response to 10 and 50 U/ml IL-10, corresponding to an approximate reduction in TNF-a 
protein of 60% in response to the latter dose (p < 0.05) (Figure 6.3b). The top dose of 
100 U/ml IL-10 had no statistically significant effect. PBMs from at risk subjects once 
again produced very little TNF-a in response to LPS, and although there was a 
suggested reduction in response to 0.1, 10 and 50 U/ml IL-10, these were not 
significant.
6.3.4. IL-10 in the plasma and BALF of ARDS and at risk subjects
IL-10 was detectable in all plasma and BALF samples of both patient groups (Figure
6.4). Plasma values were 36.104 ± 9.096 pg/ml in ARDS subjects compared to 55.746 ± 
22.074 pg/ml for at risk subjects.In the BALF, however IL-10 was diminished in ARDS 
subjects where there was only 38.93 ± 8.22 pg/million BAL cells IL-10 compared to
204.9 ± 109.67 pg for at risk subjects (p < 0.01).
6.3.5 Spontaneous and LPS-induced IL-10 release by AMs and PBMs
AMs from both patient groups produced IL-10 spontaneously in culture, although less 
than 5 pg/ml. IL-10 production was significantly enhanced in ARDS AMs in response to 
10 pg/ml LPS (p  < 0.05), the AMs from at risk subjects responded significantly only to 
1 pg/ml LPS (p < 0.05) (Figure 6.5a). PBMs from both patient groups produced more 
IL-10 than AMs, both spontaneously and in response to LPS. ARDS PBMs exhibited a 
three-fold increase in IL-10 production in response to 1 pg/ml LPS, although this was 
not apparent when the dose was increased to 10 pg/ml (Figure 6.5b). The optimum dose 
of LPS for IL-10 production by at risk PBMs was 0.1 pg/ml, and this declined in 





























Figure 6.4 IL-10 DETECTED IN THE PLASMA AND BALF
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Figure 6.5 SPONTANEOUS AND LPS-INDUCED IL-10 RELEASE BY AMs AND PBMs
DERIVED FROM SUBJECTS W ITH ARDS
AND AT RISK OF ARDS
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AMs (a) and PBMs (b) cultured for 24 hours, 1 x 106 cells 
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medium alone.
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*p < 0.05 Mann Whitney U test
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6.3.6 TNF-R in the plasma and BALF of ARDS and at risk subjects
TNF-R was detectable in all plasma and BALF samples of both patient groups. ARDS 
plasma contain 7.23 ± 0.80 ng/ml TNF-R compared to 5.82 ± 1.06 ng/ml for at risk 
subjects (Figure 6.6). The BALF values for ARDS and at risk subjects groups were also 
comparable with 2.88 ± 0.60 ng/million BAL cells and 3.11 ±1.21 ng/million BAL cells 
TNF-R respectively.
6.3.7 TNF-R production by AMs and PBMs from ARDS and at risk subjects
TNF-R was below the detection limit in all supernatants from both AMs and PBMs 
derived from ARDS and at risk subjects (data not shown).
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Figure 6.6 TNF-R DETECTED IN THE PLASMA AND BALF
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The TNF-a profile of AMs derived from patients with ARDS indicates that they may be 
able to produce more TNF-a than the at risk subjects. This is reflected by the increased 
levels of TNF-a in the BALF of ARDS subjects and may suggest that regulation of 
TNF-a in ARDS subjects is abnormal. Care must be taken when interpreting this data 
however since a number of factors need to be considered. The elevated TNF-a in ARDS 
subjects may not be a feature of the disease process itself, but a result of direct injury to 
the lung. It has been demonstrated that the risk of developing ARDS is greater if the 
injury is direct (Fowler et al. 1983) and that cytokine levels are higher in ARDS with 
pneumonia than without (Jacobs et al. 1989). Since all our pneumonia subjects had 
ARDS it is difficult to conclude whether the TNF-a elevation is due entirely to ARDS or 
largely as a result of pneumonia. It would therefore be useful in further studies to treat 
the pneumonia group as a separate entity. The fact that there is slightly elevated TNF-a 
in the plasma of ARDS patients as well as the BALF may indicate that a systemic 
process is involved however and it is unlikely to be explained by TNF-a entering the 
pulmonary circulation from the lung compartment since PBMs from ARDS subjects also 
produced significantly more TNF-a in response to LPS. Since overall TNF-a release by 
ARDS AMs (and PBMs to a lesser extent) was greater than the at risk subjects this 
highlights inappropriate TNF-a regulation as a possible mechanism for the development 
of ARDS in patients at risk.
IL-10 was investigated as a potential key player in the regulation of TNF-a release, since 
it has been shown to down-regulate TNF-a production by human macrophages and 
PBMs (Bogdan and Nathan, 1993; Ralph et al. 1992). It was interesting to find that IL- 
10 was not particularly effective at inhibiting LPS-induced TNF-a release by the AMs of 
ARDS and at risk subjects. This was not a surprising finding in the at risk subjects, since 
the window for IL-10 inhibition of TNF-a production was so narrow, but the same 
cannot be said for the ARDS subjects, where TNF-a levels were higher. This raises the 
possibility that resistance to IL-10 may explain the increase in TNF-a release by ARDS 
AMs relative to at risk subjects. It should also be considered however that the timing of 
the BAL procedure in ARDS patients may be important. TNF-a may peak very early in
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the development of ARDS and thus it is conceivable that the initial inhibition of TNF-a 
by IL-10 is strong, but is then quickly down-regulated in response to over-production of 
IL-10 or TNF-a. This possibility could be explored by more performing bronchoscopy at 
regular time intervals, but repetitive bronchoscopy can potentially induce lung injury so 
less invasive AM retrieval techniques such as tracheal suction would have to be 
employed.
In order to establish an autocrine role for the effect of IL-10 on TNF-a, IL-10 was 
measured in AM supernatants. Interestingly, DL-10 production was depressed in the AMs 
of both patient groups, indicating a possible defect in IL-10 production which may 
account somewhat for the inflammatory disease seen in ARDS. Although the 24 hour 
timepoint selected for supernatant collection may not be ideal for IL-10, which peaks at 
24-48 hours in PBMs (Wanidworanun and Strober, 1993), this is an unlikely explanation 
for the findings since when plasma and BALF were examined for IL-10 the ARDS 
patients had less IL-10 in both fluids than at risk subjects. ARDS BALF contained 
significantly less IL-10 than normal BALF. A more detailed study of the time course of 
IL-10 release by AMs from ARDS subjects, as well as studying the changes over time in 
the disease process by tracheal suction retrieval would be desirable to evaluate further 
IL-10 production in ARDS. IL-10 is presumed to have a largely anti-inflammatoiy role, 
having been shown to inhibit pro-inflammatory cytokine release (Ralph et al. 1992) and 
to down regulate class II MHC and B7 which are important molecules in antigen 
presentation (de Waal Malefyt et al. 1991b; Ding et al. 1993b). IL-10 has been found to 
be elevated in rheumatoid arthritis (Katsikis et al. 1994) and that its inhibition by anti-IL- 
10 antibody leads to increases in active TNF-a and a potential exacerbation of the 
inflammation. Thus it is possible that IL-10 has a beneficial effect in inflammatory 
disease. Indeed, a recent preliminary study by Donnelly and co-workers (1995) found 
that elevated IL-10 in ARDS patients correlated with survival. Hence it may be the case 
in this study that patients with low levels of IL-10 had less control of their inflammatory 
response to the trauma they endured and were therefore more likely to develop ARDS. 
This work is very preliminary however, and a more thorough understanding of the time 
course of TNF-a and IL-10 release by AMs in ARDS may help unravel their true 
relevance to the pathophysiology of ARDS and pulmonary inflammation in general.
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Soluble TNF receptor is also considered to be anti-inflammatory, since it can inhibit the 
effects of TNF-a by binding to it in biological fluids (Haran et al. 1991). There has been 
some debate as to whether TNF-R can act as a carrier for TNF-a, so permitting a 
circulating pool of TNF-a which is resistant to degradation. There is a general 
consensus, however, that its main role is that of a biological inhibitor (Engelmann et al. 
1990; Foley et al. 1990). TNF-R has been found to be elevated in a number of diseases, 
including rheumatoid arthritis (Heilig et al. 1992; Heilig et al. 1993) and sepsis syndrome 
(Froon et al. 1994). Elevated TNF-R has also been measured in human studies following 
infusion of endotoxin (Shapiro et al. 1993; Kuhns et al. 1995). This study has 
demonstrated a substantial elevation in plasma and BALF levels of TNF-R in both 
patient groups; a substantial elevation in the former and a more moderate increase in the 
latter. TNF-R was comparable in both ARDS and at risk subjects. We failed to find 
TNF-R in any AM and PBM supernatants from the two groups however. One 
explanation for this is that BALF TNF-R is derived from the circulation and arrives in 
the lung via capillary leak, but this is a less likely explanation for the at risk subjects who 
have little or no lung injury. Another explanation is that the TNF-R detected is not 
derived from mononuclear cells. It has been reported that the p55 receptor we measured 
is more abundant on cells epithelioid in nature (Paleolog et al. 1994) which supports an 
epithelial cell or endothelial cell origin. The dominant form of TNF-R on monocytic cells 
is the p75 receptor (Leeuwenberg et al. 1994), which has not been measured in this 
study due to the unavailability of a sensitive antibody. TNF-R has also been shown to be 
shed by T cells (Tartaglia et al. 1993), and neutrophils (Porteau and Hieblot, 1994) and 
their potential as the source cannot be ruled out, although p75 TNF-R is the dominant 
form of receptor on these cells also. Another explanation which must be considered is 
that the AMs and PBMs have been stimulated prior to collection by the acute disease 
process, and their capacity to shed additional receptor in culture may be diminished. Also 
cell damage cannot be eliminated, especially in the at risk subjects, since their cells failed 
to produce significant levels of TNF-a, TNF-R or IL-10. However, viability was 
measured and found to exceed 90% in all cases.
Despite the elevated TNF-R in ARDS it does need to be seen in comparison with the at 
risk data in order to determine whether this and or the cytokines IL-10 and TNF-a are 
factors in the progression to ARDS in patients who are at risk. In this study TNF-R was
113
increased equally in both groups, suggesting a role in trauma and shock, but it is not a 
prognostic indicator for ARDS. The results for IL-10 and TNF-a however do highlight 
subtle differences. The ratio of IL-10 to TNF-a is much greater in at risk subjects when 
compared to ARDS subjects. This could be indicative of inappropriate TNF-a regulation 
and may be an important mechanism in the pathophysiology of ARDS.
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7. ALVEOLAR MACROPHAGE POPULATIONS IN 
INFLAMMATORY LUNG DISEASE
7.1 Introduction
Alveolar macrophage populations have often been considered to be composed of a 
homogeneous population of cells, and indeed earlier chapters of this thesis have referred 
to the AM as if it were a single cell species. However, it has become apparent in recent 
years that AMs are in fact a heterogeneous population of macrophage-like cells (Poulter, 
1983) which can be separated into sub-populations on the basis of cell density (Ferro et 
al. 1987; Fuchs et al. 1988) and phenotypic markers (Poulter, 1990).
There are approximately 109 resident AMs within the alveoli of the adult human lung, 
with at least one AM patrolling each alveolus. Although they have a generous life-span 
of at least several months, they do need to be replenished from time to time, or increased 
in number, especially during infection or an inflammatory response. Macrophages are 
derived from the myeloid lineage of haemopoietic cells, and the circulating PBM can be 
considered the penultimate stage of macrophage differentiation (Stites and Terr, 1987). 
It is thought that PBMs migrate from the circulation, across the vascular endothelium 
and the interstitium into the alveolar space where they undergo a final maturation into 
AMs (Thepen et al. 1994). This process is highlighted in the neonate, where at birth the 
human lung contains few, if any AMs, and over the first few days post partum the AM 
populations are established from circulating PBMs (Fry et al. 1984). Monocyte 
maturation is thought to account for a large proportion of the on-going replenishment of 
AMs, although some studies have suggested that AMs may proliferate in the lung 
(Nakata et al. 1991). It was presumed that macrophages were terminally differentiated 
and had therefore lost the capacity for cell division, but it has recently been demonstrated 
that the human AMs can proliferate, at least in vitro, in response to the cytokine GM- 
CSF (Nakata et al. 1991). This mechanism is thought to be important in smokers and 
subjects with sarcoidosis, where GM-CSF levels in the lung are significantly elevated
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(Itoh et al. 1993). Thus it seems likely that AM heterogeneity may arise from 
environmental factors in the lung which may impinge on the newly-recruited PBMs or 
the established AM populations.
AM population studies to date can be divided into two main areas of research. Some 
groups have performed density fractionation of AMs using percoll gradients and have 
noticed that different fractions possess differing functional capacities. For instance IL-1- 
6 secretion and microbicidal activity is found to be greatest in the most dense sub- 
fraction (Fuchs et al. 1988). It has also been postulated that the ability of AMs to 
suppress T cell activation (accessory cell function) is direcdy proportional to cell size 
(Holt et al. 1993). The AM increases in size, and thus becomes less dense as it matures 
from a monocyte to a tissue macrophage, so such studies suggest an increased potency 
in immature macrophages. This is underlined by studies directly comparing mediator 
release by AMs and PBMs. IL-1 and IL-6 for example are released in higher quantities 
by PBMs than AMs, although the opposite is true for TNF (Strieter et al. 1989b) and the 
anti-inflammatory prostanoid PGE2 (Hempel et al. 1994). This is appropriate since 
during an inflammatory event the resident population is likely to be enriched by 
extravasation of large numbers of circulating PBMs, thus the balance of established AMs 
to new recruits may be important in inflammatory lung disease.
Other groups, notably Dr Len Poulter and colleagues at the Royal Free Hospital in 
London have focused not on cell density, but on the expression of phenotypic markers. 
These markers have been designated the prefix RFD and are defined in the table below:
Table 7.1
MARKER MOL. WT. LOCATION
RFD1 28-33 kDa EPITOPE OF CLASS H MHC
RFDR1 28-33 kDa AS ABOVE
RFD7 77 kDa MATURE TISSUE MACROPHAGES
Janossy et al. 1986
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Using a panel of monoclonal antibodies against the RFD antigens Poulter and co­
workers have established three sub-populations of AMs:
Table 7.2




Functional studies using the autologous mixed lymphocyte reaction (MLR) have 
determined that RFD 1+D7" cells are potent APCs, expressing strongly class II MHC with 
a morphology highly suggestive of DCs (Poulter, 1990; Spiteri and Poulter, 1991). 
However, co-culture with RFD1+D7+ AMs can inhibit this accessory cell function 
(despite their possession of class II MHC), and these cells have been designated 
suppressor macrophages (Poulter, 1990). RFD1'D7+ cells form the majority of AMs in 
the normal lung and are poor accessory cells. However, functional studies with latex 
beads have demonstrated potent phagocytic capability which is lacking in the other two 
populations, and the latter are also deficient in lysosomal enzymes required for 
phagolysosome digestion (Spiteri and Poulter, 1991).
The partial characterisation of these populations has generated some interest in their role 
in inflammatory lung disease. The suppressive role of AMs has been reported in previous 
studies (Bilyk and Holt, 1993; Holt et al. 1993), and is believed to be important in the 
prevention of inappropriate inflammatory responses in an environment which is 
vulnerable to foreign particle bombardment. Indeed, AM depletion in the rat lung has 
demonstrated that accessory cell function of the remaining DCs in the alveoli, 
interstitium and BALT is greatly enhanced (Holt et al. 1993). Studies with RFD 
monoclonal antibodies appear to suggest that suppressor function is a property of
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RFDl+D7+AMs and therefore its distribution may be important in inflammatory disease. 
It has been shown that in normal gut mucosa these cell represent more than eighty per 
cent of the macrophage population, but that in the inflammatory bowel condition, 
Crohn’s disease, this is greatly reduced (Allison and Poulter, 1991). In contrast this 
population represents less than seven per cent of the total AMs in the human lung and 
appears to increase in sarcoidosis and fibrosing alveolitis (Campbell et al. 1986; Poulter, 
1990) which are both assumed to have an inflammatory component in their pathogenesis. 
It seems possible that the balance of RFD I'D?'cells is more likely to be implicated in the 
pathogenesis of interstitial lung disease.
This thesis is based upon the hypothesis that cytokine release (notably TNF-a and IL-10) 
from AMs has a role in the pathology of inflammatory lung disease. Knowing that AMs 
are a heterogeneous population of cells the following questions were addressed: (1) is 
the distribution of AM populations distorted in sarcoidosis, CFA and ARDS?; (2) do 
AM phenotypes from different diseases correspond in terms of cytokine profile? (3) can 
AM populations be generated in vitro to allow more thorough investigation of their 
functional properties? AMs from patients and normal subject were isolated from BALF 
and analysed by immunocytochemistry for RFD markers. AMs from normal subjects 
were also purified on the basis of phenotype and cultured for the presence of TNF-a. 
PBMs from normal subjects and the cell lines THP-1 and U937 were cultured in vitro to 
generate the expression of RFD markers.
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7.2 Experimental Design
7.2.1 Phenotypic distribution in normal BALF and the BALF of subjects with lung 
disease. The ability of the sub-populations to produce TNF-a.
AMs were isolated from BALF. RFD I'll?* cells were purified from the non-adherent 
BAL cells by using negative selection with magnetic beads conjugated with anti-CD3 
and anti-CD66b to remove contaminating T cells and PMNs. The other two populations 
were separated following a two hour adherence by density centrifugation on a 
metrizamide gradient (refer to Chapter 2). Cytospins of the enriched populations were 
taken to determine their purity and their intra-cellular expression of TNF-a. To assess 
distribution of RFD antigens cytospins of total AMs were taken and analysed by double­
labelled immunofluorescence (see Chapter 2). CD68 staining was also carried out to 
confirm macrophage identification. Purified AM subsets were isolated from normal 
BALF and cultured in RPMI for 24 hours to assess their ability to produce TNF-a. This 
was determined by ELISA (see Chapter 2).
7.2.2 Induction of RFD1 and RFD7 expression in MDMs, THP-1 and U92j7 cells
PBMs from normal volunteers were purified by density centrifugation and adherence. 
They were then cultured for up to twelve days in RPMI + 10% FCS alone, or in the 
presence of varying concentrations of LPS, PMA, IFN-y and dexamethasone (dex), 
separately or in combination. PBMs were cultured at 1 x 106 cells per ml in 24 well 
tissue culture plates, and cytospins were taken at daily or 2 or 3 day intervals during the 
culture period. Cytospins were stained for their expression of RFD1 and RFD7 by 
double-labelled immunofluorescence. THP-1 and U937 cell lines were similarly cultured, 
either undifferentiated, or in the presence of the maturation factors IL-l-a, PMA, 




7.3.1 Distribution of RFD antigens in normal BALF
Four AM sub-populations could be determined from normal BALF. The jmajor -j0rTi 
population, accounting for 76.77 ± 4.18% of the total AMs was the RFD1'D7+ “mature ,vVa5 
tissue macrophage” (Figure 7.1). “Accessory” AMs, RFD 1*07’ accounted for 9.15 ± ■■^37- 
2.93% and the RFD1+D7+ “suppressor" AMs represented 6.54 ± 2.77% of the total. ^  
8.08 ± 1.96% was made up of AMs which were weakly CD68 positive but which did/npkg pn, 
express RFD antigens.
7.3.2 Distribution of RFD antigens in sarcoidosis
AM populations were distorted in sarcoidosis BALF. Although the major population y r 
remained the RFD1'D7+ phenotype they only represented 34.52 ± 17.19% of thgrtotal, ; 
with 29.5 ± 12.39% RFD1+D7+ suppressor AMs and 26.25 ± 10.28%. RiprT>7' 5 - 
accessory AMs (Figure 7.2). The accessory and suppressor phenotypes were.bqth-^ 
significantly elevated when compared to normal subjects ip < 0.05). AMs lacking RFD. : q 
antigens were present in similar proportion to normal BALF, representing 10.75 ± 
2.65% of the total AMs.
7.3.3 Distribution of RFD antigens in CFA
The BALF of CFA subjects was the most distorted of all groups studied. Theiigajor ErCH 
population comprised of RFD1+D7+ suppressor AMs with 49.03 ± 20.02% of the total 49 p 
(Figure 7.3). This was significantly higher than normal subjects ip < 0.05). Likewise ^  n 
RFD1+D7‘ cells were also significantly increased to 29.78 ± 11.88% ip < 0 .05^ Bp 
contrast, the RFD1'D7+ phenotype was significantly lower ip < 0.05) representing^ly ^  . (J
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Figure 7.1 Distribution of RFD1 and RFD7 in AM s derived
from normal subjects (n = 16)
76.77 ± 4.18 % 
RFD1-D7+
6.54 ± 2.77% 
RFD1+D7+
9.154 ± 2.93% 
RFD1+D7-
8.07 ± 2.93% NO 
EXPRESSION
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Figure 7.2 Distribution of RFD1 and RFD7 in AM s derived
from subjects with sarcoidosis (n=14)
•
s  r :
10.75 ± 2.65% 
NO
EXPRESSION
16.25 ± 10.28% 
RFD1+D7-
34.52 ± 17.19% 
RFD1-D7+
29.50 ± 12.39% 
RFD1+D7+
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Figure 7.3 Distribution of RFD1 and RFD7 in AM s derived
from subjects with CFA (n = 14)
49.03 ± 20.02% 
RFD1+D7+
29.78 ± 11.88% 
RFD1+D7-
1.02 ± 0.33% NO 
EXPRESSION
20.17 ± 12.17 % 
RFD1-D7+
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20.17 ± 12.17% of total AMs. Interestingly AMs with no RFD expression formed a very 
low proportion in CFA BALF, with only 1.02 ± 0.33% (P < 0.01).
7.3.4 Distribution of RFD antigens in subjects at risk of ARDS
This group was studied in order to consider any effect of ventilation which may have 
distorted the profile for ARDS subjects. The population profile of at risk BALF was no 
different from that seen in normal subjects (Figure 7.4). The distribution was 81.11 ± 
4.84% RFD1'D7+AMs, 8.33 ± 6.01% RFD1+D7+ suppressor AMs and 3.89 ± 2.00% 
RFD 1+D7'accessory AMs. 6.67 ± 3.65% of AMs had no RFD expression.
7.3.5 Distribution of RFD antigens in subjects with ARDS
RFD1D7+ AMs formed the major population in ARDS BALF, representing 67.75 ± 
9.68% of the total (Figure 7.5). Expression of RFD14D7+ suppressor AMs and 
RFD1+D7' accessory AMs was elevated, although not significantly ( p  = 0.058), when 
compared to at risk BALF, with 19.75 ± 10.75% and 9.02 ± 4.2% respectively. Cells 
expressing neither antigen represented 3.48 ±2.61% of the total.
7.3.6 Intra-cellular TNF-a production and protein release by AM sub-populations 
from normal BALF
Intra-cellular TNF-a was determined by immunocytochemistry and visualised with DAB 
substrate (refer to Chapter 2) (see plate 7.1). Although not fully quantitative, relative 
amounts of TNF-a were expressed as below:
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Plate 7.1 TNF-a ismnimostainmg of alveolar macrophages
RFD1+D7 AMs RFD1+D7+ AMs
RFD1 D7+ AMs
SUBJECT RFD1+D7' RFD1T)7+ RFD1+D7+
1 0 + +
2 0 + +
3 0 + +
4 0 ++ +++
5 0 ++ +++
0 = NO STAINING; + = WEAK; ++ = MODERATE; +++ = STRONG
The ELISA data demonstrated that the RFD 1 “1)7' accessory macrophages were unable 
to produce TNF-a (Figure 7.6). The RFD1'D7+ AMs were able to elicit a moderate 
response to LPS, giving 1.31 ±0.71 ng/ml TNF-a in response to 10 pg/ml LPS, but 
there was very little spontaneous TNF-a production (0.103 ± 0.026 ng/ml). In contrast, 
the RFD1+D7+ suppressor AMs produced 2.27 ± 0.71 ng/ml spontaneous TNF-a, which 
rose to 6.79 ± 3.48 ng/ml in response to 10 |ig/ml LPS.
7.3.7 Induction of RFD1 and RFD7 in cultured, unstimulated monocyte-derived 
macrophages
PBMs were cultured for a total of eleven days without media change. Maturity of 
MDMs as assessed by CD68 expression was achieved by 5 days in culture (Figure 7.7). 
RFD1 expression was first observed at day 2, peaking at day 4 with 13% of cells 
expressing it (p < 0.05). By day 10 no RFD1 expression remained. RFD7 expression 
was delayed until day 3. By day 6 more than 50% of MDMs were expressing RFD7 and 
this level was maintained throughout the culture period. At no time was dual expression 
observed.
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Figure 7.4 Distribution of RFD 1 and RFD7 in AM s derived
from subjects at risk of ARDS (n=15)
81.11 ±4.84%  
RFD1-D7+
6.67 ± 3.65% NO 
EXPRESSION
3.89 ± 2.00% 
RFD1+D7-
8.33 ±6.01%  
RFD1+D7+
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Figure 7.5 Distribution of RFD1 and RFD7 in AM s derived
from subjects with ARDS (n=16)
9.02 ± 4.20% 
RFD1+D7-
3.48 ±2.61% NO 
EXPRESSION
19.75 ± 10.75% 
RFD1+D7+
67.75 ± 9.68 % 
RFD1-D7+
12?
Figure 7.6 SPONTANEOUS AND LPS-INDUCED TN F-a
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Purified populations of AMs cultured for 24 hours, 1 x 106 cells 
per ml, with a dose range of LPS. Control AMs cultured in medium 
alone.
Figure 7.7 EXPRESSION OF RFD1 AND RFD7 PHENOTYPIC MARKERS ON 
PBMS CULTURED IN RPMI + 10% FCS (n = 4)
H  RFD1 
I I RFD7 
■ CD68
0 1 2 3 4 5 6 7 8 9  10 11 12
DAYS IN CULTURE
PBMs from healthy subjects, cultured for up to 11 
days, 1 x 106 cells per ml. Cytospins taken a daily 
intervals to assess expression of RFD markers and 
CD68 by immunocytochemistry
130
7.3.8 The effect of LPS and PMA treatment on RFD antigen expression on MDMs
PBMs were isolated and cultured for up to 11 days with 10 pg/ml LPS and 10'7 M PMA. 
Cytospins were taken at intervals and analysed for RFD expression. LPS increased 
RFD1 expression after 8 days, peaking at day 11 at 31.79 ± 11.36% whereas RFD7 
expression declined after day 8 with only 38.06 ±12.01% expression at 11 days (Figure 
7.8). In contrast PMA inhibited expression of RFD1 and RFD7 at all time points.
7.3.9 The effect of IFN-y on RFD expression on MDMs
IFN-y is known to up-regulate class II MHC expression on monocytes (Trinchieri and 
Perussia, 1985), and has also been observed to increase RFD1 expression (Dr Len 
Poulter, personal communication). Various doses of IFN-y were tried and 250 U/ml was 
found to be the optimum concentration. In our system IFN-y did indeed induce RFD1, 
maximally at day 9, with more than 80% expressing RFD1 ip < 0.001) (Figure 7.9). In 
contrast RFD7 expression was almost totally inhibited at all time points (p < 0.001). No 
dual expression was observed.
7.3.10 The effect of dexamethasone on RFD expression by MDMs
Steroids such as budesonide have been shown to reduce RFD1 expression in diseases 
such as asthma and CFA (Marianayagam and Poulter, 1991), and Poulter and co- 
workers have also observed an effect in vitro (personal communication). 10‘7 M dex 
(optimum concentration) totally inhibited RFD1 expression on MDMs ip < 0.05) 
(Figure 7.10), and in contrast RFD7 was strongly up-regulated to more than 95% 
positive cells ip < 0.05). RFD7 also appeared as early as day 1 in culture and the high 
level of expression was maintained throughout the culture period. No dual expression 
was observed.
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Figure 7.8 THE EFFECT OF LPS AND PMA ON RFD1 AND RFD7
EXPRESSION ON PBMs IN CULTURE (n = 4)
RFD1 CONTROL 
RFD7CONTROL 
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DAYS IN CULTURE
PBMs from healthy subjects, 1 x 106 cells per ml, cultured 
with or without 10 pg/ml LPS and 10"7 M PMA. Control cells 









Figure 7.9 THE EFFECT OF IFN-y ON RFD1 AND RFD7
EXPRESSION ON CULTURED PBMS (n = 4)
100 RFD1 CONTROL 
RFD7 CONTROL 







0 1 2 3 4 5 6 7 8 9 10 11
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PBMs from healthy subjects, 1 x 106 cells per ml, cultured 










Figure 7.10 THE EFFECT OF DEXAMETHASONE ON RFD1 AND RFD7
EXPRESSION ON CULTURED PBMS (n = 4)
RFD1 CONTROL 
RFD7 CONTROL 







2 7 8 10 110 1 3 4 5 6 9
DAYS IN CULTURE
PBMs fom healthy subjects, 1 x 106 cells per ml, cultured
n
with and without 1 O' M dexamethasone. Control PBMs 
cultured in medium containing 0.1% ethanol (vehicle)
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7.3.11 The effect of IFN-y and dex co-culture on RFD expression on MDMs
Failure to induce the RFD1+D7+ phenotype in vitro when using compounds in isolation 
led to the hypothesis that in combination, IFN-y and dex may cause a dual up-regulation 
of RFD1 and RFD7. However this was not achieved in any combination (data not 
shown).
7.3.12 RFD and CD68 expression in undifferentiated U937 and THP-1 cells in 
culture
U937 and THP-1 cells did not express RFD antigens at any point during a 10 day culture 
period. THP-1 cells expressed high levels of CD68 expression (in excess of 90%) from 
day 0, but U937 cells expressed only 45% CD68 maximally throughout culture (Figure 
7.11). This suggests that THP-1 cells have a stronger macrophage phenotype than U937 
cells.
7.3.13 Induction of RFD antigens in THP-1 cells in response to IL-l-a, retinoic 
acid (RA) and dibutyryl cAMP
IL-l-a, retinoic acid and dibutyryl cAMP are all recognised inducers of macrophage 
differentiation in THP-1 cells (Tsuchiya et al. 1982). Overnight treatment with 10'7 M 
RA and 10 ng/ml IL-l-a had no recognisable effect on THP-1 cells (Figure 7.12), 
whereas 10'7 M dibutyryl cAMP had the effect of reducing CD68 expression. No 
changes in morphology were observed following treatment with any compound, 
indicating that full differentiation had not occurred. There was no RFD antigen 
induction.
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Figure 7.11 THE EXPRESSION OF CD68 ON UNSTIMULATED
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Ten day culture of U937 and THP-1 cells, 1 x 106 per ml. Cytospins 










Figure 7.12 THE EFFECT OF RETINOIC ACID, DIBUTYRYL cAMP, AND IL-1
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7THP-1 cell line , 1 x 1 0  per ml, cultured with 10' M retinoic acid, 
10 ng/ml IL-l-a or 10"7 M dibutyryl cAMP. Control cells cultured 
in medium alone.
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7.3.14 Induction of RFD antigens in U937 cells by PM A and vitamin D3
PMA, at 10’7 M induced a morphological change, inducing adherence and cell 
proliferation was arrested indicating terminal differentiation. CD68 was upregulated to 
83% after 2 days in culture (Figure 7.13), but cells could not be maintained alive for 
longer than 72 hours following overnight PMA treatment. Vitamin D3 is a known 
maturation agent for U937 cells (Amento et al. 1984), but 10'7 M failed to have any 
effect on the cells. There was no morphological change or alteration in CD68 expression 
in response to vitamin D3. RFD antigen expression was not induced on U937 cells in 









Figure 7.13 THE EFFECT OF PMA AND VITAMIN D3
ON MACROPHAGE DIFFERENTIATION IN U937 CELLS (n = 3)
100 n
KTM PMA/CD68 
—• — 10-7M VITAMIN D3/CD68 
—♦ — RFD1 (ALL STIMULI) 





0 1 2 3 4 6 8 9 105 7
DAYS IN CULTURE
U937 cell line, 1 x 106 cells per ml, cultured with 10"7 M PMA or 
10'7 M vitamin D3.
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7.4 Discussion
The purpose of this study was to examine the distribution of AM sub-populations in the 
lungs of normal subjects, and the lungs of patients with inflammatory lung disease, and 
to determine the consequences of any phenotypic variation by measuring the cytokine 
profiles of AM sub-populations from BALF and phenotypes generated in vitro. This 
would tell us whether a cell exhibiting a specific phenotype e.g. RFD1+D7+ would exhibit 
a similar cytokine profile whether it was derived from the lungs of normal subjects and 
those with inflammatory lung disease, or from MDMs. This would help to address one 
aspect of the role of sub-populations in the pathogenesis of pulmonary inflammation. •
In normal BALF the distribution of AM sub-populations was relatively constant, with the 
tissue macrophage phenotype of RFD1'D7+ in the majority. There were relatively low 
numbers of accessory (RFD1+D7‘) and suppressor (RFD1+D7+) AMs, as previously 
reported (Spiteri and Poulter, 1991). Functional studies suggest that such a distribution 
would be suitable for the normal lung environment, with the emphasis on scavenging and 
phagocytosis, but with a moderate ability to trigger T cell responses without excessive 
influence of either accessory or suppressor AMs. Such a balance was also found in 
subjects with ARDS and at risk of ARDS, (although the former had a slight elevation in 
the numbers of suppressor macrophages), indicating that phenotype distribution may not 
be an important element in the pathogenesis of acute lung injury. In BALF from CFA 
subjects, however, there was a difference, since the highest proportion of AMs were the 
suppressor macrophages, as previously reported (Noble et al. 1989; Campbell et al. 
1985), but there was also a significantly higher proportion of accessory AMs. Mature 
tissue macrophages were markedly reduced. This may shift the balance of macrophage 
activity in the lung away from phagocytosis, but it does not demonstrate whether a cell- 
mediated inflammatory response is more likely, since accessory AMs are out-numbered 
by almost 2:1 by suppressor AMs, which have previously been demonstrated to inhibit T 
cell activation by accessory AMs (Spiteri et al. 1992; Spiteri and Poulter, 1991). 
Sarcoidosis BALF also exhibited elevated populations of AMs expressing the RFD1 
antigen, as previously shown (Spiteri et al. 1992; Campbell et al. 1986; Ainslie et al. 
1989).
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It is difficult to speculate at this time what relevance AM sub-populations may have to 
the pathogenesis of interstitial lung disease, since functional studies have been limited to 
accessory cell function and phagocytosis, with no studies as yet on cytokine profiles. 
This study attempted to examine the TNF-a profiles of the populations so that we may 
have a preliminary indication of their ability to produce a pro-inflammatory cytokine 
which is implicated in the pathogenesis of both sarcoidosis and CFA (refer to Chapters’ 
4 and 5). Isolating the populations for this study was not without its difficulties. The 
methodology was long-winded, with a number of steps which could have lead to 
activation or alteration of the cell phenotypes. Also the yield was such that only very low 
numbers of suppressor and accessory AMs could be purified for culture. Sub-populated 
AMs were purified from normal BALF and cultured alone and in the presence of LPS. 
Interestingly the suppressor phenotype produced the most TNF-a, with a moderate yield 
from RFD1‘D7+ macrophages and little or no production by accessory AMs. Localisation 
of TNF-a production to a distinct sub-population has previously been demonstrated in a 
culture system which allowed determination of TNF-a production by individual AMs 
(Taylor et al. 1993), and showed that TNF-a production in response to LPS was limited 
to just 20% of the AM population. This thesis has previously demonstrated elevated 
TNF-a production by AMs in CFA (Chapter 5) and this may now be at least partially 
explained by the increase in suppressor macrophages in these subjects. Indeed the term 
“suppressor” AM could be considered a misnomer. The finding that accessory AMs. 
produced barely measurable TNF-a supports the theory that these cells may be closely 
related to DC, which themselves are very poor producers of soluble mediators (Toews, 
1991). Since accessory AMs account for more than 25% of AMs in sarcoidosis, with a 
ratio of approximately 1:1 to suppressor AMs, compared to 2:1 in CFA, this may help to 
account for the relatively low production of TNF-a detected in sarcoidosis subjects 
(refer to Chapter 4), although the adherence purification method used should have 
eliminated accessory AMs from the culture. Caution must be observed when interpreting 
this data since cell purity rarely exceeded 80% and contaminating populations was a 
constant problem. Also AMs in which TNF-a was determined were derived only from 
normal subjects, so it cannot be automatically assumed that sub-populations from 
patients with interstitial lung disease would behave in the same manner. An additional 
problem is the long-winded purification process which could easily distort the behaviour
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of the AM sub-populations, either by cell activation or the artificial separation preventing 
possible cross-talk between the subsets.
One of the greatest problems encountered during this study was low cell numbers. 
Although a reasonable yield of mature tissue AMs could be purified from normal BALF, 
only the occasional subject (n = 4) yielded enough AMs to purify the other two 
populations. Although these populations may be obtained more easily from sarcoidosis 
and CFA subjects, it is not yet known how they may be altered by disease. This lead to 
the pursuit of in vitro generation of RFD antigens using MDMs, THP-1 cells and U937 
cells. MDM cultures are useful for generating macrophage morphology in vitro and are 
thus widely used as macrophage substitutes (Gessani et al. 1993; Elias et al. 1985; 
Mayemik et al. 1983). Eleven day culture of MDMs did indeed express the RFD 
antigens, RFD1 early and RFD7 later, but at no time point could a very high yield of 
either population be obtained. The use of the class IIMHC inducer IFN-y and the steroid 
dexamethasone succeeded in generating relatively pure populations of RFD 1 "1)7' and 
RFD1D7+ MDMs respectively. However attempts to generate RFD1+D7+ cells failed. It 
may be that another cytokine found in the lung environment is required, or the AM close 
association with DC and epithelial cells in the lung is required for full differentiation. 
Further attempts to generate the suppressor phenotype in cell lines such as U937 and 
THP-1 also failed; in fact they could not be stimulated to express any RFD antigens at 
any stage. This finding stresses the distinction between human cell lines and primary cells 
in culture and underlines the importance of using fresh human tissue whenever possible 
in cell biology studies.
The inability to induce all three sub-populations prevented a meaningful functional study 
of the phenotypes. Although we managed to carry out some very preliminary work 
measuring TNF-a production, many questions remain. Cytokine production is clearly 
important in the arena of pulmonary inflammation and it is important to assess how the 
sub-populations compare to one another in healthy and diseased subjects. One 
outstanding question is the true relevance of the RFD antigen. RFD7 has been proposed 
to be a cytoskeletal component, and RFD1 is an epitope of class II MHC, but further 
characterisation is required. The RFD antigens have been recognised since 1985 and it is 
somewhat disappointing that no comprehensive characterisation studies have been
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performed which may have lead to a CD (cluster of differentiation) classification and a 
wider body of interest
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8. GENERAL DISCUSSION
The purpose of this thesis was to address the regulation of TNF-a in normal AMs and to 
determine whether any abnormality in the regulatory mechanisms could be implicated in 
the pathology of the inflammatory lung diseases sarcoidosis, CFA and ARDS.
The overall findings of this study have demonstrated that TNF-a protein and mRNA can 
be inhibited by the addition of IL-10 to human AMs and PBMs in culture, but the 
mechanisms of this inhibition are not fully understood. In addition, it has highlighted a 
role for soluble TNF-R as an inhibitor of TNF-a bio-activity. In Chapter 3, northern 
analysis of AMs and PBMs revealed that TNF-a mRNA expression was reduced in 
response to IL-10, optimally at 50-100 U/ml (5-10 ng/ml). A decrease in the 
transcription rate of the TNF-a gene in response to LPS would be an explanation for 
this, but was not investigated here. To clarify this nuclear run on assays would need to 
be performed, where cell nuclei are isolated, protein synthesis is arrested, and the 
formation rate of newly transcribed mRNA is measured using incorporated radio-active 
nucleotides. Unfortunately, this procedure contains a high degree of difficulty and it 
takes several months to make the technique reproducible, thus it was not possible to 
perform nuclear run-on assays in the time-frame of this study. The protein synthesis 
inhibitor actinomycin was utilised however to ascertain any effect that IL-10 may have 
on the half-life of TNF-a transcripts. This experiment showed that mRNA degradation 
was not enhanced by addition of IL-10, an interesting finding, since the TNF-a gene 
does contain a UA-rich sequence which is thought to confer instability on the resultant 
transcript. It can therefore be concluded that IL-10 is working at least in part by 
reducing transcription of the TNF-a gene.
The switching on of gene transcription is a complex process involving the interplay of 
many intra-cellular messengers. The first step in the process is the binding of the ligand, 
in this instance IL-10, to its cell surface receptor. Unfortunately, the human IL-10 
receptor has as yet not been characterised, and the amino acid sequences of IL-10 which
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are critical for binding are unknown. It is well known however that receptor density is an 
important factor in determining the sensitivity of a cell to the actions of a given cytokine. 
It is interesting to note that AMs from CFA subjects did show TNF-a inhibition in 
response to IL-10 at a dose 100 times lower that the minimal response seen in AMs from 
normal subjects. An increase in IL-10 receptor density could be an explanation for this 
which is worthy of investigation, but enhanced affinity of the receptor is equally 
plausible.
Once the ligand has bound to its receptor a cascade of intra-cellular events is initiated, 
which ultimately leads to the switching on or off of gene transcription. There is currently 
no published literature on the nature of IL-10 signalling in human cells, but its known 
that the receptor belongs to the superfamily of class II cytokine receptors which includes 
the interferon receptor group (Ihle et al. 1996). These receptors have been demonstrated 
to signal through the JAKs (Janus protein tyrosine kinases) and STATs (signal 
transduction activated transcription) system as illustrated below:
Figure 8.1 Mechanisms of activation of STATs in signalling by the cytokine 





Ligand-induced receptor aggregation initiates a response by bringing the associated 
JAKs into sufficient proximity to allow trans-phosphorylation and activation of catalytic 
activity. The JAKs subsequently phosphorylate the receptor chains at multiple sites. 
STATs are then recruited from the cytoplasm where they interact with tyrosine kinases, 
resulting in dimerization and translocation into the nucleus. The STAT dimers bind to 
response elements in the promoter of the cytokine gene, resulting in activation, or in the 
case of IL-10, inhibition.
This scheme is an over-simplification of events, since there are at least 5 different STAT 
dimers known, all recognising different sequences in cytokine gene promoters, but it 
does give an indication of a mechanism by which IL-10 may inhibit TNF-a directly. This 
mechanism does remain to be confirmed, however and there is strong evidence that LPS- 
induction of TNF-a in macrophages is dependent upon another type of transcription 
factor known as nuclear factor kappa B (NF-kB), which is activated by another intra­
cellular pathway incorporating protein kinase C phosphorylation (Vincenti et al. 1992). 
In this instance NF-kB dissociates from its cytoplasmic inhibitor IF-kB and translocates 
into the nucleus, where it associates with the appropriate cytokine genes and enhances 
transcription. There are four known binding sites for NF-kB on the human TNF-a gene 
(Vincenti et al. 1992). It is not presently known whether IL-10 itself has a direct effect 
on transciption through the JAK STAT pathway, or whether the effect is indirectly 
inhibiting the pathway of LPS induction. IL-10 inhibition was not compromised by 
addition of the transcription inhibitor cyclohexamide thus excluding the requirement for 
de novo protein synthesis for the inhibitory activity of IL-10. This is more indicative of a 
direct effect. Another line of inquiry which is opened by this study is the role of TNF-a 
polymorphisms in lung disease. Previous studies have shown the existence of TNF-a 
variants, which are associated with auto-immunity, and possibly enhanced production of 
TNF-a (Wilson et al. 1993). The most studied variant has an adenine in place of a 
guanine residue at position 308 in the promoter region of the gene . It would be of great 
interest to know whether these polymorphisms are regulated differently in response to 
cytokines such as IL-10 which leads to their pathological effects.
Once these regulatory pathways have been elucidated in normal macrophages it can then 
be postulated that abnormalities in signalling may account for the heightened sensitivity
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to IL-10 in CFA, but in sarcoidosis and ARDS IL-10 inhibition of TNF-a did not appear 
to be abnormal. Indeed in ARDS patients it was production of IL-10 which appeared to
published reports of IL-10 production in alveolar macrophages specifically, but studies 
have demonstrated an enhancement of IL-10 production by PBMs in response to TNF- 
a , which is an interesting feedback loop worthy of investigation. This highlights this 
importance of TNF-R, which in its cell-bound form is the major signalling receptor for 
TNF-a and therefore its presence on the cell surface could be critical to the amount of 
IL-10 produced in environment containing TNF-a. In its alternative form, shed from the 
membrane in response to matrix metalloproteinase enzymes, it is able to inhibit the 
bioactivity of TNF-a. Either way it seems possible that TNF-R up-regulation may lead 
to inhibition of TNF-a, either directly by mopping it up in biological fluids, or indirectly 
by facilitating IL-10 production by macrophages. It is becoming clear that individual 
cytokines may have limited importance and it is the inter-play of these factors which may 
result in pathology, as described below:
Figure 8.2 Putative regulatory network for TNF-a in AMs from normal subjects
be compromised, which is a process barely touched upon in this thesis. There are no
LPS
T N F - a  "  , TNF-R IL-10
^  I N D U C T I O N  
Q  I N H I B I T I O N
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This scheme represents a simplified view of TNF-a regulation in normal AMs, based on 
data in this thesis and published findings in human PBMs. It does not indicate a role of 
IL-13, another regulatory cytokine, since this remains to be established, but even with 
this omission it is clear that the regulation is complex and there is a great deal of overlap 
between TNF-a, TNF-R and IL-10. A shift in the balance of this network, for instance, 
too little TNF-R or IL-10 production, could lead to inappropriate TNF-a bio-activity 
resulting in a pathological effect. The thesis does propose a role for reduced IL-10 in the 
pathogenesis of ARDS, as well as demonstrating the masking of immuno-reactive TNF- 
a  by soluble TNF-R in sarcoidosis and CFA, but many questions remain unanswered. 
This highlights a desirability to examine in some detail TNF-a regulation in a more user- 
friendly system such as a monocytic/macrophage cell line where limited cell numbers are 
not an issue and a greater range of experiments could be performed. However it remains 
the case that human cells, especially those derived from disease subjects do not mirror 
events seen in cell lines, thus research utilising clinical material is still the most relevant in 
the arena of biomedical research. Since this is an inescapable fact, methods must be 
sought to allow a more detailed study of AMs from subjects with inflammatory lung 
disease.
Isolation of AMs from human subjects has never been a straightforward procedure. 
Bronchoalveolar lavage is invasive and could lead to activation of AMs during the 
process of retrieval. Activation as well as cell damage may also occur in the purification 
process, which in this thesis utilised adherence, followed by cell scraping. There is no 
easier way of obtaining AMs form human subjects - lung biopsy is even more invasive - 
but selection by magnetic beads may be a better alternative to adherence purification. 
This was the protocol of choice in ventilated subjects on ITU since contaminating PMNs 
in these subjects were often adherent, and it was interesting to note that AMs from 
subjects at risk of ARDS produce much less TNF-a in vitro that normal subjects, 
perhaps indicating activation of normal AMs prior to culture. Of course, this could also 
be explained by suppression of AM function in vivo by ventilation or the cocktail of 
drugs administered to ITU patients.
Much of the data in this thesis is of a preliminary nature and increased numbers of 
patients need to be recruited to establish any strong significance to many of the findings.
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There is still much scope also for unraveling the relationship between IL-10, TNF-a and 
TNF-R in inflammatory lung disease. In terms of the supernatant data obtained, twenty 
four hours was the chosen time point since this is considered optimum for assessing 
TNF-a production, but this time point is unlikely to be appropriate for assessing IL-10 
and TNF-R production, especially if responding in an autocrine fashion to TNF-a. 
Further studies with later time points are required to give a more detailed profile analysis 
of cytokine production in AMs. Unfortunately this does require greater cell numbers. 
BAL gives a limited return of AMs, usually no more than ten million per subject. The 
usual cell culture density is one million per ml which does restrict the number of 
experiments one may carry out on each subject. This difficulty may be solved by 
adopting a procedure known as ELISPOT, which permits protein determination on only 
a handful of cells using antibodies added directly to the cell culture. Polymerase chain 
reaction (PCR) is another technique which would eliminate the requirement for large cell 
numbers. Northern analysis requires at least five million cells per point to isolate 
sufficient mRNA for study, but reverse transcriptase PCR, which makes DNA copies of 
the mRNA and amplifies it many times, requires one hundred thousand cells per point, so 
permitting a more detailed investigation of cytokine expression and regulation at the 
molecular level. The detection of TNF-R could also be improved by assaying for p75 
receptor as well as p55. The antibody for p75 detection has recently become available, 
and we have preliminary indications suggesting that it is produced in higher quantities 
than p55, especially in sarcoidosis and CFA. The IL-10 receptor is also likely to be an 
important factor, since increased potency of IL-10 inhibition of TNF-a may be explained 
by IL-10R up-regulation, either spontaneously or in response to LPS. An appropriate 
antibody is unavailable at this time, but binding studies using labelled IL-10 could give 
insight into its recognition by AMs. Also, it is not appropriate to concentrate solely on 
the AM as a source of these proteins. Other cells are undoubtedly indicated, including T 
and B lymphocytes, PMNs and epithelial cells. Immunocytochemistry and in situ PCR of 
lung biopsy tissue could give insight into the possible sources of TNF-a, IL-10 and 
TNF-R and explain the finding that although BALF TNF-a is elevated without exception 
in all three inflammatory lung diseases investigated, there was not always increased TNF- 
a  production by AMs. Finally, it was attempted to purify the AM sub-populations in this 
study in order to evaluate whether it is appropriate to examine cytokine profiles on a
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heterogeneous population of AMs in disease. However, methodological problems 
compromised this particular study and it was not possible to perform cultures on 
separated AMs from disease subjects, or even carry out a more detailed study on 
cytokine profiles in AM sub-populations from the normal lung. Thus it must be 
understood that the majority of conclusions drawn refer to cytokine release by co­
cultured tissue and suppressor macrophages only.
In summary this study has attempted to unravel the nature of the relationship between 
AM-derived TNF-a and the regulatory proteins IL-10 and TNF-R. In so doing it has 
raised a multitude of questions and opened up many possible avenues of investigation. 
By pursuing one or more of these lines of investigation it is hoped that one would be 
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Lysis of Erythrocytes with Ammonium Chloride
Add 10 ml of 0.17 M tris buffer (20.6 g/1) to 90 ml of 0.16 M Ammonium Chloride 
solution (8.3 g/1) and incubate for 5 minutes at 37°c. Wash in complete media and 
resuspend.
Diff-Quick Staining (Baxter-Dade)
Immerse air-dried cytospins for 5 seconds in the fixative solution before 5 second 
immersion in solution 1, followed by 5 seconds in solution 2. Wash the slides in distilled 
water and examine under the microscope at x 400 magnification.
TNF-a ELISA BUFFERS
COATING BUFFER
Dissolve 4.27g BES (N, N-bis (2-hydroxyethyl)-2-amino ethane sulphonic acid - SIGMA 
B-9879) in 1 litre deionised water, adjust to pH 7 using 10% NaOH (BDH Analar). 
Store at ambient temperature for up to 1 week.
GLAZING BUFFER
Dissolve lOg lactose (BDH Analar) and O.lg BSA (SIGMA) in 100 mis water on day of 
use.
BLOCKING BUFFER
1% BSA (SIGMA) in coating buffer on day of use.
185
PBS SOLUTION
Dissolve Dulbecco’s formula (modified) without magnesium and calcium (Imperial labs) 
- 9.55g/litre deionised water. Store at ambient temperature for up to 2 weeks.
SAMPLE DILUENT
Add 200 mis heat inactivated normal mouse serum (Sigma) to 10 mis PBS containing 
1% BSA.
CITRATE PHOSPHATE SUBSTRATE BUFFER
6.3 g citric acid monohydrate (Fluka) in 800 mis of deionised water. pH to 4.1 with 
KOH and adjust volume to 1 litre with deionised water. Stable for 6 months at 4°C.
TMB SUBSTRATE
Dissolve 120 mg tetramethylbenzidine substrate (Fluka) in 5 mis acetone. Make up to 50 
mis with ethanol and add 500 pi of 30% H2O2. Store at an ambient temperature in the 
dark for up to 6 months.
IL-10 ELISA Buffers
COATING BUFFER
0.1M NaHC03 pH 8.2 in deionised water. Store at 4°C for up to 6 months.
PBS SOLUTION
80.0g NaCl, 11.6g Na2HP04, 2.0g KH2P04, 2.0g KCL (all Fisons) in 10 litres of 
deionised water, pH to 7.0. Store at ambient temperature for up to 2 weeks.
WASH BUFFER






3.45 g NaH2P04 and 4.45 g Na2HP04 (Fisons) in 400 mis deionised water, pH 6.5. Store 
at an ambient temperature for 6 months.
PBS SOLUTION
80.0g NaCl, 11,6g Na2HP04, 2.0g KH2P04, 2.0g KCL (all Fisons) in 10 litres of 
deionised water, pH to 7.0. Store at ambient temperature for up to 2 weeks.
SAMPLE BUFFER
PBS solution plus 0.1% Tween 20 (Sigma) and 2% FCS 
WASH BUFFER
0.5 ml Tween 20 (Sigma) added to 1 litre of PBS from above 
TNF-a Immunostaining Buffers
PBS SOLUTION Dissolve 1 PBS tablet, without calcium and magnesium (Sigma) in 
200 mis of deionised water. pH to 7.6 with NaOH. Store at ambient temperature for up 
to 2 weeks.
SUBSTRATE SOLUTION
Dissolve 1 tablet of 3,3’-diaminobenzidine (DAB) and 1 tablet of H20 2 (Sigma FAST™ 
DAB kit) in 1 ml of deionised water immediately before use.
Buffers used for Northern Analysis (all BDH-supplied unless stated) 
DEPC-TREATMENT
Add 500 pi of DEPC (Sigma) to 500 mis of solution and incubate overnight at 37°C. 
Autoclave.
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GUANIDINE ISQTHIOCYANATE (GITC) LYSIS BUFFER
4 M GITC (Fluka), 25 mM sodium citrate, 0.5% sarcosyl in sterile deionised water. Add 
0.1 M 2-mercaptoethanol (Sigma) immediately prior to use. Store in the dark at 4°C for 
up to 4 weeks.
PHENOL EXTRACTION BUFFER
100 mM TRIS, 10 mM EDTA, 1% SDS (Sigma) made up in deionised water and 
autoclaved. Store at an ambient temperature for up to 1 month.
ETHIDIUM BROMIDE
Dissolve ethidium bromide (Sigma) in DEPC-treated water to 10 mg/ml. Store for up to 
6 months at 4°C.
20X MOPS RUNNING BUFFER
0.4 M MOPS (Sigma), 0.02M EDTA, 0.2 M sodium acetate in DEPC-treated water. pH 
to 7.0 with solid NaOH and filter sterilise. Make up on day of use.
BROMOPHENOL BLUE SOLUTION
0.025g bromophenol blue and 3 mis of glycerol in 7 mis of DEPC-treated water. Store 
for up to 6 months at an ambient temperature.
AGAROSE GELS
3g of agarose (Sigma) in 230 mis of DEPC-treated water, microwaved for 4 minutes to 
dissolve. Add 15 mis of 20x MOPS buffer and 54 mis of 37% formaldehyde solution. 
Leave to cool slightly before pouring.
SAMPLE BUFFER
Add to each sample: 7 |il of 37% formaldehyde
5 pi of 20x MOPS buffer 




3 M NaCl, 0.3 M sodium citrate in deionised water. Adjust to pH 7.0, DEPC-treat and 
autoclave. Store for up to 1 month at an ambient temperature.
HYBRIDISATION SOLUTION
5X SSC, 0.1% sarcosyl, 0.02% SDS and 1% Blocking Buffer (Boehringer Mannheim) in 
DEPC-treated water. Store for up to 1 month at 4°C.
BUFFER 1
0.1 M maleic acid, 0.15 M NaCl in deionised water. pH to 7.5 with NaOH, DEPC-treat 
and autoclave. Store for up to 1 month at an ambient temperature.
BLOCKING STOCK SOLUTION
lOg blocking reagent (Boehringer Mannheim) in 100 mis of buffer 1. Microwave to 
dissolve and autoclave. Store for up to 6 months at 4°C.
WASHING BUFFER
0.3% Tween 20 in buffer 1, on day of use.
BUFFER 2
1:10 dilution of blocking stock solution in buffer 1. Store for up to 1 month at an 
ambient temperature.
BUFFER 3
0.1 M TRIS, 0.1 M NaCl, 50 mM MgCl2 in deionised water. Adjust to pH 9.5 with 
HCL. Store in the dark for up to 6 months.
SODIUM SULPHITE
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